<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Higher versus lower fractions of inspired oxygen or targets of arterial oxygenation for adults admitted to the intensive care unit - Klitgaard, TL - 2023 | Cochrane Library</title> <meta content="Higher versus lower fractions of inspired oxygen or targets of arterial oxygenation for adults admitted to the intensive care unit - Klitgaard, TL - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012631.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Higher versus lower fractions of inspired oxygen or targets of arterial oxygenation for adults admitted to the intensive care unit - Klitgaard, TL - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012631.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012631.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Higher versus lower fractions of inspired oxygen or targets of arterial oxygenation for adults admitted to the intensive care unit" name="citation_title"/> <meta content="Thomas L Klitgaard" name="citation_author"/> <meta content="tlk@rn.dk" name="citation_author_email"/> <meta content="Olav L Schjørring" name="citation_author"/> <meta content="Frederik M Nielsen" name="citation_author"/> <meta content="Christian S Meyhoff" name="citation_author"/> <meta content="Bispebjerg and Frederiksberg Hospital, University of Copenhagen" name="citation_author_institution"/> <meta content="Anders Perner" name="citation_author"/> <meta content="Jørn Wetterslev" name="citation_author"/> <meta content="Bodil S Rasmussen" name="citation_author"/> <meta content="Marija Barbateskovic" name="citation_author"/> <meta content="Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD012631.pub3" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/09/13" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012631.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012631.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012631.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Arteries; Intensive Care Units; *Lung Injury; Oxygen [adverse effects]; *Respiratory Distress Syndrome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012631.pub3&amp;doi=10.1002/14651858.CD012631.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012631.pub3&amp;doi=10.1002/14651858.CD012631.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012631.pub3&amp;doi=10.1002/14651858.CD012631.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012631.pub3&amp;doi=10.1002/14651858.CD012631.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012631.pub3&amp;doi=10.1002/14651858.CD012631.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012631.pub3&amp;doi=10.1002/14651858.CD012631.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012631.pub3&amp;doi=10.1002/14651858.CD012631.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012631.pub3&amp;doi=10.1002/14651858.CD012631.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012631.pub3&amp;doi=10.1002/14651858.CD012631.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012631.pub3&amp;doi=10.1002/14651858.CD012631.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012631.pub3&amp;doi=10.1002/14651858.CD012631.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012631.pub3&amp;doi=10.1002/14651858.CD012631.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012631.pub3&amp;doi=10.1002/14651858.CD012631.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012631.pub3&amp;doi=10.1002/14651858.CD012631.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012631.pub3&amp;doi=10.1002/14651858.CD012631.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012631.pub3&amp;doi=10.1002/14651858.CD012631.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012631.pub3&amp;doi=10.1002/14651858.CD012631.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012631.pub3&amp;doi=10.1002/14651858.CD012631.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012631.pub3&amp;doi=10.1002/14651858.CD012631.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012631.pub3&amp;doi=10.1002/14651858.CD012631.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012631.pub3&amp;doi=10.1002/14651858.CD012631.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012631.pub3&amp;doi=10.1002/14651858.CD012631.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012631.pub3&amp;doi=10.1002/14651858.CD012631.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="Oy81c7tH";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012631\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012631\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012631\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012631\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","th","ko","ms","fa","id","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012631.pub3",title:"Higher versus lower fractions of inspired oxygen or targets of arterial oxygenation for adults admitted to the intensive care unit",firstPublishedDate:"Sep 13, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Emergency and Critical Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Oy81c7tH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012631.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012631.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012631.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012631.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012631.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012631.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;riskOfBias2&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of Bias&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012631.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012631.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012631.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012631.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3120 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012631.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-sec-0162"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-sec-0043"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-sec-0154"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/appendices#CD012631-sec-0167"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#riskOfBias2"> Risk of bias </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/supinfo/CD012631-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/supinfo/CD012631-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Higher versus lower fractions of inspired oxygen or targets of arterial oxygenation for adults admitted to the intensive care unit </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/information#CD012631-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Thomas L Klitgaard</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/information#CD012631-cr-0005">Olav L Schjørring</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/information#CD012631-cr-0006">Frederik M Nielsen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/information#CD012631-cr-0007">Christian S Meyhoff</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/information#CD012631-cr-0008">Anders Perner</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/information#CD012631-cr-0009">Jørn Wetterslev</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/information#CD012631-cr-0010">Bodil S Rasmussen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012631.pub3/information#CD012631-cr-0011">Marija Barbateskovic</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/information/en#CD012631-sec-0196">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 13 September 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012631.pub3">https://doi.org/10.1002/14651858.CD012631.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012631-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012631-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012631-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012631-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012631-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012631-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD012631-abs-0004">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012631-abs-0001" lang="en"> <section id="CD012631-sec-0001"> <h3 class="title" id="CD012631-sec-0001">Background</h3> <p>This is an updated review concerning 'Higher versus lower fractions of inspired oxygen or targets of arterial oxygenation for adults admitted to the intensive care unit'. </p> <p>Supplementary oxygen is provided to most patients in intensive care units (ICUs) to prevent global and organ hypoxia (inadequate oxygen levels). Oxygen has been administered liberally, resulting in high proportions of patients with hyperoxemia (exposure of tissues to abnormally high concentrations of oxygen). This has been associated with increased mortality and morbidity in some settings, but not in others. Thus far, only limited data have been available to inform clinical practice guidelines, and the optimum oxygenation target for ICU patients is uncertain. Because of the publication of new trial evidence, we have updated this review. </p> </section> <section id="CD012631-sec-0002"> <h3 class="title" id="CD012631-sec-0002">Objectives</h3> <p>To update the assessment of benefits and harms of higher versus lower fractions of inspired oxygen (FiO<sub>2</sub>) or targets of arterial oxygenation for adults admitted to the ICU. </p> </section> <section id="CD012631-sec-0003"> <h3 class="title" id="CD012631-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Science Citation Index Expanded, BIOSIS Previews, and LILACS. We searched for ongoing or unpublished trials in clinical trial registers and scanned the reference lists and citations of included trials. Literature searches for this updated review were conducted in November 2022. </p> </section> <section id="CD012631-sec-0004"> <h3 class="title" id="CD012631-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) that compared higher versus lower FiO<sub>2</sub> or targets of arterial oxygenation (partial pressure of oxygen (PaO<sub>2</sub>), peripheral or arterial oxygen saturation (SpO<sub>2</sub> or SaO<sub>2</sub>)) for adults admitted to the ICU. We included trials irrespective of publication type, publication status, and language. </p> <p>We excluded trials randomising participants to hypoxaemia (FiO<sub>2</sub> below 0.21, SaO<sub>2</sub>/SpO<sub>2</sub> below 80%, or PaO<sub>2</sub> below 6 kPa) or to hyperbaric oxygen, and cross‐over trials and quasi‐randomised trials. </p> </section> <section id="CD012631-sec-0005"> <h3 class="title" id="CD012631-sec-0005">Data collection and analysis</h3> <p>Four review authors independently, and in pairs, screened the references identified in the literature searches and extracted the data. Our primary outcomes were all‐cause mortality, the proportion of participants with one or more serious adverse events (SAEs), and quality of life. We analysed all outcomes at maximum follow‐up. Only three trials reported the proportion of participants with one or more SAEs as a composite outcome. However, most trials reported on events categorised as SAEs according to the International Conference on Harmonisation Good Clinical Practice (ICH‐GCP) criteria. We, therefore, conducted two analyses of the effect of higher versus lower oxygenation strategies using 1) the single SAE with the highest reported proportion in each trial, and 2) the cumulated proportion of participants with an SAE in each trial. Two trials reported on quality of life. </p> <p>Secondary outcomes were lung injury, myocardial infarction, stroke, and sepsis. No trial reported on lung injury as a composite outcome, but four trials reported on the occurrence of acute respiratory distress syndrome (ARDS) and five on pneumonia. We, therefore, conducted two analyses of the effect of higher versus lower oxygenation strategies using 1) the single lung injury event with the highest reported proportion in each trial, and 2) the cumulated proportion of participants with ARDS or pneumonia in each trial. </p> <p>We assessed the risk of systematic errors by evaluating the risk of bias in the included trials using the Risk of Bias 2 tool. We used the GRADEpro tool to assess the overall certainty of the evidence. We also evaluated the risk of publication bias for outcomes reported by 10b or more trials. </p> </section> <section id="CD012631-sec-0006"> <h3 class="title" id="CD012631-sec-0006">Main results</h3> <p>We included 19 RCTs (10,385 participants), of which 17 reported relevant outcomes for this review (10,248 participants). For all‐cause mortality, 10 trials were judged to be at overall low risk of bias, and six at overall high risk of bias. For the reported SAEs, 10 trials were judged to be at overall low risk of bias, and seven at overall high risk of bias. Two trials reported on quality of life, of which one was judged to be at overall low risk of bias and one at high risk of bias for this outcome. </p> <p>Meta‐analysis of all trials, regardless of risk of bias, indicated no significant difference from higher or lower oxygenation strategies at maximum follow‐up with regard to mortality (risk ratio (RR) 1.01, 95% confidence interval (C)I 0.96 to 1.06; I<sup>2</sup> = 14%; 16 trials; 9408 participants; very low‐certainty evidence); occurrence of SAEs: the highest proportion of any specific SAE in each trial RR 1.01 (95% CI 0.96 to 1.06; I<sup>2</sup> = 36%; 9466 participants; 17 trials; very low‐certainty evidence), or quality of life (mean difference (MD) 0.5 points in participants assigned to higher oxygenation strategies (95% CI ‐2.75 to 1.75; I<sup>2</sup> = 34%, 1649 participants; 2 trials; very low‐certainty evidence)). Meta‐analysis of the cumulated number of SAEs suggested benefit of a lower oxygenation strategy (RR 1.04 (95% CI 1.02 to 1.07; I<sup>2</sup> = 74%; 9489 participants; 17 trials; very low certainty evidence)). However, trial sequential analyses, with correction for sparse data and repetitive testing, could reject a relative risk increase or reduction of 10% for mortality and the highest proportion of SAEs, and 20% for both the cumulated number of SAEs and quality of life. Given the very low‐certainty of evidence, it is necessary to interpret these findings with caution. </p> <p>Meta‐analysis of all trials indicated no statistically significant evidence of a difference between higher or lower oxygenation strategies on the occurrence of lung injuries at maximum follow‐up (the highest reported proportion of lung injury RR 1.08, 95% CI 0.85 to 1.38; I<sup>2</sup> = 0%; 2048 participants; 8 trials; very low‐certainty evidence). </p> <p>Meta‐analysis of all trials indicated harm from higher oxygenation strategies as compared with lower on the occurrence of sepsis at maximum follow‐up (RR 1.85, 95% CI 1.17 to 2.93; I<sup>2</sup> = 0%; 752 participants; 3 trials; very low‐certainty evidence). Meta‐analysis indicated no differences regarding the occurrences of myocardial infarction or stroke. </p> </section> <section id="CD012631-sec-0007"> <h3 class="title" id="CD012631-sec-0007">Authors' conclusions</h3> <p>In adult ICU patients, it is still not possible to draw clear conclusions about the effects of higher versus lower oxygenation strategies on all‐cause mortality, SAEs, quality of life, lung injuries, myocardial infarction, stroke, and sepsis at maximum follow‐up. This is due to low or very low‐certainty evidence. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012631-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012631-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012631-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012631-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012631-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/id#CD012631-abs-0011">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012631-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012631-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD012631-abs-0005">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012631-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012631-abs-0002" lang="en"> <h3>Higher or lower levels of oxygen for adults admitted to the intensive care unit</h3> <p><b>Review question</b> </p> <p>We set out to update the assessment on whether more supplemental oxygen is better than less supplemental oxygen for adults admitted to the intensive care unit (ICU). </p> <p><b>Background</b> </p> <p>Adults admitted to the ICU are critically ill and have a high risk of dying. Oxygen supplementation, or therapy, is provided to most adult ICU patients. Severe illness can result in a lack of oxygen in the blood which puts patients at risk of low tissue levels of oxygen and organ failure. The use of sedatives and strong pain relief medications can also depress breathing and therefore oxygen levels. Supplemental oxygen has generally been administered freely, possibly resulting in too high oxygen levels. Despite a lack of robust evidence of effectiveness, supplemental oxygen administration has been widely recommended in international clinical practice guidelines. However, newer guidelines recommend against high oxygen levels as some, but not all, trials have indicated a link between this practice and an increased risk of dying. The potential benefits of supplemental oxygen must be weighed against the potentially harmful effects of providing too much. </p> <p><b>Trial characteristics</b> </p> <p>We identified 19 randomised controlled trials (RCTs) where participants were randomly allocated to either a higher or a lower level of oxygen, involving 10.385 participants up to November 2022. Seventeen of the trials (10,248 participants) provided findings on the number of deaths, serious adverse events (SAEs), quality of life, and risk of lung injuries, heart attack, or stroke at any time point following oxygen therapy in the ICU. The occurrence of lung injury was measured as the number of participants developing acute respiratory distress syndrome or pneumonia. Four trials included medically ill participants only; two included surgical patients only. Two trials assessed adults with traumatic brain injury; two trials assessed adults resuscitated from out‐of‐hospital cardiac arrest; and one trial assessed adults with stroke. In 11 trials, all participants received invasive mechanical ventilation via a tube inserted into the trachea; six trials involved adults who were both mechanically ventilated and others who were not. Two trials involved naturally breathing adults given oxygen. The use of more oxygen was compared with less oxygen in all trials, but the actual levels of oxygen differed greatly amongst the identified trials. </p> <p>Oxygen therapy was provided for different time periods of time, ranging from one hour to the entire intensive care admission (up to 90 days). </p> <p><b>Key results</b> </p> <p>After this review update, we are still uncertain about the effects of higher versus lower levels of oxygen as our findings are based on low‐ or very low‐certainty evidence. </p> <p>We did not find evidence for a beneficial effect of higher compared with lower levels of oxygen for adult ICU patients, neither on the risk of death (16 trials; 9408 participants), the risk of SAEs (17 trials, 9466 participants), the quality of life (2 trial, 1649 participants), the risk of lung injury (8 trials; 2048 participants), the risk of heart attack (4 trials, 5002 participants), nor the risk of stroke (5 trials, 6110 participants). We found a potential reduction of the risk of developing new sepsis ('blood poisoning') during ICU admission with higher levels of oxygen (3 trials, 752 participants). </p> <p><b>What are the limitations of this evidence?</b> </p> <p>The number of participants enroled in the trials was too small to permit a clear judgement about the interventions' effect sizes on the outcomes examined in this review. The trials varied in the types of illness of the participants, their associated clinical care, disease severity, the targets for how much oxygen was given, and for how long this was supplied. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012631-sec-0162" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012631-sec-0162"></div> <h3 class="title" id="CD012631-sec-0163">Implications for practice</h3> <section id="CD012631-sec-0163"> <p>In this updated review, the certainty of evidence regarding the effects of higher versus lower oxygenation strategies for adults admitted to the intensive care unit (ICU) on all‐cause mortality, serious adverse events (SAEs), quality of life, lung injuries, acute myocardial infarction, stroke, and sepsis at maximum follow‐up, as defined by trialists, still remains low or very low. This limits any ability to draw clear conclusions on the effects of higher versus lower oxygenation strategies on these outcomes. Based on the available data, if there is an intervention effect that differs from zero, it is likely to be small; Trial Sequential Analyses enabled rejecting a relative risk increase or reduction of 10% for mortality and the highest reported proportion of any SAE, and 20% for the cumulated number of SAEs and quality of life. Also, our results suggest, with very low‐certainty of evidence, that lower oxygenation strategies may yield some benefit regarding the occurrence of new episodes of sepsis. </p> </section> <h3 class="title" id="CD012631-sec-0164">Implications for research</h3> <section id="CD012631-sec-0164"> <p>Randomised controlled trials (RCTs) assessing the benefits and harms of higher versus lower oxygen supplementation strategies are still warranted. Such trials should be conducted with the lowest possible risks of bias, other design errors, and of random errors. This includes ensuring adequately low 'loss to follow‐up' rates, adherence to trial protocols, considerations of blinding the interventions, avoidance of post‐randomisation exclusions in open‐label trials, and predefining both outcomes of interest and statistical analyses. In addition, justifications for changes in trial conduct need to be transparently reported. </p> <p>Oxygen is, in most countries worldwide, considered a medical drug. Thus, it must be prescribed to patients balancing potential harmful and beneficial effects. The assessed interventions and durations of such should reflect clinically relevant and accepted strategies of oxygen supplementation. Future trials should thus focus on identifying those patients who require oxygen supplementation. </p> <p>Future trials should aim to differentiate the intervention groups ensuring that trials are actually comparing higher versus lower oxygenation levels, minimising overlap in interventions. Based on the available evidence, no recommendations can be made on what a higher or a lower target exactly entails, nor the required amount of separation in oxygenation levels. Adherence to allocated oxygenation strategies should be implemented for the entire duration of ICU admission to further evaluate the potential effects of long term oxygen exposure. </p> <p>Future trials should also focus their assessments on multidisciplinary ICUs and critically ill adults in general, but should also incorporate stratification for important baseline risk factors that subsequently may allow for testing of differences in outcomes in such groups. If possible, stratification according to the presence or absence of hypoxaemia at baseline should be considered. </p> <p>As only a few trials have reported outcome data beyond 90 days, extended follow‐up periods, e.g. up to or beyond one year, should be considered to provide information on the long‐term effects of higher versus lower oxygenation strategies. Reporting of core outcome sets, relevant to patients, should also be implemented. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012631-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012631-sec-0008"></div> <div class="table" id="CD012631-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Higher vs lower FiO2 or targets of arterial oxygenation for adults admitted to the ICU</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Higher vs lower FiO<sub>2</sub> or targets of arterial oxygenation for adults admitted to the ICU</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Participant or population:</b> adults admitted to the ICU<br/><b>Setting:</b> trials were conducted in ICU departments in Europe (n = 9); China (n = 3); Iran (n = 2); Australia, New Zealand (n = 1); Australia, New Zealand, and France (n = 1); Hong Kong (n = 1); Japan (n = 1); and United States of America (n = 1).<br/><b>Intervention:</b> higher FiO<sub>2</sub> or targets of arterial oxygenation<br/><b>Comparison:</b> lower FiO<sub>2</sub> or targets of arterial oxygenation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>a</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with lower FiO<sub>2</sub> or targets of arterial oxygenation (№ of events per 1000 participants)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with higher FiO<sub>2</sub> or targets of arterial oxygenation (№ of events per 1000 participants)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality: range 1 mo to 1 y</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.96 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>9408<br/>(16 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Meta‐analysis from the analysis of trials at overall low risk of bias showed a RR of 1.01 (95% CI 0.94 to 1.08; I<sup>2</sup> = 7%; 5733 participants; 9 RCTs). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>387 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>390 per 1000<br/>(371 to 410) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Proportion of participants with ≥ 1 serious adverse events according to International Conference on Harmonisation Good Clinical Practice: range 3 d to 180 d </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.96 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>9466<br/>(17 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Very low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Reported results are derived by taking the highest proportion reported in each trial, which addresses the lowest possible proportion of participants with ≥ 1 serious adverse events. </p> <p>The following outcomes and numbers of trials and participants have been included:</p> <p> <ol id="CD012631-list-0001"> <li> <p>mortality: 13 trials, 8540 participants;</p> </li> <li> <p>proportion of participants with ≥ 1 serious adverse events: 2 trials, 834 participants;</p> </li> <li> <p>acute myocardial infarction: 1 trial, 58 participants; and</p> </li> <li> <p>mechanical ventilation (reported as a poor outcome): 1 trials, 34 participants.</p> </li> </ol> </p> <p>Meta‐analysis from the analysis of cumulating all reported serious adverse events, which address the highest possible reported proportion of participants with ≥ 1 serious adverse events, showed a RR of 1.04 (95% CI 1.02 to 1.07; I<sup>2</sup> = 75%; 9489 participants; 17 RCTs). </p> <p>Meta‐analysis from the analysis of trials at overall low risk of bias showed a RR of 1.01 (95% CI 0.95 to 1.07; I<sup>2</sup> = 33%; 5733 participants; 9 RCTs). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>411 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>415 per 1000<br/>(394 to 436) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (any measure): range 180 d to 1 y</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 points lower in participants assigned to a higher oxygenation strategy (2.75 points lower to 1.75 points higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1649 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Lung injury diagnosed after randomisation (composite outcome): range 4 d to 23 d</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.08<br/>(0.85 to 1.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2048<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Very low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Reported results are derived by taking the highest proportion reported in each trial, which addresses the lowest possible proportion of participants with ≥ 1 lung injuries. </p> <p>The following outcomes and numbers of trials and participants have been included:</p> <p> <ol id="CD012631-list-0002"> <li> <p>ARDS: 4 trials, 862 participants; and</p> </li> <li> <p>pneumonia: 5 trials, 1251 participants.</p> </li> </ol> </p> <p>Meta‐analysis from the analysis cumulating all reported lung injuries, which address the highest possible reported proportion of participants with ≥ 1 lung injuries, showed a RR of 1.04 (95% CI 0.82 to 1.33; I<sup>2</sup> = 0%; 2048 participants; 8 RCTs). </p> <p>Meta‐analysis from the analysis of ARDS showed a RR of 0.86 (95% CI 0.43 to 1.69; I² = 0%; 862 participants; 4 RCTs). </p> <p>Meta‐analysis from the analysis of pneumonia showed a RR of 1.10 (95% CI 0.85 to 1.42; I<sup>2</sup> = 0%; 1251 participants; 5 RCTs). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>104 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>112 per 1000<br/>(88 to 143) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Myocardial infarction diagnosed after randomisation: range ≤ 90 d</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.77 (0.51 to 1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5002 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Very low<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>–</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> <p>(11 to 24)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Stroke diagnosed after randomisation: range 1 mo to 3 mo</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.08 (0.72 to 1.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6110 (5</p> <p>RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Very low<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Meta‐analysis from the analysis of trials at overall low risk of bias showed a RR of 1.04 (95% CI 0.59 to 1.83; I<sup>2</sup> = 49%; 3111 participants; 2 RCTs). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> <p>(10 to 22)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Sepsis diagnosed after randomisation: range 28 d to 60 d</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.85 (1.17 to 2.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>752 (3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Very low<sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>–</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>124 per 1000</p> <p>(78 to 196)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ARDS:</b> acute respiratory distress syndrome; <b>CI:</b> confidence interval; <b>FiO<sub>2</sub>:</b> fraction of inspired oxygen; <b>GRADE:</b> grading of recommendations, assessment, development, and evaluations; <b>ICU:</b> intensive care unit; <b>OIS:</b> Optimal information size; <b>RCT:</b> randomised controlled trial; <b>RIS:</b> required information size; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE working group grades of evidence:</p> <p> <ol id="CD012631-list-0003"> <li> <p>High certainty: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low certainty: our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low certainty: we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </li> </ol> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The risk in the intervention (higher) group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). The risk in the control (lower) group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/><sup>b</sup>Downgraded 3 levels: 1 level owing to risk of bias because only 10 trials of 16 trials were judged to be at overall low risk of bias; 2 levels owing to indirectness because of differences in the inspiratory oxygen fraction and the target of arterial oxygenation in the experimental and control groups amongst trials and owing to differences in inclusion criteria amongst trials. The RIS is 2026 participants. The RIS = OIS when I<sup>2</sup> = 0 and alpha is adjusted for multiple outcomes.<br/><sup>c</sup>Downgraded 3 levels: 1 level owing to risk of bias because 9 trials of 17 trials were judged to be at overall high risk of bias; 2 levels owing to indirectness because of differences in inspiratory oxygen fraction and target of arterial oxygenation in the experimental and control groups amongst trials and owing to differences in inclusion criteria amongst trials. The RIS is 1820 participants. The RIS = OIS when I<sup>2</sup> = 0 and alpha is adjusted for multiple outcomes.<br/><sup>d</sup>Downgraded 3 levels: 2 levels owing to indirectness because of differences in inspiratory oxygen fraction and target of arterial oxygenation in the experimental and control groups amongst trials and owing to differences in inclusion criteria amongst trials; 1 level because risk of bias. The RIS is 550 participants. The RIS = OIS when I<sup>2</sup> = 0 and alpha is adjusted for multiple outcomes.<br/><sup>e</sup>Downgraded 3 levels: 1 level owing to risk of bias because only 3 trials of 8 trials were judged to be at overall low risk of bias; 2 levels owing to indirectness because of differences in inspiratory oxygen fraction and target of arterial oxygenation in the experimental and control groups amongst trials and owing to differences in inclusion criteria amongst trials. The RIS is 12,193 participants. The RIS = OIS when I<sup>2</sup> = 0 and alpha is adjusted for multiple outcomes.<br/><sup>f</sup>Downgraded 3 levels: 1 level owing to risk of bias because only 1 trial of 4 trials was judged to be at overall low risk of bias; 1 level owing to indirectness because of differences in inspiratory oxygen fraction and target of arterial oxygenation in the experimental and control groups amongst trials; and 1 level owing to imprecision because the RIS was not reached (127,218 participants). The RIS = OIS when I<sup>2</sup> = 0 and alpha is adjusted for multiple outcomes.<br/><sup>g</sup>Downgraded 3 levels: 1 level owing to risk of bias because only 2 trials of 5 trials were judged to be at overall low risk of bias; 1 level owing to indirectness because of differences in inspiratory oxygen fraction and target of arterial oxygenation in the experimental and control groups amongst trials; and 1 level owing to imprecision because the RIS was not reached (108,569 participants). The RIS = OIS when I<sup>2</sup> = 0 and alpha is adjusted for multiple outcomes.<br/><sup>h</sup>Downgraded 3 levels: 1 level owing to risk of bias because only 1 trial of 3 trials was judged to be at overall low risk of bias; 1 level owing to indirectness because of differences in inspiratory oxygen fraction and target of arterial oxygenation in the experimental and control groups amongst trials; and 1 level owing to imprecision because the RIS was not reached (19,797 participants). The RIS = OIS when I<sup>2</sup> = 0 and alpha is adjusted for multiple outcomes. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012631-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012631-sec-0009"></div> <section id="CD012631-sec-0010"> <h3 class="title" id="CD012631-sec-0010">Description of the condition</h3> <p>In healthy individuals, the normal range for the partial pressure of arterial oxygen (PaO<sub>2</sub>) at sea level is 10.7 kPa (80 mmHg) to 13.3 kPa (100 mmHg) (<a href="./references#CD012631-bbs2-0144" title="KratzA , FerraroM , SlussPM , LewandrowskiKB . Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory reference values. New England Journal of Medicine2004;351(15):1548-63. [DOI: 10.1056/NEJMcpc049016] [PMID: 15470219]">Kratz 2004</a>), with a general decrease with age (<a href="./references#CD012631-bbs2-0093" title="CrapoRO , JensenRL , HegewaldM , TashkinDP . Arterial blood gas reference values for sea level and an altitude of 1,400 meters. American Journal of Respiratory and Critical Care Medicine1999;160(5 Pt 1):1525-31. [DOI: 10.1164/ajrccm.160.5.9806006] [PMID: 10556115]">Crapo 1999</a>). </p> <p>Adults admitted to the intensive care unit (ICU) are very frequently treated with supplemental oxygen to prevent or treat hypoxaemia, and ultimately hypoxia. Hypoxaemia refers to a lack of oxygen in the blood and is usually defined in terms of PaO<sub>2</sub> or arterial oxygen saturation of haemoglobin (SaO<sub>2</sub>), whilst the term hypoxia is defined as the lack of oxygen at a cellular level, e.g. in tissues, organs, alveoli, or the body as a whole (<a href="./references#CD012631-bbs2-0163" title="O’DriscollBR , HowardLS , EarisJ , MakV , British Thoracic Society Emergency Oxygen Guideline Group, BTS Emergency Oxygen Guideline Development Group. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax2017;72(Suppl 1):ii1-90. [DOI: 10.1136/thoraxjnl-2016-209729] [PMID: 28507176]">O’Driscoll 2017</a>). However, there is no clear definition of hypoxaemia; the most widely used definitions are a PaO<sub>2</sub> below 60 mmHg (8 kPa) or a SaO<sub>2</sub> below 90% (<a href="./references#CD012631-bbs2-0163" title="O’DriscollBR , HowardLS , EarisJ , MakV , British Thoracic Society Emergency Oxygen Guideline Group, BTS Emergency Oxygen Guideline Development Group. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax2017;72(Suppl 1):ii1-90. [DOI: 10.1136/thoraxjnl-2016-209729] [PMID: 28507176]">O’Driscoll 2017</a>). Conversely, hyperoxemia refers to above‐normal levels of oxygen content in the blood, typically as a result of breathing in high levels of oxygen (hyperoxia). As with hypoxia and hypoxaemia, no clear definition of hyperoxia and hyperoxemia exists, but with a suggested threshold of PaO<sub>2</sub> above 120 mmHg (16 kPa) (<a href="./references#CD012631-bbs2-0163" title="O’DriscollBR , HowardLS , EarisJ , MakV , British Thoracic Society Emergency Oxygen Guideline Group, BTS Emergency Oxygen Guideline Development Group. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax2017;72(Suppl 1):ii1-90. [DOI: 10.1136/thoraxjnl-2016-209729] [PMID: 28507176]">O’Driscoll 2017</a>). The peripheral oxygen saturation (SpO<sub>2</sub>) measured by pulse oximetry is routinely used as a non‐invasive surrogate for SaO<sub>2</sub>. Currently, oxygenation targets below the normal range, and even defined as hypoxaemic, targeting PaO<sub>2</sub> between 55 mmHg and 80 mmHg (7.3 kPa and 10.7 kPa) or SpO<sub>2</sub> between 88% and 95%, are employed in adults who are mechanically ventilated with acute respiratory distress syndrome (ARDS) in the ICU (<a href="./references#CD012631-bbs2-0075" title="BrowerRG , MatthayMA , MorrisA , SchoenfeldD , ThompsonBT , WheelerA , Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. New England Journal of Medicine2000;342(18):1301-8. [DOI: 10.1056/NEJM200005043421801] [PMID: 10793162]">ARDS Network 2000</a>; <a href="./references#CD012631-bbs2-0087" title="BrowerRG , LankenPN , MacIntyreN , MatthayMA , MorrisA , AncukiewiczM , et al. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. New England Journal of Medicine2004;351(4):327-36. [DOI: 10.1056/NEJMoa032193] [PMID: 15269312]">Brower 2004</a>). </p> <p>In adults admitted to the ICU, hypoxaemia is a common clinical manifestation of inadequate gas exchange in the lungs (<a href="./references#CD012631-bbs2-0168" title="PeterssonJ , GlennyRW . Gas exchange and ventilation-perfusion relationships in the lung. European Respiratory Journal2014;44(4):1023-41. [DOI: 10.1183/09031936.00037014] [PMID: 25063240]">Petersson 2014</a>). The condition can arise primarily from four different mechanisms: hypoventilation, ventilation or perfusion (V/Q) mismatch, right‐to‐left blood shunting, diffusion impairment, or a combination of these (<a href="./references#CD012631-bbs2-0168" title="PeterssonJ , GlennyRW . Gas exchange and ventilation-perfusion relationships in the lung. European Respiratory Journal2014;44(4):1023-41. [DOI: 10.1183/09031936.00037014] [PMID: 25063240]">Petersson 2014</a>; <a href="./references#CD012631-bbs2-0179" title="RoussosC , KoutsoukouA . Respiratory failure. European Respiratory Journal Supplement2003;47:3S-14S. [DOI: 10.1183/09031936.03.00038503] [PMID: 14621112]">Roussos 2003</a>). Hypoventilation in the ICU is typically caused by an acute depression of the central nervous system, either through administration of sedative or analgesic agents, or due to critical illness with indirect (e.g. circulatory, hypoxic, or hypercapnic failure) or direct (e.g. traumatic brain injury, intracranial haemorrhage, or meningoencephalitis) cerebral affection. Hypoxaemia due to hypoventilation is always accompanied by hypercapnia since hypoventilation affects the alveolar clearance of carbon dioxide to a larger degree than the alveolar oxygenation, and hypoventilation does not affect the alveolar‐arterial gradient (<a href="./references#CD012631-bbs2-0168" title="PeterssonJ , GlennyRW . Gas exchange and ventilation-perfusion relationships in the lung. European Respiratory Journal2014;44(4):1023-41. [DOI: 10.1183/09031936.00037014] [PMID: 25063240]">Petersson 2014</a>; <a href="./references#CD012631-bbs2-0179" title="RoussosC , KoutsoukouA . Respiratory failure. European Respiratory Journal Supplement2003;47:3S-14S. [DOI: 10.1183/09031936.03.00038503] [PMID: 14621112]">Roussos 2003</a>). V/Q mismatch with a low V/Q ratio evolves when ventilation in certain lung regions is disproportionally decreased as compared to perfusion. This is seen in various conditions including pneumonia, ARDS, pulmonary oedema, and chronic obstructive pulmonary disease (COPD) (<a href="./references#CD012631-bbs2-0168" title="PeterssonJ , GlennyRW . Gas exchange and ventilation-perfusion relationships in the lung. European Respiratory Journal2014;44(4):1023-41. [DOI: 10.1183/09031936.00037014] [PMID: 25063240]">Petersson 2014</a>; <a href="./references#CD012631-bbs2-0141" title="KentBD , MitchellPD , McNicholasWT . Hypoxemia in patients with COPD: cause, effects, and disease progression. International Journal of Chronic Obstructive Pulmonary Disease2011;6:199-208. [DOI: 10.2147/COPD.S10611] [PMID: 21660297]">Kent 2011</a>). The impact of a low V/Q ratio is partially compensated by physiological hypoxic pulmonary vasoconstriction in the affected segments of the lung (<a href="./references#CD012631-bbs2-0176" title="Rodríguez-RoisinR , RocaJ . Mechanisms of hypoxemia. Intensive Care Medicine2005;31(8):1017-9. [DOI: 10.1007/s00134-005-2678-1] [PMID: 16052273]">Rodríguez‐Roisin 2005</a>). V/Q mismatch with a high V/Q ratio evolves when perfusion in certain lung regions is disproportionally decreased as compared to ventilation, as is classically seen in pulmonary embolism (<a href="./references#CD012631-bbs2-0168" title="PeterssonJ , GlennyRW . Gas exchange and ventilation-perfusion relationships in the lung. European Respiratory Journal2014;44(4):1023-41. [DOI: 10.1183/09031936.00037014] [PMID: 25063240]">Petersson 2014</a>), but is also prevalent in COPD (<a href="./references#CD012631-bbs2-0199" title="WagnerPD , DantzkerDR , DueckR , ClausenJL , WestJB . Ventilation-perfusion inequality in chronic obstructive pulmonary disease. Journal of Clinical Investigation1977;59(2):203-16. [DOI: 10.1172/JCI108630] [PMID: 833271]">Wagner 1977</a>), and ARDS (<a href="./references#CD012631-bbs2-0106" title="DonahoeM . Acute respiratory distress syndrome: a clinical review. Pulmonary Circulation2011;1(2):192-211. [DOI: 10.4103/2045-8932.83454] [PMID: 22034606]">Donahoe 2011</a>). Intrapulmonary shunting is the consequence of complete V/Q mismatch with abolished ventilation which allows the passing of blood through sections of the pulmonary vascular bed without being oxygenated. This is seen in all types of pulmonary atelectasis (including absorption atelectasis) and is especially prevalent in ARDS and pneumonia (<a href="./references#CD012631-bbs2-0168" title="PeterssonJ , GlennyRW . Gas exchange and ventilation-perfusion relationships in the lung. European Respiratory Journal2014;44(4):1023-41. [DOI: 10.1183/09031936.00037014] [PMID: 25063240]">Petersson 2014</a>). V/Q mismatch and intrapulmonary shunting are the most common causes of hypoxaemia in the ICU (<a href="./references#CD012631-bbs2-0168" title="PeterssonJ , GlennyRW . Gas exchange and ventilation-perfusion relationships in the lung. European Respiratory Journal2014;44(4):1023-41. [DOI: 10.1183/09031936.00037014] [PMID: 25063240]">Petersson 2014</a>). Diffusion impairment occurs when the diffusion pathway for oxygen from the alveolar space to the pulmonary capillaries is pathologically increased, either acutely as seen in pneumonia, pulmonary oedema, or ARDS, or chronically as seen in the large group of interstitial lung diseases (<a href="./references#CD012631-bbs2-0168" title="PeterssonJ , GlennyRW . Gas exchange and ventilation-perfusion relationships in the lung. European Respiratory Journal2014;44(4):1023-41. [DOI: 10.1183/09031936.00037014] [PMID: 25063240]">Petersson 2014</a>). </p> </section> <section id="CD012631-sec-0011"> <h3 class="title" id="CD012631-sec-0011">Description of the intervention</h3> <p>Administration of supplemental oxygen, defined as a fraction of inspired oxygen (FiO<sub>2</sub>) above 0.21, is a frequent intervention in adults admitted to the ICU. Oxygen is often administered during acute conditions in the pre‐hospital setting and during hospital admission. Adults admitted to the ICU often receive mechanical ventilation, and oxygen support to correct or prevent hypoxaemia. Treatment is usually a combination of ventilatory and non‐ventilatory strategies where the aim is to reduce morbidity and mortality associated with hypoxaemia by restoring arterial oxygenation to normal values (<a href="./references#CD012631-bbs2-0109" title="EsanA , HessDR , RaoofS , GeorgeL , SesslerCN . Severe hypoxemic respiratory failure: part 1 – ventilatory strategies. Chest2010;137(5):1203-16. [DOI: 10.1378/chest.09-2415] [PMID: 20442122]">Esan 2010</a>; <a href="./references#CD012631-bbs2-0174" title="RaoofS , GouletK , EsanA , HessDR , SesslerCN . Severe hypoxemic respiratory failure: part 2 – nonventilatory strategies. Chest2010;137(6):1437-48. [DOI: 10.1378/chest.09-2416] [PMID: 20525656]">Raoof 2010</a>). Due to the administration of oxygen, adults often achieve supranormal levels of PaO<sub>2</sub> (<a href="./references#CD012631-bbs2-0100" title="deGraaffAE , DongelmansDA , BinnekadeJM , deJongeE . Clinicians’ response to hyperoxia in ventilated patients in a Dutch ICU depends on the level of FiO2 . Intensive Care Medicine2011;37(1):46-51. [DOI: 10.1007/s00134-010-2025-z] [PMID: 20878146]">de Graaff 2011</a>; <a href="./references#CD012631-bbs2-0101" title="deJongeE , PeelenL , KeijzersPJ , JooreH , deLangeD , van derVoortPH , et al. Association between administered oxygen, arterial partial oxygen pressure and mortality in mechanically ventilated intensive care unit patients. Critical Care2008;12(6):R156. [DOI: 10.1186/cc7150] [PMID: 19077208]">de Jonge 2008</a>; <a href="./references#CD012631-bbs2-0107" title="EastwoodG , BellomoR , BaileyM , TaoriG , PilcherD , YoungP , et al. Arterial oxygen tension and mortality in mechanically ventilated patients. Intensive Care Medicine2012;38(1):91-8. [DOI: 10.1007/s00134-011-2419-6] [PMID: 22127482]">Eastwood 2012</a>; <a href="./references#CD012631-bbs2-0134" title="ItagakiT , NakanoY , OkudaN , IzawaM , OnoderaM , ImanakaH , et al. Hyperoxemia in mechanically ventilated, critically ill subjects: incidence and related factors. Respiratory Care2015;60(3):335-40. [DOI: 10.4187/respcare.03451] [PMID: 25389354]">Itagaki 2015</a>; <a href="./references#CD012631-bbs2-0143" title="KraftF , AndelH , GamperJ , MarkstallerK , UllrichR , KleinKU . Incidence of hyperoxia and related in-hospital mortality in critically ill patients: a retrospective data analysis. Acta Anaesthesiologica Scandinavica2018;62(3):347-56. [DOI: 10.1111/aas.13047] [PMID: 29210062]">Kraft 2018</a>; <a href="./references#CD012631-bbs2-0191" title="SuzukiS , EastwoodGM , PeckL , GlassfordNJ , BellomoR . Current oxygen management in mechanically ventilated patients: a prospective observational cohort study. Journal of Critical Care2013;28(5):647-54. [DOI: 10.1016/j.jcrc.2013.03.010] [PMID: 23683560]">Suzuki 2013</a>; <a href="./references#CD012631-bbs2-0213" title="ZhangZ , JiX . Quadratic function between arterial partial oxygen pressure and mortality risk in sepsis patients: an interaction with simplified acute physiology score. Scientific Reports2016;6:35133. [DOI: 10.1038/srep35133] [PMID: 27734905]">Zhang 2016</a>; <a href="./references#CD012631-bbs2-0182" title="SchjørringOL , JensenAKG , NielsenCG , CiubotariuA , PernerA , WetterslevJ , et al. Arterial oxygen tensions in mechanically ventilated ICU patients and mortality: a retrospective, multicentre, observational cohort study. British Journal of Anaesthesia2020;124(4):420-29. [DOI: 10.1016/j.bja.2019.12.039] [PMID: 32753102]">Schjørring 2020</a>). </p> </section> <section id="CD012631-sec-0012"> <h3 class="title" id="CD012631-sec-0012">How the intervention might work</h3> <p>The purpose of oxygen therapy is to increase oxygen delivery to tissues. Tissue hypoxia can cause cell death, but the precise level at which this occurs has not been determined and the level may differ between tissues, organs, and individuals (<a href="./references#CD012631-bbs2-0163" title="O’DriscollBR , HowardLS , EarisJ , MakV , British Thoracic Society Emergency Oxygen Guideline Group, BTS Emergency Oxygen Guideline Development Group. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax2017;72(Suppl 1):ii1-90. [DOI: 10.1136/thoraxjnl-2016-209729] [PMID: 28507176]">O’Driscoll 2017</a>). </p> <p>Supplemental oxygen therapy has several potential advantages including the maintenance of oxygen delivery to tissues and the prevention of organ dysfunction followed by anoxic injury (<a href="./references#CD012631-bbs2-0088" title="BudingerGR , MutluGM . Balancing the risks and benefits of oxygen therapy in critically ill adults. Chest2013;143(4):1151-62. [DOI: 10.1378/chest.12-1215] [PMID: 23546490]">Budinger 2013</a>). Several additional beneficial effects of supplemental oxygen have been proposed and include: induction of antioxidant enzymes, anti‐inflammatory proteins, anti‐inflammatory cytokines, and certain growth factors; reduced postoperative infections, neutrophil activation, and markers of cerebral tissue breakdown; anti‐apoptotic effects in brain and myocardium; normalisation of cerebral extracellular homeostasis; and stabilisation of the blood‐brain barrier (<a href="./references#CD012631-bbs2-0192" title="TanHL , WijeweeraO . Oxygen in critical care. Trends in Anaesthesia and Critical Care2014;4(4):102-8. [DOI: 10.1016/j.tacc.2014.05.001]">Tan 2014</a>). </p> <p>High FiO<sub>2</sub> has been associated with adverse outcomes in emergency medical conditions in patients with exacerbation of COPD (<a href="./references#CD012631-bbs2-0023" title="AustinMA , WillsKE , BlizzardL , WaltersEH , Wood-BakerR . Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. British Medical Journal2010;341:c5462. [DOI: 10.1136/bmj.c5462] [PMID: 20959284]">Austin 2010</a>); after resuscitation after cardiac arrest (<a href="./references#CD012631-bbs2-0142" title="KilgannonJH , JonesAE , ShapiroNI , AngelosMG , MilcarekB , HunterK , et al, Emergency Medicine Shock Research Network (EMShockNet) Investigators. Association between arterial hyperoxia following resuscitation from cardiac arrest and in-hospital mortality. Journal of the American Medical Association2010;303(21):2165-71. [DOI: 10.1001/jama.2010.707] [PMID: 20516417]">Kilgannon 2010</a>); in patients with myocardial infarction (<a href="./references#CD012631-bbs2-0190" title="StubD , SmithK , BernardS , NehmeZ , StephensonM , BrayJE , et al, AVOID Investigators. Air versus oxygen in ST-segment–elevation myocardial infarction. Circulation2015;131(24):2143-50. [DOI: 10.1161/CIRCULATIONAHA.114.014494] [PMID: 26002889]">Stub 2015</a>; <a href="./references#CD012631-bbs2-0089" title="CabelloJB , BurlsA , EmparanzaJI , BaylissS , QuinnT . Oxygen therapy for acute myocardial infarction. Cochrane Database of Systematic Reviews2016, Issue 12. Art. No: CD007160. [DOI: 10.1002/14651858.CD007160.pub4] [PMID: 27991651]">Cabello 2016</a>); and in patients with traumatic brain injury (<a href="./references#CD012631-bbs2-0084" title="BrennerM , SteinD , HuP , KuferaJ , WoofordM , ScaleaT . Association between early hyperoxia and worse outcomes after traumatic brain injury. Archives of Surgery2012;147(11):1042-6. [DOI: 10.1001/archsurg.2012.1560] [PMID: 22801994]">Brenner 2012</a>). Additionally, treating perioperative adults with high FiO<sub>2</sub> may be associated with increased mortality without reducing surgical site infections in adult surgical patients (<a href="./references#CD012631-bbs2-0203" title="WetterslevJ , MeyhoffCS , JørgensenLN , GluudC , LindschouJ , RasmussenLS . The effects of high perioperative inspiratory oxygen fraction for adult surgical patients. Cochrane Database of Systematic Reviews2015, Issue 6. Art. No: CD008884. [DOI: 10.1002/14651858.CD008884.pub2]">Wetterslev 2015</a>). These adverse outcomes may be caused by postoperative pulmonary complications due to atelectasis formation (partial collapse of the lungs) (<a href="./references#CD012631-bbs2-0083" title="BenoîtZ , WickyS , FischerJF , FrascaroloP , ChapuisC , SpahnDR , et al. The effect of increased FiO2 before tracheal extubation on postoperative atelectasis. Anesthesia and Analgesia2002;95(6):1777-81. [DOI: 10.1097/00000539-200212000-00058] [PMID: 12456458]">Benoît 2002</a>; <a href="./references#CD012631-bbs2-0177" title="RothenHU , SporreB , EngbergG , WegeniusG , HögmanM , HedenstiernaG . Influence of gas composition on recurrence of atelectasis after a reexpansion maneuver during general anesthesia. Anesthesiology1995;82(4):832-42. [DOI: 10.1097/00000542-199504000-00004] [PMID: 7717553]">Rothen 1995a</a>; <a href="./references#CD012631-bbs2-0178" title="RothenHU , SporreB , EngbergG , WegeniusG , ReberA , HedenstiernaG . Prevention of atelectasis during general anaesthesia. Lancet1995;345(8962):1387-91. [DOI: 10.1016/s0140-6736(95)92595-3] [PMID: 7760608]">Rothen 1995b</a>) or pulmonary formation of reactive oxygen species (unstable molecule that contains oxygen and that easily reacts with other molecules in a cell) (<a href="./references#CD012631-bbs2-0090" title="ChowCW , Herrera AbreuMT , SuzukiT , DowneyGP . Oxidative stress and acute lung injury. American Journal of Respiratory Cell and Molecular Biology2003;29(4):427-31. [DOI: 10.1165/rcmb.F278] [PMID: 14500253]">Chow 2003</a>; <a href="./references#CD012631-bbs2-0119" title="HelmerhorstHJ , Roos-BlomMJ , vanWesterlooDJ , deJongeE . Association between arterial hyperoxia and outcome in subsets of critical illness: a systematic review, meta-analysis, and meta-regression of cohort studies. Critical Care Medicine2015;43(7):1508-19. [DOI: 10.1097/CCM.0000000000000998] [PMID: 25855899]">Helmerhorst 2015</a>; <a href="./references#CD012631-bbs2-0139" title="KalletRH , MatthayMA . Hyperoxic acute lung injury. Respiratory Care2013;58(1):123-41. [DOI: 10.4187/respcare.01963] [PMID: 23271823]">Kallet 2013</a>). However, they may also be related to decreased local blood flow on normal and non‐diseased vasculature induced by hyperoxemic vasoconstriction (<a href="./references#CD012631-bbs2-0186" title="SjöbergF , SingerM . The medical use of oxygen: a time for critical reappraisal. Journal of Internal Medicine2013;274(6):505-28. [DOI: 10.1111/joim.12139] [PMID: 24206183]">Sjöberg 2013</a>), which has been described in the vascular system, for example in the heart and brain (<a href="./references#CD012631-bbs2-0140" title="KenmureAC , BeatsonJM , CameronAJ , HortonPW . Effects of oxygen on myocardial blood flow and metabolism. Cardiovascular Research1971;5(4):483-9. [DOI: 10.1093/cvr/5.4.483] [PMID: 5160452]">Kenmure 1971</a>; <a href="./references#CD012631-bbs2-0200" title="WatsonNA , BeardsSC , AltafN , KassnerA , JacksonA . The effect of hyperoxia on cerebral blood flow: a study in healthy volunteers using magnetic resonance phase-contrast angiography. European Journal of Anaesthesiology2000;17(3):152-9. [DOI: 10.1046/j.1365-2346.2000.00640.x] [PMID: 10758463]">Watson 2000</a>). </p> <p>Knowledge about cell biology also suggests that oxygen might have harmful effects. Prolonged exposure to hyperoxia causes lung injury, which is thought to be caused by the production and accumulation of reactive oxygen species that overwhelm natural antioxidant defences and destroy cellular structures (<a href="./references#CD012631-bbs2-0139" title="KalletRH , MatthayMA . Hyperoxic acute lung injury. Respiratory Care2013;58(1):123-41. [DOI: 10.4187/respcare.01963] [PMID: 23271823]">Kallet 2013</a>). Exposure to hyperoxia is associated with a boost in the production of reactive oxygen species, which eventually may overwhelm the cell's repair processes, thereby causing cell injury (<a href="./references#CD012631-bbs2-0092" title="CrapoJD . Morphologic changes in pulmonary oxygen toxicity. Annual Review of Physiology1986;48:721-31. [DOI: 10.1146/annurev.ph.48.030186.003445] [PMID: 3518622]">Crapo 1986</a>). It has been proposed that reactive oxygen species may trigger apoptosis (programmed cell death) within pulmonary cells leading to necrosis, thereby causing an inflammation that damages lung tissue further (<a href="./references#CD012631-bbs2-0211" title="ZaherTE , MillerEJ , MorrowDM , JavdanM , MantellLL . Hyperoxia-induced signal transduction pathways in pulmonary epithelial cells. Free Radical Biology and Medicine2007;42(7):897-908. [DOI: 10.1016/j.freeradbiomed.2007.01.021] [PMID: 17349918]">Zaher 2007</a>). </p> <p>Mechanical ventilation may in itself also be associated with complications including increased risk of pneumonia, impaired cardiac performance, and neuromuscular problems relating to sedation and muscle relaxants (<a href="./references#CD012631-bbs2-0204" title="WhiteheadT , SlutskyAS . The pulmonary physician in critical care ∗ 7: ventilator induced lung injury. Thorax2002;57(7):635-42. [DOI: 10.1136/thorax.57.7.635] [PMID: 12096209]">Whitehead 2002</a>). Also, applying pressure to the lungs can cause damage, which is known as ventilator‐induced lung injury. Ventilator‐associated lung injury has been shown to be augmented by hyperoxia in animal studies (<a href="./references#CD012631-bbs2-0077" title="BaileyTC , MartinEL , ZhaoL , VeldhuizenRA . High oxygen concentrations predispose mouse lungs to the deleterious effects of high stretch ventilation. Journal of Applied Physiology (1985)2003;94(3):975-82. [DOI: 10.1152/japplphysiol.00619.2002] [PMID: 12571129]">Bailey 2003</a>; <a href="./references#CD012631-bbs2-0121" title="HelmerhorstHJF , SchoutenLRA , WagenaarGTM , JuffermansNP , RoelofsJJTH , SchultzMJ , et al. Hyperoxia provokes a time- and dose-dependent inflammatory response in mechanically ventilated mice, irrespective of tidal volumes. Intensive Care Medicine Experimental2017;5(1):27. [DOI: 10.1186/s40635-017-0142-5] [PMID: 28550659]">Helmerhorst 2017b</a>; <a href="./references#CD012631-bbs2-0185" title="SinclairSE , AltemeierWA , Matute-BelloG , ChiEY . Augmented lung injury due to interaction between hyperoxia and mechanical ventilation. Critical Care Medicine2004;32(12):2496-501. [DOI: 10.1097/01.ccm.0000148231.04642.8d] [PMID: 15599157]">Sinclair 2004</a>). </p> </section> <section id="CD012631-sec-0013"> <h3 class="title" id="CD012631-sec-0013">Why it is important to do this review</h3> <p>The mainstay treatment for hypoxaemia is supplemental oxygen therapy, which is given to the vast majority of adults admitted to the ICU, especially during mechanical ventilation. It is estimated that 2 to 3 million adults yearly require mechanical ventilation in the ICU in high‐income countries (<a href="./references#CD012631-bbs2-0071" title="AdhikariNK , FowlerRA , BhagwanjeeS , RubenfeldGD . Critical care and the global burden of critical illness in adults. Lancet2010;376(9749):1339-46. [DOI: 10.1016/S0140-6736(10)60446-1] [PMID: 20934212]">Adhikari 2010</a>), and is associated with both morbidity (<a href="./references#CD012631-bbs2-0138" title="KahnJM , BensonNM , ApplebyD , CarsonSS , IwashynaTJ . Long-term acute care hospital utilization after critical illness. Journal of American Medical Associate2010;303(22):2253-9. [DOI: 10.1001/jama.2010.761] [PMID: 20530778]">Kahn 2010</a>) and mortality (<a href="./references#CD012631-bbs2-0152" title="MetnitzPG , MetnitzB , MorenoRP , BauerP , Del SorboL , HoermannC , et al, SAPS 3 Investigators. Epidemiology of mechanical ventilation: analysis of the SAPS 3 database. Intensive Care Medicine2009;35(5):816-25. [DOI: 10.1007/s00134-009-1449-9] [PMID: 19288079]">Metnitz 2009</a>; <a href="./references#CD012631-bbs2-0206" title="WunschH , Linde-ZwirbleWT , AngusDC , HartmanME , MilbrandtEB , KahnJM . The epidemiology of mechanical ventilation use in the United States. Critical Care Medicine2010;38(10):1947-53. [DOI: 10.1097/CCM.0b013e3181ef4460] [PMID: 20639743]">Wunsch 2010</a>). </p> <p>Oxygen administration has typically been liberal and resulted in hyperoxemia or hyperoxia in the lungs (<a href="./references#CD012631-bbs2-0100" title="deGraaffAE , DongelmansDA , BinnekadeJM , deJongeE . Clinicians’ response to hyperoxia in ventilated patients in a Dutch ICU depends on the level of FiO2 . Intensive Care Medicine2011;37(1):46-51. [DOI: 10.1007/s00134-010-2025-z] [PMID: 20878146]">de Graaff 2011</a>; <a href="./references#CD012631-bbs2-0101" title="deJongeE , PeelenL , KeijzersPJ , JooreH , deLangeD , van derVoortPH , et al. Association between administered oxygen, arterial partial oxygen pressure and mortality in mechanically ventilated intensive care unit patients. Critical Care2008;12(6):R156. [DOI: 10.1186/cc7150] [PMID: 19077208]">de Jonge 2008</a>; <a href="./references#CD012631-bbs2-0134" title="ItagakiT , NakanoY , OkudaN , IzawaM , OnoderaM , ImanakaH , et al. Hyperoxemia in mechanically ventilated, critically ill subjects: incidence and related factors. Respiratory Care2015;60(3):335-40. [DOI: 10.4187/respcare.03451] [PMID: 25389354]">Itagaki 2015</a>; <a href="./references#CD012631-bbs2-0143" title="KraftF , AndelH , GamperJ , MarkstallerK , UllrichR , KleinKU . Incidence of hyperoxia and related in-hospital mortality in critically ill patients: a retrospective data analysis. Acta Anaesthesiologica Scandinavica2018;62(3):347-56. [DOI: 10.1111/aas.13047] [PMID: 29210062]">Kraft 2018</a>; <a href="./references#CD012631-bbs2-0166" title="PanwarR , CapellierG , SchmutzN , DaviesA , CooperDJ , BaileyM , et al. Current oxygenation practice in ventilated patients – an observational cohort study. Anaesthesia and Intensive Care2013;41(4):505-14. [DOI: 10.1177/0310057X1304100412] [PMID: 23808511]">Panwar 2013</a>; <a href="./references#CD012631-bbs2-0172" title="RachmaleS , LiG , WilsonG , MalinchocM , GajicO . Practice of excessive FiO2 and effect on pulmonary outcomes in mechanically ventilated patients with acute lung injury. Respiratory Care2012;57(11):1887-93. [DOI: 10.4187/respcare.01696] [PMID: 22613692]">Rachmale 2012</a>; <a href="./references#CD012631-bbs2-0191" title="SuzukiS , EastwoodGM , PeckL , GlassfordNJ , BellomoR . Current oxygen management in mechanically ventilated patients: a prospective observational cohort study. Journal of Critical Care2013;28(5):647-54. [DOI: 10.1016/j.jcrc.2013.03.010] [PMID: 23683560]">Suzuki 2013</a>; <a href="./references#CD012631-bbs2-0213" title="ZhangZ , JiX . Quadratic function between arterial partial oxygen pressure and mortality risk in sepsis patients: an interaction with simplified acute physiology score. Scientific Reports2016;6:35133. [DOI: 10.1038/srep35133] [PMID: 27734905]">Zhang 2016</a>; <a href="./references#CD012631-bbs2-0182" title="SchjørringOL , JensenAKG , NielsenCG , CiubotariuA , PernerA , WetterslevJ , et al. Arterial oxygen tensions in mechanically ventilated ICU patients and mortality: a retrospective, multicentre, observational cohort study. British Journal of Anaesthesia2020;124(4):420-29. [DOI: 10.1016/j.bja.2019.12.039] [PMID: 32753102]">Schjørring 2020</a>). Some observational studies and randomised trials have indicated an association between hyperoxemia and mortality (<a href="./references#CD012631-bbs2-0098" title="DahlRM , GrønlykkeL , HaaseN , HolstLB , PernerA , WetterslevJ , et al. Variability in targeted arterial oxygenation levels in patients with severe sepsis or septic shock. Acta Anaesthesiologica Scandinavia2015;59(7):859-69. [DOI: 10.1111/aas.12528.] [PMID: 25914095]">Dahl 2015</a>; <a href="./references#CD012631-bbs2-0120" title="HelmerhorstHJ , ArtsDL , SchultzMJ , van derVoortPH , Abu-HannaA , deJongeE , et al. Metrics of arterial hyperoxia and associated outcomes in critical care. Critical Care Medicine2017;45(2):187-95. [DOI: 10.1097/CCM.0000000000002084] [PMID: 27763912]">Helmerhorst 2017a</a>; <a href="./references#CD012631-bbs2-0142" title="KilgannonJH , JonesAE , ShapiroNI , AngelosMG , MilcarekB , HunterK , et al, Emergency Medicine Shock Research Network (EMShockNet) Investigators. Association between arterial hyperoxia following resuscitation from cardiac arrest and in-hospital mortality. Journal of the American Medical Association2010;303(21):2165-71. [DOI: 10.1001/jama.2010.707] [PMID: 20516417]">Kilgannon 2010</a>; <a href="./references#CD012631-bbs2-0153" title="MeyhoffCS , JorgensenLN , WetterslevJ , ChristensenKB , RasmussenLS , PROXI Trial Group. Increased long-term mortality after a high perioperative inspiratory oxygen fraction during abdominal surgery: follow-up of a randomized clinical trial. Anesthesia and Analgesia2012;115(4):849-54. [DOI: 10.1213/ANE.0b013e3182652a51] [PMID: 22798533]">Meyhoff 2012</a>; <a href="./references#CD012631-bbs2-0213" title="ZhangZ , JiX . Quadratic function between arterial partial oxygen pressure and mortality risk in sepsis patients: an interaction with simplified acute physiology score. Scientific Reports2016;6:35133. [DOI: 10.1038/srep35133] [PMID: 27734905]">Zhang 2016</a>; <a href="./references#CD012631-bbs2-0164" title="PalmerE , PostB , lapaukhR , MarraG , MacCallumNS , BrealeyD , et al. The association between supraphysiologic arterial oxygen levels and mortality in critically ill patients. A multicenter observational cohort study. American Journal of Respiratory and Critical Care Medicine2019;200(11):1373-80. [DOI: 10.1164/rccm.201904-0849OC] [PMID: 31513754]">Palmer 2019</a>; <a href="./references#CD012631-bbs2-0182" title="SchjørringOL , JensenAKG , NielsenCG , CiubotariuA , PernerA , WetterslevJ , et al. Arterial oxygen tensions in mechanically ventilated ICU patients and mortality: a retrospective, multicentre, observational cohort study. British Journal of Anaesthesia2020;124(4):420-29. [DOI: 10.1016/j.bja.2019.12.039] [PMID: 32753102]">Schjørring 2020</a>), whilst other studies have not (<a href="./references#CD012631-bbs2-0082" title="BellomoR , BaileyM , EastwoodGM , NicholA , PilcherD , HartGK . Arterial hyperoxia and in-hospital mortality after resuscitation from cardiac arrest. Critical Care2011;15(2):R90. [DOI: 10.1186/cc10090] [PMID: 21385416]">Bellomo 2011</a>; <a href="./references#CD012631-bbs2-0107" title="EastwoodG , BellomoR , BaileyM , TaoriG , PilcherD , YoungP , et al. Arterial oxygen tension and mortality in mechanically ventilated patients. Intensive Care Medicine2012;38(1):91-8. [DOI: 10.1007/s00134-011-2419-6] [PMID: 22127482]">Eastwood 2012</a>; <a href="./references#CD012631-bbs2-0143" title="KraftF , AndelH , GamperJ , MarkstallerK , UllrichR , KleinKU . Incidence of hyperoxia and related in-hospital mortality in critically ill patients: a retrospective data analysis. Acta Anaesthesiologica Scandinavica2018;62(3):347-56. [DOI: 10.1111/aas.13047] [PMID: 29210062]">Kraft 2018</a>; <a href="./references#CD012631-bbs2-0173" title="RajR , BendelS , ReinikainenM , KivisaariR , SiironenJ , LångM , et al. Hyperoxemia and long-term outcome after traumatic brain injury. Critical Care2013;17(4):R177. [DOI: 10.1186/cc12856] [PMID: 23958227]">Raj 2013</a>; <a href="./references#CD012631-bbs2-0208" title="YoungP , BeasleyR , BaileyM , BellomoR , EastwoodGM , NicholA , et al, Study of Oxygen in Critical Care (SOCC) Group. The association between early arterial oxygenation and mortality in ventilated patients with acute ischaemic stroke. Critical Care and Resuscitation2012;14(1):14-9. [PMID: 22404056]">Young 2012</a>), possibly because adults who receive excessive oxygen supplementation in the ICU are the most ill, but it may also be that 'too much' oxygen is as harmful as 'too little' (<a href="./references#CD012631-bbs2-0139" title="KalletRH , MatthayMA . Hyperoxic acute lung injury. Respiratory Care2013;58(1):123-41. [DOI: 10.4187/respcare.01963] [PMID: 23271823]">Kallet 2013</a>). The harms associated with lung injury caused by mechanical ventilation as well as by oxygen toxicity following high FiO<sub>2</sub> may exceed the benefit of normalising oxygenation (PaO<sub>2</sub> and SaO<sub>2</sub>). </p> <p>Two meta‐analyses of observational data found an association between hyperoxemia and mortality after cardiac arrest, stroke, and traumatic brain injury (<a href="./references#CD012631-bbs2-0099" title="DamianiE , AdrarioE , GirardisM , RomanoR , PelaiaP , SingerM , et al. Arterial hyperoxia and mortality in critically ill patients: a systematic review and meta-analysis. Critical Care2014;18(6):711. [DOI: 10.1186/s13054-014-0711-x] [PMID: 25532567]">Damiani 2014</a>), and overall across critically ill adults (<a href="./references#CD012631-bbs2-0119" title="HelmerhorstHJ , Roos-BlomMJ , vanWesterlooDJ , deJongeE . Association between arterial hyperoxia and outcome in subsets of critical illness: a systematic review, meta-analysis, and meta-regression of cohort studies. Critical Care Medicine2015;43(7):1508-19. [DOI: 10.1097/CCM.0000000000000998] [PMID: 25855899]">Helmerhorst 2015</a>). Permissive hypoxaemia has been studied by Gilbert‐Kawai and colleagues (<a href="./references#CD012631-bbs2-0112" title="Gilbert-KawaiET , MitchellK , MartinD , CarlisleJ , GrocottMPW . Permissive hypoxaemia versus normoxaemia for mechanically ventilated critically ill patients. Cochrane Database of Systematic Reviews2014, Issue 5. Art. No: CD009931. [DOI: 10.1002/14651858.CD009931.pub2]">Gilbert‐Kawai 2014</a>), who compared permissive hypoxaemia to normoxemia (normal concentrations of oxygen in the blood) in critically ill adults in a systematic review, but found no relevant randomised controlled trials (RCTs). A recent systematic review of acutely ill adults found no evidence of a difference in mortality or serious adverse events when comparing the use of higher versus lower oxygenation strategies (<a href="./references#CD012631-bbs2-0079" title="BarbateskovicM , SchjørringOL , KraussSR , MeyhoffCS , JakobsenJC , RasmussenBS , et al. Higher vs lower oxygenation strategies in acutely ill adults: a systematic review with meta-analysis and trial sequential analysis. Chest2021;159(1):154-73. [DOI: 10.1016/j.chest.2020.07.015] [PMID: 32687907]">Barbateskovic 2021a</a>) in contrast to a previous review of similar design (<a href="./references#CD012631-bbs2-0091" title="ChuDK , KimLH , YoungPJ , ZamiriN , AlmenawerSA , JaeschkeR , et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet2018;391(10131):1693-705. [DOI: 10.1016/S0140-6736(18)30479-3] [PMID: 29726345]">Chu 2018</a>). </p> <p>Although the possible adverse effects of hyperoxemia are known, prevention of hypoxia through hyperoxemia seems to be prioritised (<a href="./references#CD012631-bbs2-0165" title="PannuSR , DziadzkoMA , GajicO . How much oxygen? Oxygen titration goals during mechanical ventilation. American Journal of Respiratory and Critical Care Medicine2016;193(1):4-5. [DOI: 10.1164/rccm.201509-1810ED] [PMID: 26720783]">Pannu 2016</a>). The ideal oxygenation target for adults admitted to the ICU is uncertain due to limited evidence from RCTs. Despite a lack of robust evidence of effectiveness, oxygen administration is widely recommended in international clinical practice guidelines (<a href="./references#CD012631-bbs2-0068" title="KallstromTJ , American Association for Respiratory Care. AARC clinical practice guideline. Oxygen therapy for adults in the acute care facility – 2002 revision &amp; update. Respiratory Care2002;47(6):717-20. [PMID: 12078655]">AARC 2002</a>; <a href="./references#CD012631-bbs2-0073" title="Australian Resuscitation Council. Guideline 11.6.1. targeted oxygen therapy in adult advanced life support; 2014. Available at: https://www.resus.org.nz/assets/Uploads/ANZCOR-Guideline-11.6.1-Targeted-Oxygen-Therapy-Jan2.pdf (accessed 17 December 2015).">ARC 2014</a>; <a href="./references#CD012631-bbs2-0103" title="DellingerRP , LevyMM , RhodesA , AnnaneD , GerlachH , OpalSM , et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Critical Care Medicine2013;41(2):580-637. [DOI: 10.1097/CCM.0b013e31827e83af] [PMID: 23353941]">Dellinger 2013</a>; <a href="./references#CD012631-bbs2-0163" title="O’DriscollBR , HowardLS , EarisJ , MakV , British Thoracic Society Emergency Oxygen Guideline Group, BTS Emergency Oxygen Guideline Development Group. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax2017;72(Suppl 1):ii1-90. [DOI: 10.1136/thoraxjnl-2016-209729] [PMID: 28507176]">O’Driscoll 2017</a>). However, it appears that a change towards a more restrictive approach is under way (<a href="./references#CD012631-bbs2-0091" title="ChuDK , KimLH , YoungPJ , ZamiriN , AlmenawerSA , JaeschkeR , et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet2018;391(10131):1693-705. [DOI: 10.1016/S0140-6736(18)30479-3] [PMID: 29726345]">Chu 2018</a>; <a href="./references#CD012631-bbs2-0184" title="SiemieniukRAC , ChuDK , KimLH , Güell-RousMR , AlhazzaniW , SoccalPM , et al. Oxygen therapy for acutely ill medical patients: a clinical practice guideline. British Medical Journal2018;363:k4169. [DOI: 10.1136/bmj.k4169] [PMID: 30355567]">Siemieniuk 2018</a>). </p> <p>Oxygen is a common intervention in adults admitted to the ICU and might have beneficial as well as harmful effects (<a href="./references#CD012631-bbs2-0116" title="HafnerS , BeloncleF , KochA , RadermacherP , AsfarP . Hyperoxia in intensive care, emergency, and peri-operative medicine: Dr. Jekyll or Mr. Hyde? A 2015 update. Annals of Intensive Care2015;5(1):42. [DOI: 10.1186/s13613-015-0084-6] [PMID: 26585328]">Hafner 2015</a>). The potential benefit of supplemental oxygen must be weighed against the potentially harmful effects of hyperoxemia. This is an update of a Cochrane Review (<a href="./references#CD012631-bbs2-0215" title="BarbateskovicM , SchjørringOL , KraussSR , JakobsenJC , MeyhoffCS , DahlRM , et al. Higher versus lower fraction of inspired oxygen or targets of arterial oxygenation for adults admitted to the intensive care unit. Cochrane Database of Systematic Reviews2019, Issue 11. Art. No: CD012631. [DOI: 10.1002/14651858.CD012631.pub2] [PMID: 31773728]">Barbateskovic 2019</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012631-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012631-sec-0014"></div> <p>To update the assessment of benefits and harms of higher versus lower fractions of inspired oxygen (FiO<sub>2</sub>) or targets of arterial oxygenation for adults admitted to the intensive care unit (ICU). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012631-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012631-sec-0015"></div> <section id="CD012631-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012631-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs), irrespective of publication status, reported outcomes, publication date, and language. </p> <p>We included unpublished trials only if methodological descriptions and trial data were provided by direct contact with trial authors or in written form. </p> <p>We excluded randomised cross‐over trials and quasi‐randomised trials.</p> </section> <section id="CD012631-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included trials on any adult participant aged 18 years or older admitted to the intensive care unit (ICU). We only included participants if they were admitted to the ICU when randomisation was performed. </p> </section> <section id="CD012631-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included trials having a clear differentiation of participants randomised to either a high or a low oxygenation strategy. Both mechanically ventilated and non‐mechanically ventilated adults were eligible for inclusion. In order to include all relevant trials, we did not use predefined arbitrary thresholds of oxygenation for the two groups. </p> <p><b>Experimental group:</b> adults receiving a high oxygenation strategy administered by any device, the aim of which was to ensure adequate oxygenation through exposure to hyperoxia in the lungs, either by high fraction of inspired oxygen (FiO<sub>2</sub>) or high‐target partial pressure of oxygen (PaO<sub>2</sub>) or arterial/peripheral oxygen saturation (SaO<sub>2</sub>/SpO<sub>2</sub>). </p> <p><b>Control group:</b> adults receiving a low oxygenation strategy administered by any device, the aim of which was to minimise exposure to hyperoxia in the lungs and reduce exposure to high FiO<sub>2</sub> or using a low‐target PaO<sub>2</sub> or SaO<sub>2</sub>/SpO<sub>2</sub>. </p> <p>Eligible trials were required to have a difference between the intervention and control groups of a minimum of 1 kPa (0.13 mmHg) in PaO<sub>2</sub>, 10% in FiO<sub>2</sub>, or 2% in SaO<sub>2</sub>/SpO<sub>2</sub>, either as aimed or achieved FiO<sub>2</sub> or oxygenation. We only required one of these separation criteria to be fulfilled (PaO<sub>2</sub>, SaO<sub>2</sub>, or FiO<sub>2</sub>), either aimed or achieved, for the trial to be eligible for inclusion. </p> <p>We excluded trials/groups randomised to hypoxaemia (FiO<sub>2</sub> below 0.21, SaO<sub>2</sub>/SpO<sub>2</sub> below 80%, and PaO<sub>2</sub> below 6 kPa). We furthermore excluded interventions with hyperbaric oxygen. </p> </section> <section id="CD012631-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We chose the following measures as outcomes.</p> <section id="CD012631-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012631-list-0004"> <li> <p>All‐cause mortality at maximum follow‐up.</p> </li> <li> <p>Proportion of participants with one or more serious adverse events (SAEs), defined as a dichotomous outcome according to participants having at least one SAE or none at maximum follow‐up. We defined an SAE as any untoward medical occurrence that: resulted in death; was life‐threatening; required hospitalisation, or prolongation of existing hospitalisation; resulted in persistent or significant disability; or jeopardised the participant, according to the International Conference on Harmonisation Good Clinical Practice (<a href="./references#CD012631-bbs2-0130" title="International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH) adopts consolidated guideline on good clinical practice in the conduct of clinical trials on medicinal products for human use. International Digest of Health Legislation1997;48(2):231-4. [PMID: 11656783]">ICH‐GCP 1997</a>). We considered all other adverse events as non‐serious (<a href="./references#CD012631-bbs2-0130" title="International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH) adopts consolidated guideline on good clinical practice in the conduct of clinical trials on medicinal products for human use. International Digest of Health Legislation1997;48(2):231-4. [PMID: 11656783]">ICH‐GCP 1997</a>). We performed two analyses being the highest proportion reported of any specific SAE and the cumulated number of SAEs. As secondary analyses, we analysed each SAE separately, and conducted an analysis including only trials specifically reporting 'proportion of participants with one or more SAEs'. </p> </li> <li> <p>Quality of life (any valid scale such as the 36‐item Short Form Health Survey (SF‐36)) at maximum follow‐up. </p> </li> </ol> </p> </section> <section id="CD012631-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012631-list-0005"> <li> <p>Lung injury diagnosed after randomisation (composite outcome) at maximum follow‐up. This composite outcome was defined as either: acute respiratory distress syndrome (ARDS) (as defined by the Berlin criteria (<a href="./references#CD012631-bbs2-0074" title="RanieriVM , RubenfeldGD , ThompsonBT , FergusonND , CaldwellE , FanE , et al, ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin definition. Journal of American Medical Association2012;307(23):2526-33. [DOI: 10.1001/jama.2012.5669] [PMID: 22797452]">ARDS Definition Task Force 2012</a>), or as defined by trialists); pulmonary fibrosis (defined as evolved from any cause, or as defined by trialists); or pneumonia (defined as pneumonia occurring 48 hours or more after admission in non‐intubated participants, or pneumonia arising more than 48 to 72 hours after endotracheal intubation (<a href="./references#CD012631-bbs2-0076" title="American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. American Journal of Respiratory and Critical Care Medicine2005;171(4):388-416. [DOI: 10.1164/rccm.200405-644ST] [PMID: 15699079]">ATS 2005</a>), or as defined by trialists). As a secondary analysis, we analysed each component of the composite outcome separately. We performed two analyses on the proportion of participants with one or more lung injuries. </p> </li> <li> <p>Myocardial infarction diagnosed after randomisation at maximum follow‐up (defined as the demonstration of myocardial cell death due to significant and sustained ischaemia (<a href="./references#CD012631-bbs2-0195" title="ThygesenK , AlpertJS , JaffeAS , SimoonsML , ChaitmanBR , WhiteHD , Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction, Authors/Task Force Members Chairpersons, Biomarker Subcommittee, ECG Subcommittee, Imaging Subcommittee, Classification Subcommittee, et al. Third universal definition of myocardial infarction. Journal of American College of Cardiology2012;60(16):1581-98. [DOI: 10.1016/j.jacc.2012.08.001] [PMID: 22923432]">Thygesen 2012</a>), or as defined by trialists). </p> </li> <li> <p>Stroke diagnosed after randomisation at maximum follow‐up (defined as central nervous system infarction, ischaemic stroke, silent central nervous system infarction, intracerebral haemorrhage, stroke caused by intracerebral haemorrhage, silent cerebral haemorrhage, subarachnoid haemorrhage, stroke caused by subarachnoid haemorrhage, stroke caused by cerebral venous thrombosis, and stroke not otherwise specified (<a href="./references#CD012631-bbs2-0180" title="SaccoRL , KasnerSE , BroderickJP , CaplanLR , ConnorsJJ , CulebrasA , et al, American Heart Association Stroke Council, Council on Cardiovascular Surgery and Anesthesia, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, Council on Peripheral Vascular Disease, Council on Nutrition, Physical Activity and Metabolism. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke2013;44(7):2064-89. [DOI: 10.1161/STR.0b013e318296aeca] [PMID: 23652265]">Sacco 2013</a>), or as defined by trialists). </p> </li> <li> <p>Sepsis diagnosed after randomisation at maximum follow‐up (defined as sepsis plus sepsis‐induced organ dysfunction or tissue hypoperfusion (<a href="./references#CD012631-bbs2-0103" title="DellingerRP , LevyMM , RhodesA , AnnaneD , GerlachH , OpalSM , et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Critical Care Medicine2013;41(2):580-637. [DOI: 10.1097/CCM.0b013e31827e83af] [PMID: 23353941]">Dellinger 2013</a>), or as defined by trialists). </p> </li> </ol> </p> </section> </section> </section> <section id="CD012631-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for trials as described in Cochrane Handbook of Systematic Reviews of Intervention Chapter 4 (<a href="./references#CD012631-bbs2-0146" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Lefebvre 2021</a>). For the Embase search we used the trial filter suggested in the Cochrane Handbook version 5.1.0 (<a href="./references#CD012631-bbs2-0125" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011b</a>). For the rest of the searches, we used a search filter that was reviewed and adjusted by a Cochrane Information specialist (<a href="#CD012631-sec-0200">Differences between protocol and review</a>). Details on search filters are provided below. We identified eligible RCTs through literature searching with systematic and sensitive search strategies specifically designed to identify relevant RCTs without restrictions to language, publication year, and journal. </p> <section id="CD012631-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases:</p> <p> <ol id="CD012631-list-0006"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 10, 2022 (<a href="./appendices#CD012631-sec-0168">Appendix 1</a>); </p> </li> <li> <p>MEDLINE (Ovid, 1946 to 22 November 2022) (<a href="./appendices#CD012631-sec-0169">Appendix 2</a>); </p> </li> <li> <p>Embase (Ovid, 1974 to 22 November 2022) (<a href="./appendices#CD012631-sec-0170">Appendix 3</a>); </p> </li> <li> <p>Web of Science/BIOSIS Previews (1969 to 22 November 2022) (<a href="./appendices#CD012631-sec-0171">Appendix 4</a>); </p> </li> <li> <p>Latin American and Caribbean Health Science Information database (LILACS) (1982 to 22 November 2022) (<a href="./appendices#CD012631-sec-0172">Appendix 5</a>). </p> </li> </ol> </p> <p>CINAHL was searched for the primary edition of this review (<a href="./references#CD012631-bbs2-0215" title="BarbateskovicM , SchjørringOL , KraussSR , JakobsenJC , MeyhoffCS , DahlRM , et al. Higher versus lower fraction of inspired oxygen or targets of arterial oxygenation for adults admitted to the intensive care unit. Cochrane Database of Systematic Reviews2019, Issue 11. Art. No: CD012631. [DOI: 10.1002/14651858.CD012631.pub2] [PMID: 31773728]">Barbateskovic 2019</a>), but not for the updated version due to access restrictions. </p> </section> <section id="CD012631-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We manually screened the reference lists of included trial reports, reviews, relevant papers, randomised and non‐randomised trials, and editorials for potentially relevant trials. </p> <p>Furthermore, two review authors independently and in pair, searched for ongoing and unpublished trials in the following trial registers: </p> <p> <ol id="CD012631-list-0007"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://ClinicalTrials.gov" target="_blank">clinicaltrials.gov</a>) (searched 28 October 2022); </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>) (searched 28 October 2022); </p> </li> <li> <p>EU Clinical Trials Register (<a href="https://www.clinicaltrialsregister.eu/" target="_blank">www.clinicaltrialsregister.eu/</a>) (searched 28 October 2022); </p> </li> <li> <p>Australian New Zealand Clinical Trials Registry (ANZCTR) (<a href="http://www.anzctr.org.au/" target="_blank">www.anzctr.org.au/</a>) (searched 28 October 2022). </p> </li> </ol> </p> <p>See <a href="./appendices#CD012631-sec-0173">Appendix 6</a> for trial registry search strategy. </p> <p>We searched for systematic reviews in Epistemonikos (<a href="https://www.epistemonikos.org" target="_blank">www.epistemonikos.org</a>) (<a href="./appendices#CD012631-sec-0174">Appendix 7</a>).<br/>Backward and forward citation searches for all included trials were performed using Web of Science.<br/>We also checked for retractions using the Retraction Watch database (<a href="http://retractiondatabase.org/" target="_blank">retractiondatabase.org</a>).<br/>We used Covidence to reduplicate the references before screening the search result.<br/>The searches were developed and run by the review authors and peer‐reviewed by the Cochrane Emergency and Critical Care Information Specialist.<br/>We contacted trial authors and experts in the field for additional information. </p> </section> </section> <section id="CD012631-sec-0026"> <h3 class="title" id="CD012631-sec-0026">Data collection and analysis</h3> <p>We used the following methods for data collection and data analyses. Any discrepancies between the primary review and this updated version are described in detail in the following sections, and any changes made from the protocol are summarised in <a href="#CD012631-sec-0200">Differences between protocol and review</a>. </p> <section id="CD012631-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Four review authors (TLK, OLS, FMN, or MB), independently and in pairs, screened each title and abstract of all reports identified by the searches. We obtained the full texts of those reports deemed potentially relevant and assessed these for inclusion in the review. Disagreements were resolved by consensus or by consulting another review author (OLS, MB, or JW) when necessary. </p> </section> <section id="CD012631-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Four review authors (TLK, OLS, FMN, or MB) independently and in pairs, extracted predefined data of the included trials using a data collection form that was specifically designed and piloted by the review team (<a href="./appendices#CD012631-sec-0175">Appendix 8</a>). We collected the following data. </p> <p> <ol id="CD012631-list-0008"> <li> <p>Trial: country, duration of the trial, date of publication, and type of trial.</p> </li> <li> <p>Participants: numbers randomised, numbers analysed, numbers lost to follow‐up or withdrawn, type of population, mean or median age, sex, inclusion criteria, and exclusion criteria. </p> </li> <li> <p>Interventions: intervention, comparator, and concomitant interventions.</p> </li> <li> <p>Outcomes: predefined primary and secondary outcomes.</p> </li> </ol> </p> <p>Any disagreements concerning the extracted data were resolved by discussion or by consulting a third review author (OLS, MB, or JW) when necessary. </p> </section> <section id="CD012631-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For this updated review we assessed risk of bias according to the latest <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012631-bbs2-0128" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021</a>) using the risk of bias tool 2, (RoB 2) (<a href="./references#CD012631-bbs2-0126" title="HigginsJPT , SterneJAC , SavovićJ , PageMJ , HróbjartssonA , BoutronI , et al. A revised tool for assessing risk of bias in randomized trials. In: Chandler J, McKenzie J, Boutron I, Welch V (editors). Cochrane Methods. Cochrane Database of Systematic Reviews, 2016. Available from cochranelibrary.com/cdsr/doi/10.1002/14651858.CD201601/full. [DOI: dx.doi.org/10.1002/14651858.CD201601]">Higgins 2016</a>; <a href="./references#CD012631-bbs2-0189" title="SterneJAC , SavovićJ , PageMJ , ElbersRG , BlencoweNS , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. British Medical Journal2019;366:l4898. [DOI: 10.1136/bmj.l4898] [PMID: 31462531]">Sterne 2019</a>), employing the criteria described in <a href="./appendices#CD012631-sec-0176">Appendix 9</a>. For cluster‐randomised trials we used the dedicated tool updated 18 March 2021. </p> <p>Two review authors (TLK or FMN) independently assessed the methodological quality of each included trial and outcome, as defined by the design of the trial and reporting. Any disagreements were resolved by discussion or consultation with a third review author (OLS or MB). </p> <p>We assessed the following risk of bias domains for all included trials and outcomes: 1) risk of bias arising from the randomisation process; 2) risk of bias due to deviations from the intended interventions (effect of assignment to intervention); 3) risk of bias due to missing outcome data; 4) risk of bias in measurement of the outcome; and 5) risk of bias in selection of the reported result. </p> <p>Each domain was judged as being at “low risk of bias”, “some concerns”<b><i>,</i> </b> or “high risk of bias”. RCTs with “low risk of bias” in all domains were classified as being at overall “low risk of bias”. RCTs with one domain judged to be at “some concerns”, but no domain judged to be at “high risk of bias”, were classified as being at overall “some concerns” of risk of bias. RCTs were classified as being at overall “high risk of bias” if at least one domain was judged as being at “high risk of bias”. However, if a trial was judged to be at “some concerns” due to risk of bias for multiple domains, it may have been judged as being at overall “high risk of bias” if the assessors judged that the multiple concerns amounted to a serious risk of bias (<a href="./references#CD012631-bbs2-0126" title="HigginsJPT , SterneJAC , SavovićJ , PageMJ , HróbjartssonA , BoutronI , et al. A revised tool for assessing risk of bias in randomized trials. In: Chandler J, McKenzie J, Boutron I, Welch V (editors). Cochrane Methods. Cochrane Database of Systematic Reviews, 2016. Available from cochranelibrary.com/cdsr/doi/10.1002/14651858.CD201601/full. [DOI: dx.doi.org/10.1002/14651858.CD201601]">Higgins 2016</a>; <a href="./references#CD012631-bbs2-0189" title="SterneJAC , SavovićJ , PageMJ , ElbersRG , BlencoweNS , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. British Medical Journal2019;366:l4898. [DOI: 10.1136/bmj.l4898] [PMID: 31462531]">Sterne 2019</a>). </p> <p>We provided a summary assessment of the risk of bias across trials and for each important outcome (across domains) by preparing a summary of findings table, risk of bias graph, and a risk of bias summary figure (<a href="./references#CD012631-bbs2-0126" title="HigginsJPT , SterneJAC , SavovićJ , PageMJ , HróbjartssonA , BoutronI , et al. A revised tool for assessing risk of bias in randomized trials. In: Chandler J, McKenzie J, Boutron I, Welch V (editors). Cochrane Methods. Cochrane Database of Systematic Reviews, 2016. Available from cochranelibrary.com/cdsr/doi/10.1002/14651858.CD201601/full. [DOI: dx.doi.org/10.1002/14651858.CD201601]">Higgins 2016</a>; <a href="./references#CD012631-bbs2-0189" title="SterneJAC , SavovićJ , PageMJ , ElbersRG , BlencoweNS , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. British Medical Journal2019;366:l4898. [DOI: 10.1136/bmj.l4898] [PMID: 31462531]">Sterne 2019</a>). This was also done for trials judged to be at overall 'low risk of bias' only. </p> </section> <section id="CD012631-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated the risk ratio (RR) with 95% confidence interval (Cl) and Trial Sequential Analysis (TSA) CI, adjusted for multiple outcomes, sparse data, and repetitive testing due to updating with new trials for dichotomous outcomes. For continuous outcomes, we planned to include both end scores and change scores in the analyses; we planned to use end scores if both were reported. We planned to calculate the mean difference (MD) and standardised mean difference (SMD) with 95% CIs and TSA CI, adjusted for multiple outcomes, sparse data, and repetitive testing for continuous outcomes. </p> </section> <section id="CD012631-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>If trials were identified employing three different oxygenation targets, we would have combined the two experimental intervention groups of the study (if they each fulfilled the minimum difference compared with the control group of 1 kPa (0.13 mmHg) in PaO<sub>2</sub>, 10% in FiO<sub>2</sub>, or 2% in SaO<sub>2</sub>/SpO<sub>2</sub>) into a single group and compared these with the control group. If only one of the experimental groups fulfilled the minimum difference to the control, this group was compared to the control group. </p> <p>For multi‐arm trials that compare, for example, three different oxygenation targets, where the control group is the middle group, and the minimum difference in oxygenation target was fulfilled, we planned to compare the higher oxygenation group with the control group, as the lower group would be excluded due to being randomised to an extreme permissive hypoxaemia. </p> <p>For cluster‐randomised trials, we planned to define the ICU as the unit of allocation, and we would have used the generic inverse‐variance method in Review Manager 5 to calculate effect estimates for these trials (<a href="./references#CD012631-bbs2-0175" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> </section> <section id="CD012631-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We contacted trial investigators of the original reports for important missing data.</p> <p>We did not impute missing data for any outcomes in the primary analysis, and we did not use intention‐to‐treat data if the original report did not contain such data. </p> <p>If trial reports did not report standard deviations (SDs), we planned to calculate the SDs using data from the trial report if possible. </p> <p>We used imputed data in the sensitivity analysis for dichotomous and continuous outcomes (see <a href="#CD012631-sec-0041">Sensitivity analysis</a>). </p> </section> <section id="CD012631-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed signs of heterogeneity by visual inspection of the forest plots.</p> <p>We assessed the presence of statistical heterogeneity using the Chi<sup>2</sup> test with significance set at P &lt; 0.10, and by measuring the quantities of heterogeneity using the I<sup>2</sup> statistic (<a href="./references#CD012631-bbs2-0123" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. British Medical Journal2003;327(7414):557-60. [DOI: 10.1136/bmj.327.7414.557] [PMID: 12958120]">Higgins 2003</a>). Overall, we considered an I<sup>2</sup> statistic of 0% to 40% as not important, 30% to 60% as moderate, 50% to 90% as substantial, and 75% to 100% as considerable heterogeneity (<a href="./references#CD012631-bbs2-0128" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021</a>). High statistical heterogeneity is generally more prevalent when meta‐analysing continuous outcomes (<a href="./references#CD012631-bbs2-0072" title="AlbaAC , AlexanderPE , ChangJ , MacIsaacJ , DeFryS , GuyattGH . High statistical heterogeneity is more frequent in meta-analysis of continuous than binary outcomes. Journal of Clinical Epidemiology2016;70:129-35. [DOI: 10.1016/j.jclinepi.2015.09.005] [PMID: 26386323]">Alba 2016</a>). Because we anticipated large clinical heterogeneity as well as statistical heterogeneity, we generally preferred to use a random‐effects model. However, if one or two trials dominate the acquired evidence (e.g. with more than 80% of the randomised participants) the random‐effects model may grossly overestimate the intervention effect (<a href="./references#CD012631-bbs2-0122" title="HigginsJP , SpiegelhalterDJ . Being sceptical about meta-analyses: a Bayesian perspective on magnesium trials in myocardial infarction. International Journal of Epidemiology2002;31(1):96-104. [DOI: 10.1093/ije/31.1.96] [PMID: 11914302]">Higgins 2002</a>; <a href="./references#CD012631-bbs2-0149" title="Magnesium in Coronaries (MAGIC) Trial Investigators. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. Lancet2002;360(9341):1189-96. [DOI: 10.1016/s0140-6736(02)11278-5] [PMID: 12401244]">MAGIC 2002</a>; <a href="./references#CD012631-bbs2-0205" title="WoodsKL , AbramsK . The importance of effect mechanism in the design and interpretation of clinical trials: the role of magnesium in acute myocardial infarction. Progress in Cardiovascular Diseases2002;44(4):267-74. [DOI: 10.1053/pcad.2002.31595] [PMID: 12007082]">Woods 2002</a>). In such a situation, we would primarily have reported the results from a fixed‐effect model. Hence, we primarily reported the result from the model with the most conservative point estimate of the two, being the estimate closest to zero effect (<a href="./references#CD012631-bbs2-0135" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [DOI: 10.1186/1471-2288-14-120] [PMID: 25416419]">Jakobsen 2014a</a>). If the two estimates were approximately equal, we used the estimate with the widest CI. </p> <p>We explored potential clinical heterogeneity by conducting the prespecified subgroup analyses (see <a href="#CD012631-sec-0040">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> <section id="CD012631-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We visually assessed funnel plots for signs of asymmetry if an analysis included 10 or more trials (<a href="./references#CD012631-bbs2-0128" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021</a>; <a href="./references#CD012631-bbs2-0135" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [DOI: 10.1186/1471-2288-14-120] [PMID: 25416419]">Jakobsen 2014a</a>). </p> <p>We tested asymmetry within dichotomous outcomes using the Harbord test (<a href="./references#CD012631-bbs2-0118" title="HarbordRM , EggerM , SterneJA . A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Statistics in Medicine2006;25(20):3443-57. [DOI: 10.1002/sim.2380] [PMID: 16345038]">Harbord 2006</a>), and for continuous outcomes using the asymmetry test (<a href="./references#CD012631-bbs2-0108" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. British Medical Journal1997;315(7109):629-34. [DOI: 10.1136/bmj.315.7109.629] [PMID: 9310563]">Egger 1997</a>). We also used the adjusted rank correlation (<a href="./references#CD012631-bbs2-0081" title="BeggCB , MazumdarM . Operating characteristics of a rank correlation test for publication bias. Biometrics1994;50(4):1088-101. [PMID: 7786990]">Begg 1994</a>). </p> </section> <section id="CD012631-sec-0035"> <h4 class="title">Data synthesis</h4> <section id="CD012631-sec-0036"> <h5 class="title">Meta‐analysis</h5> <p>We undertook the systematic review according to the recommendations provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> and the eight‐step assessment suggested by Jakobsen and colleagues (<a href="./references#CD012631-bbs2-0128" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al. Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021</a>; <a href="./references#CD012631-bbs2-0135" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [DOI: 10.1186/1471-2288-14-120] [PMID: 25416419]">Jakobsen 2014a</a>), including trial sequential analysis (TSA)and calculation of Bayes factors. We performed meta‐analyses of outcomes with comparable effect measures where more than one trial was included. If clinical and statistical heterogeneity were large or unexpected, we planned to reconsider performing meta‐analysis. We used the statistical software Review Manager Web (RevMan Web, version 3.6.0, The Cochrane Collaboration, 28 June 2021, available at <a href="http://revman.cochrane.org/" target="_blank">revman.cochrane.org</a>) and the TSA software version 0.9 CTU to analyse data (<a href="./references#CD012631-bbs2-0175" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>; <a href="./references#CD012631-bbs2-0196" title="Trial sequential analysis. Version 0.9 Beta. Copenhagen: Copenhagen Trial Unit, 2011. www.ctu.dk/tsa/downloads.aspx.">TSA 2011</a>) and the STATA software version 17 (<a href="./references#CD012631-bbs2-0187" title="Stata. Version 15. College Station, TX, USA: StataCorp, 2017. Available at www.stata.com.">STATA 2017</a>). </p> </section> <section id="CD012631-sec-0037"> <h5 class="title">Assessment of significance</h5> <p>We assessed our intervention effects with both random‐effects model meta‐analyses (<a href="./references#CD012631-bbs2-0102" title="DeeksJJ , HigginsJPT . Statistical algorithms in Review Manager 5.1. Cochran, 2010. Available from training.cochrane.org/handbook/current/statistical-methods-revman52010.">Deeks 2010</a>; <a href="./references#CD012631-bbs2-0105" title="DerSimonianR , LairdN . Meta-analysis in clinical trials. Controlled Clinical Trials1986;7(3):177-88. [DOI: 10.1016/0197-2456(86)90046-2] [PMID: 3802833]">DerSimonian 1986</a>; <a href="./references#CD012631-bbs2-0150" title="MantelN , HaenszelW . Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute1959;22(4):719-48. [PMID: 13655060]">Mantel 1959</a>) and fixed‐effect model meta‐analyses (<a href="./references#CD012631-bbs2-0104" title="DeMetsDL . Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine1987;6(3):341-50. [DOI: 10.1002/sim.4780060325] [PMID: 3616287]">DeMets 1987</a>; <a href="./references#CD012631-bbs2-0150" title="MantelN , HaenszelW . Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute1959;22(4):719-48. [PMID: 13655060]">Mantel 1959</a>), and reported the most conservative estimate, being the point estimate closest to no effect, or the estimate with the widest CI if the two models produced comparable point estimates. </p> <p>We used three co‐primary outcomes and therefore considered P ≤ 0.025 as statistically significant in the analyses of the primary outcomes (<a href="./references#CD012631-bbs2-0135" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [DOI: 10.1186/1471-2288-14-120] [PMID: 25416419]">Jakobsen 2014a</a>; <a href="./references#CD012631-bbs2-0137" title="JakobsenJC , WetterslevJ , LangeT , GluudC . Comment on: Taking into account risks of random errors when analysing multiple outcomes in systematic reviews. www.cochranelibrary.com/cdsr/doi/10.1002/14651858.ED000111/full 18 March 2016. [DOI: 10.1002/14651858.ED000111] [PMID: 27030037]">Jakobsen 2016</a>). We used four co‐secondary outcomes and therefore considered P ≤ 0.02 as statistically significant when analysing the secondary outcomes (<a href="./references#CD012631-bbs2-0135" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [DOI: 10.1186/1471-2288-14-120] [PMID: 25416419]">Jakobsen 2014a</a>). We used the eight‐step procedure to assess if the thresholds for significance were crossed (<a href="./references#CD012631-bbs2-0135" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [DOI: 10.1186/1471-2288-14-120] [PMID: 25416419]">Jakobsen 2014a</a>). </p> </section> <section id="CD012631-sec-0038"> <h5 class="title">Trial Sequential Analysis (TSA)</h5> <p>We analysed all primary and secondary outcomes with TSA. We estimated the diversity (meta‐analytic heterogeneity‐adjustment factor) and calculated the required information size (<a href="./references#CD012631-bbs2-0202" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology2009;9:86. [DOI: 10.1186/1471-2288-9-86] [PMID: 20042080]">Wetterslev 2009</a>), based on the proportion of participants with an outcome in the control group. In addition, we used a family‐wise error rate of 5% (<a href="./references#CD012631-bbs2-0135" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [DOI: 10.1186/1471-2288-14-120] [PMID: 25416419]">Jakobsen 2014a</a>), leading to a statistical significance level of 2.5% for each of the co‐primary outcomes, a beta of 10%, and a diversity (D<sup>2</sup>) (<a href="./references#CD012631-bbs2-0202" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology2009;9:86. [DOI: 10.1186/1471-2288-9-86] [PMID: 20042080]">Wetterslev 2009</a>) suggested by the trials in the meta‐analysis (<a href="./references#CD012631-bbs2-0135" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [DOI: 10.1186/1471-2288-14-120] [PMID: 25416419]">Jakobsen 2014a</a>). We have presented TSA CIs, adjusted for multiple outcomes, sparse data, and repetitive testing (<a href="./references#CD012631-bbs2-0113" title="GluudC , ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG . User manual for Trial Sequential Analysis (TSA). ctu.dk/wp-content/uploads/2021/03/2017-10-10-TSA-Manual-ENG_ER.pdf (accessed February 2016).">Gluud 2011</a>). As a sensitivity analysis, we used a diversity of 20% if the actual, measured heterogeneity was zero because in this case heterogeneity will most likely increase when further trials are added until the required information size is reached. As anticipated intervention effects for the primary and secondary outcomes in the TSA, we used realistic a priori relative risk reduction (RRR) of 20% or a 20% relative risk increase (RRI). Furthermore, we used an RRR or an RRI based on the confidence limit closest to null effect in the 95% Cl in the traditional meta‐analysis, i.e the expected intervention effect would equal the difference from no effect (RR = 1) and the confidence limit closest to 1. As a post‐hoc sensitivity analysis we performed TSA using an anticipated RRR or RRI of 10%. See <a href="#CD012631-sec-0200">Differences between protocol and review</a>. </p> <p>No TSA‐plot or TSA CI was presented if the information size for any outcome was less than 5%. </p> <p>For additional details see <a href="./appendices#CD012631-sec-0183">Appendix 10</a>. </p> </section> <section id="CD012631-sec-0039"> <h5 class="title">Bayes factor</h5> <p>We calculated Bayes factors for the co‐primary outcomes, which is the ratio between the probability of the meta‐analysis result given the null hypothesis (H₀) is true divided by the probability of the meta‐analysis result given the alternative hypothesis (H<sub>A</sub>) is true using a Bayes factor calculator (<a href="./references#CD012631-bbs2-0080" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Bayes factor calculation. https://ctu.dk/tools-and-links/bayes-factor-calculation/ (accessed 13 August 2019).">Bayes factor calculator 2014</a>). </p> </section> </section> <section id="CD012631-sec-0040"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We meta‐analysed all included trials regardless of oxygenation strategy (PaO<sub>2</sub>, SaO<sub>2</sub>, SpO<sub>2</sub>, FiO<sub>2</sub>). We believed a meta‐analysis of the specified strategies was feasible, as the amount of oxygen absorbed overlaps to a great extent. Whether FiO<sub>2</sub> is raised, or the aim is a higher target oxygenation, the result is that more oxygen is delivered, and the oxygenation parameters will be elevated in both strategies. However, we recognise that, especially in adults with acute respiratory distress syndrome (ARDS), there are individuals where it would be extremely difficult to reach a predefined target of oxygenation by either strategy, but both strategies would certainly expose the lungs to high oxygen levels, whilst other individuals may subsequently develop different PaO<sub>2</sub> levels with the two strategies. </p> <p>We sought to determine if the efficacy and safety of the treatment options were influenced by types of ICU populations and type of oxygen administration. </p> <p>We performed the following subgroup analyses.</p> <p>1. According to overall risk of bias.</p> <p> <ol id="CD012631-list-0009"> <li> <p>Overall low risk of bias</p> </li> <li> <p>Overall some concern</p> </li> <li> <p>Overall high risk of bias</p> </li> </ol> </p> <p>2. According to different types of oxygen interventions.</p> <p>a. Oxygenation target measured using either PaO<sub>2</sub>, SaO<sub>2</sub>, or SpO<sub>2</sub> (as defined by trialists) </p> <p>b.Oxygen level defined by FiO<sub>2</sub> (as defined and set by trialists) </p> <p>c. Difference between groups (as defined by trialists)</p> <p>3. According to FiO<sub>2</sub> or oxygenation/target in the higher‐oxygen‐administration group. </p> <p>a. Low targets defined as FiO<sub>2</sub> of 0.5 or lower, or PaO<sub>2</sub> of 10 kPa (75 mmHg) or lower, or SaO<sub>2</sub>/SpO<sub>2</sub> of 95% or lower </p> <p>b, High targets defined as FiO<sub>2</sub> above 0.5, or PaO<sub>2</sub> above 10 kPa (75 mmHg), or SaO<sub>2</sub>/SpO<sub>2</sub> above 95% </p> <p>4. According to FiO<sub>2</sub> or oxygenation/target in the lower‐oxygen‐administration group. </p> <p>a.Low targets defined as FiO<sub>2</sub> between or at 0.21 to 0.30, or PaO<sub>2</sub> between or at 6 kPa to 8 kPa (45 to 60 mmHg), or SaO<sub>2</sub>/SpO<sub>2</sub> between or at 85% to 90% </p> <p>b. High targets defined as FiO<sub>2</sub> above 0.30 to 0.40, or PaO<sub>2</sub> above 8 kPa to 10 kPa (60 to 75 mmHg), or SaO<sub>2</sub>/SpO<sub>2</sub> above 90% </p> <p>5. According to ICU population.</p> <p> <ol id="CD012631-list-0010"> <li> <p>Medical</p> </li> <li> <p>Surgical</p> </li> <li> <p>Mixed</p> </li> <li> <p>Adults with any respiratory failure</p> </li> <li> <p>Adults with any cerebral disease</p> </li> <li> <p>Adults with any heart disease</p> </li> <li> <p>Adults with any trauma</p> </li> <li> <p>Adults with chronic obstructive pulmonary disease (COPD)</p> </li> </ol> </p> <p>6. According to oxygen delivery system.</p> <p>a. Invasive mechanical ventilation with an endotracheal tube</p> <p>b. Any non‐invasive oxygen administration</p> <p>c. Mixed oxygen delivery system</p> </section> <section id="CD012631-sec-0041"> <h4 class="title">Sensitivity analysis</h4> <p>To assess the potential impact of bias, we planned to conduct a sensitivity analysis for each outcome including only trials at overall 'low risk of bias'. </p> <p>To assess the potential impact of the missing data for dichotomous outcomes, we performed the two following analyses. </p> <p> <ol id="CD012631-list-0011"> <li> <p>'Best‐worst‐case' scenario: we assumed that all participants lost to follow‐up in the experimental group survived, had no serious adverse event, and had no morbidity; and all participants with missing outcomes in the control group did not survive, had a serious adverse event, and had morbidity. </p> </li> <li> <p>'Worst‐best‐case' scenario: we assumed that all participants lost to follow‐up in the experimental group did not survive, had a serious adverse event, and had morbidity; and all participants with missing outcomes in the control group did survive, had no serious adverse event, and had no morbidity. </p> </li> </ol> </p> <p>Results from both scenarios are presented in the review.</p> <p>To assess the potential impact of the missing data for continuous outcomes, we planned to perform the two following analyses. </p> <p> <ol id="CD012631-list-0012"> <li> <p>'Best‐worst‐case' scenario: we assumed that all participants lost to follow‐up in the experimental group had mean (from participants with follow‐up) + 2 × SD, and all participants with missing outcomes in the control group had mean (from participants with follow‐up) − 2 × SD. </p> </li> <li> <p>'Worst‐best‐case' scenario: we assumed that all participants lost to follow‐up in the experimental group had mean (from participants with follow‐up) − 2 × SD, and all participants with missing outcomes in the control group had mean (from participants with follow‐up) + 2 × SD (<a href="./references#CD012631-bbs2-0135" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [DOI: 10.1186/1471-2288-14-120] [PMID: 25416419]">Jakobsen 2014a</a>). </p> </li> </ol> </p> <p>To assess the potential impact of missing SDs for continuous outcomes, we planned to perform the following sensitivity analyses. Where SDs were missing, and it was not possible to calculate them, we planned to impute SDs from trials with similar populations and low risk of bias. If there were no such trials, we planned to impute SDs from trials with a similar population. As the final option, we planned to impute SDs from all trials. </p> <p>To assess the potential impact of meta‐analysing trials comparing two low targets (FiO<sub>2</sub> below 0.5, or PaO<sub>2</sub> below 10 kPa (75 mmHg), or SaO<sub>2</sub>/SpO<sub>2</sub> below 95%) or two high targets (FiO<sub>2</sub> above 0.5, or PaO<sub>2</sub> above 10 kPa (75 mmHg), or SaO<sub>2</sub>/SpO<sub>2</sub> above 95%), we performed sensitivity analyses excluding trials comparing two low targets or two high targets. </p> </section> <section id="CD012631-sec-0042"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADEpro GDT system (<a href="./references#CD012631-bbs2-0114" title="GRADEpro GDT. Version accessed 25 March 2019. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a>) to assess the certainty of the body of evidence associated with each of the primary outcomes (all‐cause mortality, proportion of participants with one or more serious adverse events, quality of life) and secondary outcomes (lung injury, acute myocardial infarction, stroke, sepsis) and constructed summary of findings tables (<a href="./references#CD012631-bbs2-0115" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al, GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. British Medical Journal2008;336(7650):924-6. [DOI: 10.1136/bmj.39489.470347.AD] [PMID: 18436948]">Guyatt 2008</a>); one including data only from trials at overall low risk of bias and one including data from all trials. </p> <p>The GRADE approach appraises the certainty of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. The measure of a body of evidence considers the within‐trial risks of bias, directness of the evidence, heterogeneity of the data, precision of effect estimates (<a href="./references#CD012631-bbs2-0135" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [DOI: 10.1186/1471-2288-14-120] [PMID: 25416419]">Jakobsen 2014a</a>), and risk of publication bias. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012631-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012631-sec-0043"></div> <section id="CD012631-sec-0044"> <h3 class="title">Description of studies</h3> <p>The identified trials are described below.</p> <section id="CD012631-sec-0045"> <h4 class="title">Results of the search</h4> <p>The searches have been run several times with records imported to Covidence during the process of the first version and this updated review. In total 167,270 records have been imported. </p> <p>For the first version of this review, a total of 32,813 titles and abstracts were screened, which entailed forward and backward citation searches, clinical trial registers, and grey literature. Of these, a total of 303 full‐text records were assessed, excluding 293, resulting in 10 trials included in the qualitative synthesis, and seven trials in the quantitative synthesis. </p> <p>In this updated review, a total of 24,899 new titles and abstracts were screened, which entailed forward and backward citation searches, clinical trial registers, and grey literature. </p> <p>In total, we obtained 721 full‐text reports to assess eligibility, and excluded 711 references (190 wrong intervention, 169 duplicate full‐text, 161 wrong patient population (34 key trials), 102 wrong study design, 76 wrong publication type, 13 ongoing trials (<a href="./references#CD012631-bbs2-0055" title="ACTRN12620000391976. The mega randomised registry trial comparing conservative vs. liberal oxygenation targets [A randomised, registry-embedded, single blinded clinical trial comparing conservative oxygen therapy to liberal oxygen therapy in mechanically ventilated adults in the intensive care unit]. anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379432&amp;isReview=true (first received 10 March 2020). ">ACTRN12620000391976</a>; <a href="./references#CD012631-bbs2-0056" title="ChiCTR-INR-17012800. The effect of conservative oxygen therapy in the mechanical ventilation patients. chictr.org.cn/showproj.html?proj=21892 (first received 26 September 2017). ">ChiCTR‐INR‐17012800</a>; <a href="./references#CD012631-bbs2-0057" title="ChiCTR-IOR-17011717. Comparing the effects of conservative oxygen therapy vs conventional oxygen therapy on outcomes in critically ill patients [The effects of conservative oxygen therapy vs conventional oxygen therapy on outcomes in critically ill patients: a randomised controlled trial]. chictr.org.cn/showproj.html?proj=19990 (first received 21 June 2017). ">ChiCTR‐IOR‐17011717</a>; <a href="./references#CD012631-bbs2-0058" title="CTRI/2020/12/029614. Liberal use of oxygen in early stage of COVID-19 patients [Early liberal oxygen therapy in COVID-19: an open-labeled randomised control trial]. ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=49680&amp;EncHid=&amp;modid=&amp;compid=%27,%2749680det%27 (first received 2 November 2020). ">CTRI/2020/12/029614</a>; <a href="./references#CD012631-bbs2-0059" title="ISRCTN13384956. Intensive care unit randomised trial comparing two approaches to oxygen therapy (UK-ROX). isrctn.com/ISRCTN13384956 (first received 8 December 2020). ">ISRCTN13384956</a>; <a href="./references#CD012631-bbs2-0060" title="JPRN-UMIN000046914. Early restricted oxygen therapy after resuscitation from cardiac arrest trial [Early restricted oxygen therapy after resuscitation from cardiac arrest trial – ER-OXYTRAC trial]. trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000046914 (first received 14 February 2022). ">JPRN‐UMIN000046914</a>; <a href="./references#CD012631-bbs2-0061" title="NCT02999932. Pulse Oxygen Saturation (SpO2) Directed Oxygen Therapy (POSDOT) [Effect of low vs high peripheral oxygen saturation (SpO 2 ) directed oxygen therapy on mortality among critically ill patients]. clinicaltrials.gov/show/NCT02999932 (first received 14 December 2016). ">NCT02999932</a>; <a href="./references#CD012631-bbs2-0062" title="NCT04144868. Safety and efficacy of NBO in acute intracerebral hemorrhage. clinicaltrials.gov/show/NCT04144868 (first received 30 December 2019). ">NCT04144868</a>; <a href="./references#CD012631-bbs2-0063" title="NCT04198077. Conservative versus conventional oxygen administration in critically ill patients [Conservative vs conventional oxygen administration in critically ill patients: effects on ICU mortality. A multicentre randomized open label clinical trial]. clinicaltrials.gov/show/NCT04198077 (first received 10 December 2019). ">NCT04198077</a>; <a href="./references#CD012631-bbs2-0064" title="NCT04425031. Handling oxygenation targets in COVID-19 (HOT-COVID) [Handling oxygenation targets in COVID-19 patients with acute hypoxaemic respiratory failure in the intensive care unit: a randomised clinical trial of a lower versus a higher oxygenation target]. clinicaltrials.gov/show/NCT04425031 (first received 5 June 2020). ">NCT04425031</a>; <a href="./references#CD012631-bbs2-0065" title="NCT04824703. Comparative study between liberal and conservative oxygen therapy in mechanically ventilated intensive care patients. clinicaltrials.gov/show/NCT04824703 (first received 26 March 2021). ">NCT04824703</a>; <a href="./references#CD012631-bbs2-0066" title="NCT05404373. Treatment duration on normobaric hyperoxia in acute ischemic stroke [The efficacy and safety of normobaric hyperoxia on treatment duration for acute ischemic stroke patients with endovascular treatment]. clinicaltrials.gov/show/NCT05404373 (first received 3 June 2022). ">NCT05404373</a>; <a href="./references#CD012631-bbs2-0067" title="NL7185. Arterial oxygenation targets in intensive care patients [ICONIC study − conservative versus conventional oxygenation targets in intensive care patients: study protocol for a randomized clinical trial]. onderzoekmetmensen.nl/en/trial/19970 (first received 20 July 2018). ">NL7185</a>)) from the meta‐analyses. </p> <p>Of the 10 RCTs identified in the original review, we excluded one report (<a href="./references#CD012631-bbs2-0209" title="YoungPJ , MackleDM , BaileyMJ , BeasleyRW , BennettVL , DeaneAM , et al, The ICU-ROX pilot investigators, The Australian and New Zealand Intensive Care Society Clinical Trials Group. Intensive care unit randomised trial comparing two approaches to oxygen therapy (ICU-ROX): results of the pilot phase. Critical Care and Resuscitation2017;19(4):344-54. [PMID: 29202261]">Young 2017</a>) due to overlap in patient population with a new report (<a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>). One trial (<a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>) reported long‐term mortality and quality of life separately (<a href="./references#CD012631-bbs2-0094" title="CrescioliE , KlitgaardTL , PoulsenLM , BrandBA , SiegemundM , GrøfteT , et al. Long‑term mortality and health‑related quality of life of lower versus higher oxygenation targets in ICU patients with severe hypoxaemia. Intensive Care Medicine2022;48(6):714-22. [DOI: 10.1007/s00134-022-06695-0] [PMID: 35441849]">Crescioli 2022a</a>). We pooled data for two groups in one trial due to a three‐arm design (<a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>). </p> <p>In all, we included 19 randomised controlled trials (RCTs) involving a total of 10,385 participants randomly assigned to a higher versus lower oxygenation strategies in the qualitative synthesis (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0006" title="IshiiK , MorimatsuH , HyodoT , OnoK , HidakaH , KoyamaY , et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e]">Ishii 2018</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>; <a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>), and 17 reports in the quantitative synthesis (10,248 participants) (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>). Detailed descriptions of included trials are shown in the <a href="./references#CD012631-sec-0202" title="">Characteristics of included studies</a> table. </p> <p>For the study flow diagram see <a href="#CD012631-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD012631-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD012631-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>We approached the corresponding authors to request missing or unclear information and, in all, received a reply from six authors. </p> </section> <section id="CD012631-sec-0046"> <h4 class="title">Included studies</h4> <section id="CD012631-sec-0047"> <h5 class="title">Trial characteristics</h5> <p>A total of 10,385 participants were randomised in the 19 included trials.</p> <section id="CD012631-sec-0048"> <h6 class="title">Reporting of outcomes</h6> <p>Sixteen trials reported on mortality (10,161 participants) (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>). </p> <p>Seventeen trials reported on the proportion of participants with one or more serious adverse events (SAEs) or on individual SAEs (10,248 participants) (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>). Of additional SAEs, two trials reported on delirium (239 participants) (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>), three trials reported on pneumothorax (2269 participants) (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>), three trials reported on intestinal ischaemia (3575 participants) (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>), two trials reported on cardiovascular failure including shock (3408 participants) (<a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>), six trials reported on cardiac arrhythmia (3126 participants) (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>), three trials reported on liver failure (1164 participants) (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>), five trials reported on renal failure (4072 participants) (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>), and two trials reported on seizure (1007 participants) (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>). Bleeding, cardiac arrest not resulting in death, digestive haemorrhage, digital ischaemia, haemoptysis, respiratory failure, severe hypercapnia and respiratory acidosis, surgical site infection, and unexplained brain oedema were only reported in single trials (<a href="#CD012631-tbl-0002">Table 1</a>). </p> <div class="table" id="CD012631-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Outcomes reported only in a single trial</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Serious adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. of higher group events/analysed</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. of lower group events/analysed</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92/395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82/394</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac arrest not resulting in death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57/1187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/447</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Digestive haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/99</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Digital ischaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/217</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haemoptysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/99</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Respiratory failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/220</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe hypercapnia and respiratory acidosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgical site infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/142</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unexplained brain oedema on CT scan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/61</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>CT:</b> computerised tomography </p> </div> </div> <p>No trials reported on the proportion of participants with lung injury as a composite outcome. Four trials reported on acute respiratory distress syndrome (ARDS) (871 participants) (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>), and five trials reported on pneumonia (1307 participants) (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>). No trials reported on pulmonary fibrosis. </p> <p>Four trials reported on myocardial infarction (5002 participants) (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>, <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>). </p> <p>Five trials reported on stroke (4707 participants) (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>). </p> <p>Two trials reported on sepsis (685 participants) (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>). </p> <p>Two trials did not report on any of our pre‐defined outcomes or on any serious adverse events (<a href="./references#CD012631-bbs2-0006" title="IshiiK , MorimatsuH , HyodoT , OnoK , HidakaH , KoyamaY , et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e]">Ishii 2018</a>; <a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>). </p> </section> <section id="CD012631-sec-0049"> <h6 class="title">Trial design and conduct</h6> <p>The trials were published from 2002 to 2022.</p> <p>Fourteen trials used a two‐arm, parallel‐group design (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0006" title="IshiiK , MorimatsuH , HyodoT , OnoK , HidakaH , KoyamaY , et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e]">Ishii 2018</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>), two trials used a two‐times‐three factorial design (<a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>), one trial used a two‐factorial design (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>), and two trials used a three‐arm design (<a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>). </p> <p>Nine trials were conducted in Europe (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>); three in China (<a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>); two in Iran (<a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>; <a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>); one in Australia and New Zealand (<a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>); one in Australia, New Zealand, and France (<a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>); one in Hong Kong (<a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>); one in Japan (<a href="./references#CD012631-bbs2-0006" title="IshiiK , MorimatsuH , HyodoT , OnoK , HidakaH , KoyamaY , et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e]">Ishii 2018</a>); and one in the USA (<a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>). </p> <p>Three trials were classified as either feasibility (<a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>) or pilot trials (<a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>). </p> <p>One trial used a cluster‐randomised, cluster‐cross‐over design (<a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>). </p> </section> <section id="CD012631-sec-0050"> <h6 class="title">Loss to follow‐up</h6> <p>Loss to follow‐up varied amongst trials, the lowest being 0% in three trials (<a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>), and the highest being just over 30% (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>). </p> <p>Of the 19 included trials, 13 trials had less than 5% loss to follow‐up (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>), two trials had 5% to 10% loss to follow‐up (<a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>), one trial had 14% loss to follow‐up (<a href="./references#CD012631-bbs2-0006" title="IshiiK , MorimatsuH , HyodoT , OnoK , HidakaH , KoyamaY , et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e]">Ishii 2018</a>), and one trial more than 30% loss to follow‐up (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>). Loss to follow‐up could not be ascertained for one trial due to limited information reported (<a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>). In one trial, all adults admitted to the intensive care unit (ICU) or emergency room (with planned admission to the ICU), and invasively mechanically ventilated were randomised, but participants enroled during washout periods were excluded, as predefined in the trial protocol, and also those positive for COVID‐19 (not pre‐defined) (<a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>). This resulted in a 14.9% dropout. </p> </section> </section> <section id="CD012631-sec-0051"> <h5 class="title">Participants</h5> <section id="CD012631-sec-0052"> <h6 class="title">Number of participants</h6> <p>The number of participants in the trials ranged from 34 to 2987. The approximate mean age of participants was 60 years, and the approximate mean proportion of male participants was 63%. </p> </section> <section id="CD012631-sec-0053"> <h6 class="title">Types of intensive care units (ICUs)</h6> <p>All trials included adults admitted to the ICU: 11 trials included multidisciplinary ICU patients (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>); four trials included only medical ICU patients (<a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>); and two trials included only surgical ICU patients (<a href="./references#CD012631-bbs2-0006" title="IshiiK , MorimatsuH , HyodoT , OnoK , HidakaH , KoyamaY , et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e]">Ishii 2018</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>). Two trials included only adults with traumatic brain injury (<a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>); two trials only adults after resuscitation from out‐of‐hospital cardiac arrest (<a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>); and one trial only adults with stroke (<a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>). Two trials failed to report the type of ICU to which patients were admitted (<a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>; <a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>). </p> </section> <section id="CD012631-sec-0054"> <h6 class="title">Oxygen delivery systems</h6> <p>Eleven trials included only adults receiving invasive mechanical ventilation (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0006" title="IshiiK , MorimatsuH , HyodoT , OnoK , HidakaH , KoyamaY , et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e]">Ishii 2018</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>; <a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>); two trials included only adults receiving any non‐invasive oxygen administration (<a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>); and six trials included adults receiving invasive mechanical ventilation or non‐invasive oxygen administration (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>). </p> </section> <section id="CD012631-sec-0055"> <h6 class="title">Respiratory failure</h6> <p>Three trials restricted inclusion to adults with a PaO<sub>2</sub>/FiO<sub>2</sub> ratio ≥ 100 mmHg (13.3 kPa) (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>), one trial restricted inclusion to adults a PaO<sub>2</sub>/FiO<sub>2</sub> ratio ≥ 150 mmHg (20 kPa) (<a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>), one trial restricted inclusion to adults with a PaO<sub>2</sub>/FiO<sub>2</sub> ratio between 150 and 250 mmHg (between 20 and 33.3 kPa) (<a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>), and one trial restricted inclusion to adults not being hypoxic or for whom oxygen therapy was inevitable (selection criteria not further specified by trialists) (<a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>). One trial excluded adults with a PaO<sub>2</sub> &lt; 13 kPa (97.5 mmHg) or an SpO<sub>2</sub> &lt; 95% with an FiO<sub>2</sub> of 0.40 and positive end‐expiratory pressure (PEEP) of 10 cm H<sub>2</sub>O or oxygenation failure was judged probable during ICU admission (<a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>). </p> <p>Three trials included only adults with respiratory failure: one trial restricted inclusion to adults fulfilling the ARDS criteria (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0074" title="RanieriVM , RubenfeldGD , ThompsonBT , FergusonND , CaldwellE , FanE , et al, ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin definition. Journal of American Medical Association2012;307(23):2526-33. [DOI: 10.1001/jama.2012.5669] [PMID: 22797452]">ARDS Definition Task Force 2012</a>); one trial required participants to receive ≥ 10 litres of oxygen per minute in an open system or an FiO<sub>2</sub> ≥ 0.50 in a closed system (<a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>); and one trial required the diagnosis of respiratory failure (as defined by clinicians) (<a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>). </p> <p>Five trials excluded participants with either known chronic obstructive pulmonary disease (COPD) (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>) or acute decompensation of COPD (<a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>). Two trials restricted inclusion to adults with COPD (<a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>). One trial excluded adults with known severe COPD (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>). One trial excluded adults with known (or being highly suspected to having) chronic lung disease with a baseline SpO<sub>2</sub> in the range of 88‐92% (<a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>). </p> </section> <section id="CD012631-sec-0056"> <h6 class="title">Hypoxaemic encephalopathy or cerebral pathology</h6> <p>Five trials excluded participants resuscitated from cardiac arrest prior to randomisation (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>; <a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>), whilst two trials restricted inclusion to participants resuscitated from out of hospital cardiac arrest (<a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>). </p> <p>Five trials excluded participants with intra‐cranial pathology prior to randomisation being either: intra‐cranial hypertension (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>); intra‐cranial hypertension or traumatic brain injury (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>); confirmed or suspected acute or pre‐existing intra‐cranial pathology or suspicion of increased intra‐cranial pressure, or both (<a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>); or any penetrating traumatic brain injury (<a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>). Three trials restricted inclusion to participants with cerebral pathology only (<a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>; <a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>). </p> <p>Three trials included participants with any risk factors for either hypoxaemic encephalopathy (e.g. cardiac arrest prior to randomisation) or any cerebral pathology (e.g. traumatic brain injury) (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>). </p> </section> <section id="CD012631-sec-0057"> <h6 class="title">Limitations of care</h6> <p>Eleven trials excluded participants with limitations of care or with short remaining life‐expectancy as evaluated by clinicians (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>). </p> </section> <section id="CD012631-sec-0058"> <h6 class="title">Co‐enrolment</h6> <p>Nine trials explicitly co‐enroled participants into other clinical trials (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>). </p> </section> <section id="CD012631-sec-0059"> <h6 class="title">Pregnancy</h6> <p>Fourteen trials explicitly excluded pregnant participants (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>;<a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>; <a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>). </p> </section> <section id="CD012631-sec-0060"> <h6 class="title">Haemodynamic insufficiency</h6> <p>One trial restricted inclusion to participants with refractory septic shock (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>), whilst one trial required participants to be haemodynamically stabile (<a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>), and one trial excluded participants with either shock or malignant arrhythmia (<a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>). </p> </section> <section id="CD012631-sec-0061"> <h6 class="title">Time limits to inclusion</h6> <p>Nine trials had a minimum expectation to participants' length of stay in the ICU: one trial expected mechanical ventilation ≥ 12 hours (<a href="./references#CD012631-bbs2-0006" title="IshiiK , MorimatsuH , HyodoT , OnoK , HidakaH , KoyamaY , et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e]">Ishii 2018</a>); one trial expected ≥ 24 hours of oxygen supplementation in the ICU (<a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>); one trial expected mechanical ventilation beyond the next calendar day (<a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>); two trials expected mechanical ventilation ≥ 24 hours (<a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>); one trial expected ICU‐stay ≥ 48 hours (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>); and three trials expected ≥ 72 hours of mechanical ventilation (<a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>). </p> <p>One trial excluded participants with more than two hours of invasive mechanical ventilation or non‐invasive mechanical ventilation, or both, in an ICU during current hospital admission (<a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>); one trial restricted inclusion to less than or equal to six hours from start of vasopressors (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>); four trials had a time limit of 12 hours to inclusion from either ICU‐admission (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>), or to start of invasive mechanical ventilation (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>); and one trial required participants to be randomised within 18 hours from ICU‐admission and within 36 hours from injury (<a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>). </p> </section> <section id="CD012631-sec-0062"> <h6 class="title">Baseline severity of illness</h6> <p>Scores for baseline disease severity were reported in various manners: five trials reported Acute Physiology and Chronic Health Evaluation II (APACHE II)scores, approximate mean 21.5 (range 17.0 to 23.5) (<a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>); two trials reported the Simplified Acute Physiology Score (SAPS II), approximate mean 33 (range 28 to 38) (<a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>); two trials reported SAPS III, approximate mean 69 (range 67 to 71) (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>); two trials reported Sequential Organ Failure Assessment (SOFA) scores, approximate mean 9 (range 8 to 9) (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>); two trials reported SOFA scores excluding the respiratory component, approximate mean 5 (range 3 to 8) (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>); one trial reported APACHE III, approximate mean 75 (range 70 to 80) (<a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>); one trial reported Bartel index, mean 42 (<a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>); two trials reported Glasgow Coma Scale (<a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>). Three trials failed to report any illness severity scores (<a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0006" title="IshiiK , MorimatsuH , HyodoT , OnoK , HidakaH , KoyamaY , et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e]">Ishii 2018</a>; <a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>). </p> </section> </section> <section id="CD012631-sec-0063"> <h5 class="title">Lengths of interventions</h5> <p>The maximum duration of the applied intervention varied greatly amongst the included trials. The shortest duration was a maximum of six hours after randomisation (<a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>), whilst the longest was a maximum of 90 days after randomisation (<a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>). Seven trials failed to report the maximum duration of intervention (<a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0006" title="IshiiK , MorimatsuH , HyodoT , OnoK , HidakaH , KoyamaY , et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e]">Ishii 2018</a>; <a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>). Details on interventions are provided in <a href="#CD012631-tbl-0003">Table 2</a>. </p> <div class="table" id="CD012631-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Interventions used in the higher and lower group</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="2" valign="bottom"></td> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Higher group</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Lower group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Duration of intervention</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>FiO<sub>2</sub> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>PaO<sub>2</sub> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SaO<sub>2</sub>/SpO<sub>2</sub> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>FiO<sub>2</sub> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>PaO<sub>2</sub> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SaO<sub>2</sub>/SpO<sub>2</sub> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88% to 95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximum 24 h after randomisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 mmHg to 105 mmHg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 96%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 mmHg to 70 mmHg (7.3 kPa to 9.3 kPa)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88% to 92%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until extubation, maximum 7 d of invasive mechanical ventilation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 kPa to 12 kPa (60 mmHg to 90 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 kPa to 18 kPa (105 mmHg to 135 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until ICU discharge or death, maximum 14 d</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 20 kPa (150 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97% to 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.3 kPa to 13.3 kPa (70 mmHg to 100 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94% to 98%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Entire ICU admission, upper limit not explicitly stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 9.0 kPa (67.5 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 6.6 kPa (50 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximum 48 h after randomisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0006" title="IshiiK , MorimatsuH , HyodoT , OnoK , HidakaH , KoyamaY , et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e]">Ishii 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 mmHg (13.3 kPa)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not explicitly stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 kPa to 25 kPa (150 mmHg to 187.5 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 kPa to 15 kPa (75 mmHg to 112.5 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95% to 98%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of mechanical ventilation, maximum 14 d after randomisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.40 to 0.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30 to 0.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not explicitly stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of mechanical ventilation, maximum 14 d</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>No specific measures were taken to avoid high FiO<sub>2</sub> or SpO<sub>2</sub>. </p> <p>FiO<sub>2</sub> &lt; 0.30 discouraged </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90% to 96%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until ICU discharge, maximum 28 d</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 96%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88% to 92%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until extubation, formation of tracheostomy, transfer to other ICU, or death</p> <p>Maximum duration was not explicitly stated.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Supplemental oxygen not used.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximum 12 h after randomisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 96%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88% to 92%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of mechanical ventilation</p> <p>Maximum duration was not explicitly stated.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 kPa (90 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 kPa (60 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Entire ICU admission, including re‐admissions</p> <p>Maximum 90 d after randomisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 kPa to 14 kPa (97.5 mmHg to 105 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 kPa to 10 kPa (67.5 mmHg to 75 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until discontinuation of mechanical ventilation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94% (92% to 96%) or 98% (96% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90% (88% to 92%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until discontinuation of mechanical ventilation, transfer out of a participating unit, or the end of the 2‐months study period, whichever occurred first </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximum 6 h after randomisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 0.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96% to 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90% to 95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not explicitly stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 150 mmHg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 96%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.3 kPa to 13.3 kPa (70 mmHg to 100 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90% to 92%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not explicitly stated</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>FiO<sub>2</sub>:</b> fraction of inspired oxygen; <b>PaO<sub>2</sub>:</b> partial pressure of arterial oxygen; <b>SaO<sub>2</sub>:</b> arterial oxygen saturation of haemoglobin; <b>SpO<sub>2</sub>:</b> peripheral oxygen saturation </p> <p><sup>a</sup>Patients in lower oxygenation group also received doxapram if they developed acidosis (pH &lt; 7.2). Patients in the higher oxygenation group received doxapram if they developed symptomatic acidosis.<br/><sup>b</sup>Intermediate‐ and higher‐target groups have been combined due to the 3‐arm design of the trial. </p> </div> </div> </section> <section id="CD012631-sec-0064"> <h5 class="title">Funding</h5> <p>Fourteen trials were funded by public grants (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>); two trials did not report how they were funded (<a href="./references#CD012631-bbs2-0006" title="IshiiK , MorimatsuH , HyodoT , OnoK , HidakaH , KoyamaY , et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e]">Ishii 2018</a>; <a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>); two trials were funded by public and private grants, and specified that funding bodies had no input regarding the design, management, or reporting of the trial (<a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>). One trial was funded by public grants and specified that funding bodies had no input regarding the design, management, or reporting of the trial (<a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>). </p> </section> <section id="CD012631-sec-0065"> <h5 class="title">Experimental intervention</h5> <p>Of the 19 included trials, four trials randomised participants to higher versus lower oxygen by using FiO<sub>2</sub> (<a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>; <a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>); 13 trials randomised participants to an oxygenation target (or target range) (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>); and two trials randomised participants to a specific FiO<sub>2</sub> in the experimental group and to target specific oxygenation levels in the control group (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0006" title="IshiiK , MorimatsuH , HyodoT , OnoK , HidakaH , KoyamaY , et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e]">Ishii 2018</a>). </p> <p>Of the nine trials using FiO<sub>2</sub> in the experimental group, two trials used an FiO<sub>2</sub> of 1.0 (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0006" title="IshiiK , MorimatsuH , HyodoT , OnoK , HidakaH , KoyamaY , et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e]">Ishii 2018</a>); two trial used FiO<sub>2</sub> ≥ 0.40 (<a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>); one trial used an FiO<sub>2</sub> of 0.80 (<a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>); one trial used an FiO<sub>2</sub> of 0.70 (<a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>); one trial used an FiO<sub>2</sub> 0.40 to 0.70 (<a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>); one trial used FiO<sub>2</sub> of 0.50 (<a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>); and one trial used FiO<sub>2</sub> ≥ 0.30 (<a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>). </p> <p>In the experimental (higher) group, three trials targeted an SpO<sub>2</sub> of ≥ 96% (<a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>); one trial targeted a PaO<sub>2</sub> of 12 to 14 kPa (90 to 105 mmHg) or an SpO<sub>2</sub> of ≥ 96% (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>); one trial targeted a PaO<sub>2</sub> of 14 to 18 kPa (105 to 135 mmHg) (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>); one trial targeted an SpO<sub>2</sub> of 97% to 100% (<a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>); one trial targeted a PaO<sub>2</sub> &gt; 9.0 kPa (67.5 mmHg) (<a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>); one trial targeted a PaO<sub>2</sub> of 20 to 25 kPa (150 to 187.5 mmHg) (<a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>); one trial randomised participants to standard care (no specific measures taken to avoid high FiO<sub>2</sub> or SpO<sub>2</sub>; however, FiO<sub>2</sub> &lt; 0.30 was discouraged) (<a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>); one trial targeted a PaO<sub>2</sub> of 13 to 14 kPa (97.5 to 105 mmHg) (<a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>); and one trial targeted a PaO<sub>2</sub> of 12 kPa (90 mmHg) (<a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>). In one trial, participants were randomised to either an intermediate‐ (SpO<sub>2</sub> target 94% (range 92% to 96%)) or higher‐target group (SpO<sub>2</sub> target 98% (range 96% to 100%)) (<a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>). </p> <p>Three trials were categorised by us as using a low target in the experimental group (<a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>), and 15 trials were categorised as using a high target in the experimental group (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0006" title="IshiiK , MorimatsuH , HyodoT , OnoK , HidakaH , KoyamaY , et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e]">Ishii 2018</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>). One trial could not be categorised according to our definitions, as no specific target was used (<a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>). </p> <p>Details on interventions are provided in <a href="#CD012631-tbl-0003">Table 2</a>. </p> </section> <section id="CD012631-sec-0066"> <h5 class="title">Comparator intervention</h5> <p>Four trials used an FiO<sub>2</sub> in the control group: one trial used the expected FiO<sub>2</sub> to achieve a PaO<sub>2</sub> of 13.3 kPa (100 mmHg) (<a href="./references#CD012631-bbs2-0006" title="IshiiK , MorimatsuH , HyodoT , OnoK , HidakaH , KoyamaY , et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e]">Ishii 2018</a>); one trial used an FiO<sub>2</sub> of 0.40 (<a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>); one trial used an FiO<sub>2</sub> of 0.30 to 0.50 (<a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>); and one trial used an FiO<sub>2</sub> of 0.50 (<a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>). </p> <p>In the control group (lower) three trials targeted an SpO<sub>2</sub> 88% to 92% by itself (<a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>) or in combination with a PaO<sub>2</sub> of 7.3 to 9.3 kPa (55 to 70 mmHg) (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>); one trial targeted an SaO<sub>2</sub> between 88% and 95% (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>); one trial targeted an SpO<sub>2</sub> between 90% and 92% in combination with targeting a PaO<sub>2</sub> between 9.3 and 13.3 kPa (70 to 100 mmHg) (<a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>); one trial targeted an SpO<sub>2</sub> between 94% and 98% or a PaO<sub>2</sub> of 9.3 to 13. kPa (70 to 100 mmHg) (<a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>); one trial targeted an SpO<sub>2</sub> between 95% and 98% or a PaO<sub>2</sub> of 10 to 15 kPa (75 to 112.5 mmHg) (<a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>); one trial targeted a PaO<sub>2</sub> of 8 to 12 kPa (60 to 90 mmHg) (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>); one trial targeted a PaO<sub>2</sub> of 8 kPa (60 mmHg) (<a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>); one trial targeted an SpO<sub>2</sub> between 90% and 95% (<a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>); one trial targeted a PaO<sub>2</sub> &gt; 6.6 kPa (50 mmHg) (<a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>); one trial targeted a PaO<sub>2</sub> between 9 and 10 kPa (67.5 to 75 mmHg) (<a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>); one trial used an SaO<sub>2</sub> or SpO<sub>2</sub> between 91% to 96% (<a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>).; and one trial targeted an SpO<sub>2</sub> of 90% (range 88% to 92%) (<a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>). One trial used no supplemental oxygen (<a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>). </p> <p>Ten trials were categorised by us as using a low target in the control group (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>), and nine trials were categorised as using a high target in the control group (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0006" title="IshiiK , MorimatsuH , HyodoT , OnoK , HidakaH , KoyamaY , et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e]">Ishii 2018</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>). </p> <p>Details on interventions are provided in <a href="#CD012631-tbl-0003">Table 2</a>. </p> </section> <section id="CD012631-sec-0067"> <h5 class="title">Primary outcomes as defined by trialists</h5> <p>Six trials reported mortality at various lengths of follow‐up as their primary outcome: one within ICU‐admission (<a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>); one at 14 days (<a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>); three at 28 days (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>); and one at 90 days post‐randomisation (<a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>). </p> <p>Two trials reported the Bartel index at hospital discharge and six months (<a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>), and also at the first day of admission (<a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>), as the primary outcome. </p> <p>Two trials reported feasibility measures (as defined by trialists) as the primary outcome (<a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>). </p> <p>Two trials reported the number of ventilator‐free days at day 28 post‐randomisation as the primary outcome (<a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>). </p> <p>One trial reported all‐cause mortality or severe anoxic brain injury at three months after out of hospital cardiac arrest (<a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>). </p> <p>One trial reported mechanical ventilation time (<a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>). </p> <p>One trial reported the occurrence af atelectases within five days of randomisation as the primary outcome (<a href="./references#CD012631-bbs2-0006" title="IshiiK , MorimatsuH , HyodoT , OnoK , HidakaH , KoyamaY , et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e]">Ishii 2018</a>). </p> <p>One trial reported the need for mechanical ventilation or death within current hospital admission as the primary outcome (<a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>). </p> <p>One trial reported the serum concentration of neuro specific enolase (NSE) 48 hours after cardiac arrest as the primary outcome (<a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>). </p> <p>One trial reported a collection of laboratory markers (level of reactive oxygen species, inter‐leukin‐6 and NSE) during ICU‐care as the primary outcome (<a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>). </p> <p>One trial reported the cumulative daily delta Sequential Organ Failure Assessment (SOFA) score (omitting subscores from the respiratory component) from day 1 to 14 (SOFA<sub>rank</sub>) (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>). </p> </section> <section id="CD012631-sec-0068"> <h5 class="title">Mortality as a secondary outcome</h5> <p>Mortality was also reported as a secondary outcome at various lengths of follow‐up: seven trials reported on ICU‐mortality (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>); five trials reported on in‐hospital mortality (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>); one trial reported on in‐hospital mortality before 28 days (<a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>); four trials reported on 90‐day mortality (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>), two trials reported on 180‐day mortality (<a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>), and one trial (<a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>) reported on one‐year mortality (<a href="./references#CD012631-bbs2-0094" title="CrescioliE , KlitgaardTL , PoulsenLM , BrandBA , SiegemundM , GrøfteT , et al. Long‑term mortality and health‑related quality of life of lower versus higher oxygenation targets in ICU patients with severe hypoxaemia. Intensive Care Medicine2022;48(6):714-22. [DOI: 10.1007/s00134-022-06695-0] [PMID: 35441849]">Crescioli 2022a</a>). </p> </section> </section> <section id="CD012631-sec-0069"> <h4 class="title">Excluded studies</h4> <p>We excluded RCTs of higher versus lower oxygenation strategies that were conducted in populations not being admitted to an ICU. We listed the reasons for exclusion of 35 key excluded trials, which included RCTs of higher versus lower oxygenation strategies for participants who were acutely ill but not admitted to the ICU, as detailed in the <a href="./references#CD012631-sec-0203" title="">Characteristics of excluded studies</a> table. </p> <section id="CD012631-sec-0070"> <h5 class="title">Ongoing studies</h5> <p>We identified13 ongoing trials (<a href="./references#CD012631-bbs2-0055" title="ACTRN12620000391976. The mega randomised registry trial comparing conservative vs. liberal oxygenation targets [A randomised, registry-embedded, single blinded clinical trial comparing conservative oxygen therapy to liberal oxygen therapy in mechanically ventilated adults in the intensive care unit]. anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379432&amp;isReview=true (first received 10 March 2020). ">ACTRN12620000391976</a>; <a href="./references#CD012631-bbs2-0056" title="ChiCTR-INR-17012800. The effect of conservative oxygen therapy in the mechanical ventilation patients. chictr.org.cn/showproj.html?proj=21892 (first received 26 September 2017). ">ChiCTR‐INR‐17012800</a>; <a href="./references#CD012631-bbs2-0057" title="ChiCTR-IOR-17011717. Comparing the effects of conservative oxygen therapy vs conventional oxygen therapy on outcomes in critically ill patients [The effects of conservative oxygen therapy vs conventional oxygen therapy on outcomes in critically ill patients: a randomised controlled trial]. chictr.org.cn/showproj.html?proj=19990 (first received 21 June 2017). ">ChiCTR‐IOR‐17011717</a>; <a href="./references#CD012631-bbs2-0058" title="CTRI/2020/12/029614. Liberal use of oxygen in early stage of COVID-19 patients [Early liberal oxygen therapy in COVID-19: an open-labeled randomised control trial]. ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=49680&amp;EncHid=&amp;modid=&amp;compid=%27,%2749680det%27 (first received 2 November 2020). ">CTRI/2020/12/029614</a>; <a href="./references#CD012631-bbs2-0059" title="ISRCTN13384956. Intensive care unit randomised trial comparing two approaches to oxygen therapy (UK-ROX). isrctn.com/ISRCTN13384956 (first received 8 December 2020). ">ISRCTN13384956</a>; <a href="./references#CD012631-bbs2-0060" title="JPRN-UMIN000046914. Early restricted oxygen therapy after resuscitation from cardiac arrest trial [Early restricted oxygen therapy after resuscitation from cardiac arrest trial – ER-OXYTRAC trial]. trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000046914 (first received 14 February 2022). ">JPRN‐UMIN000046914</a>; <a href="./references#CD012631-bbs2-0061" title="NCT02999932. Pulse Oxygen Saturation (SpO2) Directed Oxygen Therapy (POSDOT) [Effect of low vs high peripheral oxygen saturation (SpO 2 ) directed oxygen therapy on mortality among critically ill patients]. clinicaltrials.gov/show/NCT02999932 (first received 14 December 2016). ">NCT02999932</a>; <a href="./references#CD012631-bbs2-0062" title="NCT04144868. Safety and efficacy of NBO in acute intracerebral hemorrhage. clinicaltrials.gov/show/NCT04144868 (first received 30 December 2019). ">NCT04144868</a>; <a href="./references#CD012631-bbs2-0063" title="NCT04198077. Conservative versus conventional oxygen administration in critically ill patients [Conservative vs conventional oxygen administration in critically ill patients: effects on ICU mortality. A multicentre randomized open label clinical trial]. clinicaltrials.gov/show/NCT04198077 (first received 10 December 2019). ">NCT04198077</a>; <a href="./references#CD012631-bbs2-0064" title="NCT04425031. Handling oxygenation targets in COVID-19 (HOT-COVID) [Handling oxygenation targets in COVID-19 patients with acute hypoxaemic respiratory failure in the intensive care unit: a randomised clinical trial of a lower versus a higher oxygenation target]. clinicaltrials.gov/show/NCT04425031 (first received 5 June 2020). ">NCT04425031</a>; <a href="./references#CD012631-bbs2-0065" title="NCT04824703. Comparative study between liberal and conservative oxygen therapy in mechanically ventilated intensive care patients. clinicaltrials.gov/show/NCT04824703 (first received 26 March 2021). ">NCT04824703</a>; <a href="./references#CD012631-bbs2-0066" title="NCT05404373. Treatment duration on normobaric hyperoxia in acute ischemic stroke [The efficacy and safety of normobaric hyperoxia on treatment duration for acute ischemic stroke patients with endovascular treatment]. clinicaltrials.gov/show/NCT05404373 (first received 3 June 2022). ">NCT05404373</a>; <a href="./references#CD012631-bbs2-0067" title="NL7185. Arterial oxygenation targets in intensive care patients [ICONIC study − conservative versus conventional oxygenation targets in intensive care patients: study protocol for a randomized clinical trial]. onderzoekmetmensen.nl/en/trial/19970 (first received 20 July 2018). ">NL7185</a>), which may be included in future updates of this review. See <a href="./references#CD012631-sec-0204" title="">Characteristics of ongoing studies</a>. </p> </section> </section> </section> <section id="CD012631-sec-0071"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed all trials according to the Risk of Bias 2 tool for all reported outcomes (<a href="./references#CD012631-bbs2-0126" title="HigginsJPT , SterneJAC , SavovićJ , PageMJ , HróbjartssonA , BoutronI , et al. A revised tool for assessing risk of bias in randomized trials. In: Chandler J, McKenzie J, Boutron I, Welch V (editors). Cochrane Methods. Cochrane Database of Systematic Reviews, 2016. Available from cochranelibrary.com/cdsr/doi/10.1002/14651858.CD201601/full. [DOI: dx.doi.org/10.1002/14651858.CD201601]">Higgins 2016</a>; <a href="./references#CD012631-bbs2-0189" title="SterneJAC , SavovićJ , PageMJ , ElbersRG , BlencoweNS , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. British Medical Journal2019;366:l4898. [DOI: 10.1136/bmj.l4898] [PMID: 31462531]">Sterne 2019</a>). </p> <p>Two trials were not evaluated in terms of risk of bias, as none of the predefined outcomes were reported on (<a href="./references#CD012631-bbs2-0006" title="IshiiK , MorimatsuH , HyodoT , OnoK , HidakaH , KoyamaY , et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e]">Ishii 2018</a>; <a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>). </p> <p>Risk of bias tables are presented along with all meta‐analyses.</p> <section id="CD012631-sec-0072"> <h4 class="title">A) Domain 1: randomisation process</h4> <p>Thirteen trials described the generation of the allocation sequence adequately, using computer‐generated random numbers, and were judged to be at low risk of bias for this domain (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>). One trial stated that the trial was randomised and used sealed, opaque envelopes, but the method of sequence generation was not described (<a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>). We judged this trial to be at low risk of bias. One trial stated that the trial was randomised using a random number table (<a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>). We judged this trial to be at some concerns of bias due to missing information on allocation concealment and limited baseline information. Two trials stated that the trial was randomised, but the method of sequence generation was not described resulting in some concerns of bias (<a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>; <a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>). </p> </section> <section id="CD012631-sec-0073"> <h4 class="title">B) Domain 2: Deviations from the intended interventions</h4> <p>Nine trials were judged to be at low risk of bias for this domain (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>). Two trials were judged to be at some concerns of bias for this domain; one due to the use of an unjustified, modified intention‐to‐treat analysis (<a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>); and one due to no information on blinding, protocol deviations, group allocation numbers, and missing event rates (<a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>). Six trials were judged to be at high risk of bias for this domain; one trial excluded one participant post‐randomisation due to development of severe ARDS (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>); one trial due to use of modified intention‐to‐treat analyses excluding two participants post‐randomisation who violated inclusion criteria (<a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>); one trial did not specify group allocation of five participants lost to follow‐up (<a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>); one trial failed at implementing the treatment protocol in the control group (<a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>); one trial excluded 14.9% of included participants post‐randomisation (<a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>); and one trial did not report on the analyses used to estimate the effect of the intervention (<a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>). </p> </section> <section id="CD012631-sec-0074"> <h4 class="title">C) Domain 3: Missing outcome data</h4> <p>Twelve trials were judged to be at low risk of bias for this domain (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>). Five trials were judged to be at high risk of bias for this domain; one trial had &gt; 30% loss to follow‐up (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>); one trial had &gt; 5% lost to follow‐up and no description on handling of missing data (<a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>); one trial had five participants lost to follow‐up, but did not report on reasons for loss to follow‐up nor group allocation (<a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>); one trial had one participant lost to follow up that was not described in the report, and did not report on the participant's group allocation (<a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>); and one trial had 14.9% loss to follow‐up and only reported outcomes for participants recruited in 24 of 36 months of trial conduct on selected outcomes (<a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>). </p> </section> <section id="CD012631-sec-0075"> <h4 class="title">D) Domain 4: Measurement of the outcome</h4> <p>All 17 trials reporting data for this review were judged to be at low risk of bias for this domain. </p> </section> <section id="CD012631-sec-0076"> <h4 class="title">E) Domain 5. Selection of the reported results</h4> <p>Eleven trials were judged to be at low risk of bias for this domain (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>). Five trials were judged to be at some concerns of risk of bias for this domain; we were unable to find a trial protocol for three trials (<a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>); one trial reported 90‐day mortality post‐hoc, and did not pre‐specify the reporting of SAEs (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>); and one trial was retrospectively registered (<a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>). One trial was judged to be at high risk of bias for this domain as the trial reported the results from an unjustified, modified intention‐to‐treat analysis as the primary outcome, and the trial was judged being registered retrospectively (<a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>). </p> </section> <section id="CD012631-sec-0077"> <h4 class="title">F) Overall risk of bias</h4> <section id="CD012631-sec-0078"> <h5 class="title">Mortality</h5> <p>Sixteen trials reported on mortality, of which nine were judged to be at overall low risk of bias in all domains for this outcome (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>). The remaining seven trials were judged to be at overall high risk of bias (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>). </p> </section> <section id="CD012631-sec-0079"> <h5 class="title">Serious adverse events</h5> <p>Seventeen trials reported on the proportion of participants with one or more SAEs or any single SAE, of which nine were judged to be at overall low risk of bias in all domains for this outcome (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>). The remaining nine trials were judged to be at overall high risk of bias (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>). </p> </section> <section id="CD012631-sec-0080"> <h5 class="title">Quality of life</h5> <p>Two trials reported on quality of life (<a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>). One trial was judged to be at overall low risk of bias (<a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>) and one at overall high risk of bias (<a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>). </p> </section> <section id="CD012631-sec-0081"> <h5 class="title">Lung injury</h5> <p>Eight trials reported on any lung injury (defined as either ARDS, pneumonia, or pulmonary fibrosis), of which three trials were judged to be at overall low risk of bias in all domains for this outcome (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>). The remaining five trials were judged to be at overall high risk of bias for this outcome (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>). </p> <p>Three trials reported on ARDS, of which two trials were judged to be at overall low risk of bias in all domains for this outcome (<a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>). The other trial was judged to be at overall high risk of bias for this outcome (<a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>). </p> <p>Five trials reported on pneumonia, of which one trial was judged to be at overall low risk of bias in all domains for this outcome (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>). One trial was judged to be at some concerns for this outcome (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>), and three trials were judged to be at overall high risk of bias for this outcome (<a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>). </p> </section> <section id="CD012631-sec-0082"> <h5 class="title">Myocardial infarction</h5> <p>Four trials reported on myocardial infarction, of which one trial was judged to be at overall low risk of bias in all domains for this outcome (<a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>). The remaining three trials were judged to be at overall high risk of bias for this outcome (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>). </p> </section> <section id="CD012631-sec-0083"> <h5 class="title">Stroke</h5> <p>Five trials reported on stroke, of which two trials were judged to be at overall low risk of bias in all domains for this outcome (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>), one trial was judged to be at some concerns for this outcome (<a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>), and two trials were judged to be at overall high risk of bias for this outcome (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>). </p> </section> <section id="CD012631-sec-0084"> <h5 class="title">Sepsis</h5> <p>Three trials reported on sepsis, of which one trial was judged to be at overall low risk of bias in all domains for this outcome (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>). The other two trials were judged to be at overall high risk of bias for this outcome (<a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>). </p> </section> <section id="CD012631-sec-0085"> <h5 class="title">Additional serious adverse events</h5> <p>Two trials reported on delirium, and both trials were judged to be at overall low risk of bias in all domains for this outcome (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>). </p> <p>Three trials reported on pneumothorax, of which one trial was judged to be at overall low risk of bias in all domains for this outcome (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>), one was judged to be at some concerns for this outcome (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>), and one was judged to be at high risk of bias (<a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>). </p> <p>Three trials reported on intestinal ischaemia, of which one trial was judged to be at overall low risk of bias in all domains for this outcome (<a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>). The other two trials were judged to be at some concerns for this outcome (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>). </p> <p>Two trials reported on cardiovascular failure including shock, of which one trial was judged to be at overall low risk of bias in all domains for this outcome (<a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>). The other trial was judged to be at overall high risk of bias for this outcome (<a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>). </p> <p>Six trials reported on cardiac arrhythmia. Four trials were judged to be at overall low risk of bias in all domains for this outcome (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>). Two trial were judged to be at overall high risk of bias for this outcome (<a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>). </p> <p>Three trials reported on liver failure, and all trials were judged to be at overall high risk of bias for this outcome (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>). </p> <p>Five trials reported on renal failure, of which two trials were judged to be at overall low risk of bias in all domains for this outcome (<a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>). The other three trials were judged to be at overall high risk of bias (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>). </p> <p>Two trials reported on the occurrence of seizure, and both were judged to be at overall low risk of bias for this outcome (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>). </p> </section> </section> </section> <section id="CD012631-sec-0086"> <h3 class="title" id="CD012631-sec-0086">Effects of interventions</h3> <p>See: <a href="./full#CD012631-tbl-0001"><b>Summary of findings 1</b> Higher vs lower FiO<sub>2</sub> or targets of arterial oxygenation for adults admitted to the ICU</a> </p> <section id="CD012631-sec-0087"> <h4 class="title">Primary outcomes</h4> <section id="CD012631-sec-0088"> <h5 class="title">All‐cause mortality</h5> <p>Sixteen of the 19 trials included reported on all‐cause mortality, with a total of 10,161 participants randomised and a mean follow‐up of approximately four months (range 1 to 12 months) (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>). </p> <p>Data for mortality at longest follow‐up for <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a> were reported in <a href="./references#CD012631-bbs2-0094" title="CrescioliE , KlitgaardTL , PoulsenLM , BrandBA , SiegemundM , GrøfteT , et al. Long‑term mortality and health‑related quality of life of lower versus higher oxygenation targets in ICU patients with severe hypoxaemia. Intensive Care Medicine2022;48(6):714-22. [DOI: 10.1007/s00134-022-06695-0] [PMID: 35441849]">Crescioli 2022a</a> (one‐year follow‐up). </p> <p>Nine trials were judged to be at overall low risk of bias for this outcome (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>). A total of 42.0% in the higher group versus 41.9% in the lower group had died. In these trials, meta‐analysis of all‐cause mortality indicated no evidence of a difference in the effect of higher versus lower oxygenation strategies (fixed‐effect model risk ratio (RR) 1.01, 95% confidence interval (CI) 0.94 to 1.08; I<sup>2</sup> = 7%; 5733 participants; 9 trials; <a href="./references#CD012631-fig-0024" title="">Analysis 1.1</a>; low‐certainty evidence). </p> <p>In all trials, a total of 38.1% in the higher group versus 38.7% in the lower group had died. In these trials, meta‐analysis of all‐cause mortality indicated no evidence of a difference in the effect of higher versus lower oxygenation strategies (fixed‐effect model RR 1.01, 95% CI 0.96 to 1.06; I<sup>2</sup> = 14%; 9408 participants; 16 trials; <a href="./references#CD012631-fig-0030" title="">Analysis 2.1</a>; very low‐certainty evidence; <a href="./full#CD012631-tbl-0001">summary of findings Table 1</a>). </p> <section id="CD012631-sec-0089"> <h6 class="title">Publication bias</h6> <p>A funnel plot of all‐cause mortality at maximum follow‐up is presented in <a href="#CD012631-fig-0002">Figure 2</a>. We found no indications of any small‐study effect by the Harbord test (P = 0.59) or Begg's test (P = 1.00). </p> <div class="figure" id="CD012631-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Funnel plot of the risk of mortality at maximum follow‐up. A relative risk (RR) &lt; 1 indicates benefit of higher oxygenation strategies, whilst an RR &gt; 1 indicate benefit of lower. Each circle represents the point estimate of the trials. The black dashed line represent the point estimate for the RR of all‐cause mortality at maximum follow‐up (1.01).Abbreviations: log: natural logarithm; SE: standard error; RR: relative risk." data-id="CD012631-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of the risk of mortality at maximum follow‐up. A relative risk (RR) &lt; 1 indicates benefit of higher oxygenation strategies, whilst an RR &gt; 1 indicate benefit of lower. Each circle represents the point estimate of the trials. The black dashed line represent the point estimate for the RR of all‐cause mortality at maximum follow‐up (1.01). </p> <p><b>Abbreviations: log:</b> natural logarithm; <b>SE:</b> standard error; <b>RR:</b> relative risk. </p> </div> </div> </div> </section> <section id="CD012631-sec-0090"> <h6 class="title">Heterogeneity</h6> <p>Neither visual inspection of the forest plot nor inconsistency factor (I<sup>2</sup> = 14%; Chi<sup>2</sup> = 17.50, P = 0.29) indicated statistical heterogeneity. </p> </section> <section id="CD012631-sec-0091"> <h6 class="title">Trial Sequential Analyses (TSA)</h6> <p>Trial Sequential Analysis of trials judged to be at overall low risk of bias showed that with an anticipated relative risk increase (RRI) of 20%, mortality in the control group of 41.9%, a type 1 error level of 2.5%, a type two error level of 10%, and a diversity of 27.9%, the required information size was 2436 participants. The cumulated Z‐curve crossed the trial sequential monitoring boundaries for futility, and with 5733 participants in the analysis, the required information size was exceeded. This indicated that, considering repetitive testing, the evidence was sufficient to refute a 20% RRI or a 20% relative risk reduction (RRR) for the benefit or harm of higher versus lower oxygenation strategies (<a href="#CD012631-fig-0003">Figure 3</a>). The TSA CI was 0.92 to 1.10. </p> <div class="figure" id="CD012631-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the risk of mortality in trials judged to be at overall low risk of bias. The analysis was based on a mortality in the control group (control event proportion = CEP) of 41.9%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 27.9%. The cumulative Z‐curve crossed the trial sequential monitoring boundaries for futility, and the required information size (RIS) was exceeded." data-id="CD012631-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the risk of mortality in trials judged to be at overall low risk of bias. The analysis was based on a mortality in the control group (control event proportion = CEP) of 41.9%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 27.9%. The cumulative Z‐curve crossed the trial sequential monitoring boundaries for futility, and the required information size (RIS) was exceeded.</b> </p> </div> </div> </div> <p>Trial Sequential Analysis of all trials showed that with an anticipated RRI of 20%, mortality in the control group of 38.7%, a type 1 error level of 2.5%, a type two error level of 10%, and a diversity of 41.1%, the required information size was 3441 participants. The cumulated Z‐curve crossed the trial sequential monitoring boundaries for futility, and with 9408 participants in the analysis the required information size was exceeded. This indicated that, considering repetitive testing, the evidence was sufficient to refute a 20% RRI or a 20% RRR for the benefit or harm of higher versus lower oxygenation strategies (<a href="#CD012631-fig-0004">Figure 4</a>). The TSA CI was 0.95 to 1.08. </p> <div class="figure" id="CD012631-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the risk of mortality. The analysis was based on a mortality in the control group (control event proportion = CEP) 38.7%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 41.1%. The cumulative Z‐curve crossed the trial sequential monitoring boundaries for futility, and the required information size (RIS) was exceeded." data-id="CD012631-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the risk of mortality. The analysis was based on a mortality in the control group (control event proportion = CEP) 38.7%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 41.1%. The cumulative Z‐curve crossed the trial sequential monitoring boundaries for futility, and the required information size (RIS) was exceeded.</b> </p> </div> </div> </div> <p>Trial Sequential Analysis with an anticipated RRI of 10%, mortality in the control group of 38.7%, a type 1 error level of 2.5%, a type two error level of 10%, and a diversity of 41.1%, the required information size was 13,584 participants. The cumulated Z‐curve crossed the trial sequential monitoring boundaries for futility. This indicated that considering sparse data and repetitive testing, evidence was sufficient to refute a 10% RRR or a 10% RRI for the benefit or harm of higher versus lower oxygenation strategies (<a href="#CD012631-fig-0005">Figure 5</a>). The TSA CI was 0.95 to 1.07. </p> <div class="figure" id="CD012631-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the risk of mortality. The analysis was based on a mortality in the control group (control event proportion = CEP) of 38.7%, a relative risk increase (RRI) of 10%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 41.1%. Required information size = RIS. The cumulative Z‐curve crossed the trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the risk of mortality. The analysis was based on a mortality in the control group (control event proportion = CEP) of 38.7%, a relative risk increase (RRI) of 10%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 41.1%. Required information size = RIS. The cumulative Z‐curve crossed the trial sequential monitoring boundaries for futility.</b> </p> </div> </div> </div> <p>Trial Sequential Analysis using an RRR or RRI based on the conventional 95% confidence interval of the analysis of mortality closest to the null‐effect (RRR of 4%), mortality in the control group of 38.7%, a type 1 error level of 2.5%, a type two error level of 10%, and a diversity of 41.1%, the required information size was 82,635 participants. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility. This indicated that considering sparse data and repetitive testing, evidence was insufficient to confirm or refute a 4% RRR or a 4% RRI for the benefit or harm of higher versus lower oxygenation strategies (<a href="#CD012631-fig-0006">Figure 6</a>). The TSA CI 0.82 to 1.25. </p> <div class="figure" id="CD012631-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the risk of mortality. The analysis was based on a mortality in the control group (control event proportion = CEP) of 38.7%, a relative risk reduction (RRR) of 4%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 41.1%. Required information size = RIS. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the risk of mortality. The analysis was based on a mortality in the control group (control event proportion = CEP) of 38.7%, a relative risk reduction (RRR) of 4%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 41.1%. Required information size = RIS. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility.</b> </p> </div> </div> </div> </section> <section id="CD012631-sec-0092"> <h6 class="title">Bayes factor</h6> <p>Bayes factors for all outcomes are presented in <a href="#CD012631-tbl-0004">Table 3</a>. </p> <div class="table" id="CD012631-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Calculated Bayes factors for all predefined outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention effect hypothesised</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention effect shown by the meta‐analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>BF</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>All‐cause mortality<sup>a</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3 × 10<sup>17</sup> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>All‐cause mortality<sup>b</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 × 10<sup>9</sup> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Highest reported proportion of serious adverse events<sup>c</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0 × 10<sup>18</sup> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Highest reported proportion of serious adverse events<sup>d</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0 × 10<sup>10</sup> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cumulated number of serious adverse events<sup>c</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1 × 10<sup>96</sup> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cumulated number of serious adverse events<sup>d</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.01 × 10<sup>27</sup> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Quality of life<sup>e</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−7 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.5 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.8 × 10<sup>7</sup> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Quality of life<sup>f</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+7 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.5 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 × 10<sup>9</sup> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Highest reported proportion of lung injuries<sup>g</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.44</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Highest reported proportion of lung injuries<sup>h</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.17</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cumulated number of lung injuries<sup>g</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.33</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cumulated number of lung injuries<sup>h</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.82</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Myocardial infarction<sup>i</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.42</p> <p>(BF<sup>−1</sup> = 2.39) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Myocardial infarction<sup>j</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.34</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Stroke<sup>k</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.61</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Stroke<sup>l</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.07</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Sepsis<sup>m</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.14</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Sepsis<sup>n</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.18</p> <p>(BF<sup>−1</sup> = 5.51) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>BF:</b> Bayes factor; <b>RR:</b> risk ratio </p> <p><sup>a</sup>The result is likely BF times more compatible with the null‐hypothesis of a RR reduction of 0% than the alternative hypothesis of a RR reduction of 20% for an effect of higher vs lower supplemental oxygen on all‐cause mortality.<br/><sup>b</sup>The result is likely BF times more compatible with the null‐hypothesis of a RR increase of 0% than the alternative hypothesis of a RR increase of 20% for an effect of higher vs lower supplemental oxygen on all‐cause mortality.<br/><sup>c</sup>The result is likely BF times more compatible with the null‐hypothesis of a RR reduction of 0% than the alternative hypothesis of a RR reduction of 20% for an effect of higher vs lower supplemental oxygen on serious adverse events.<br/><sup>d</sup>The result is likely BF times more compatible with the null‐hypothesis of a RR increase of 0% than the alternative hypothesis of a RR increase of 20% for an effect of higher vs lower supplemental oxygen on serious adverse events.<br/><sup>e</sup>The result is likely BF times more compatible with the null‐hypothesis of no difference than the alternative hypothesis of a mean difference of −7 points (minimally clinical important difference) for an effect of higher vs lower supplemental oxygen on quality of life.<br/><sup>f</sup>The result is likely BF times more compatible with the null‐hypothesis of no difference than the alternative hypothesis of a mean difference of +7 points (minimally clinical important difference) for an effect of higher vs lower supplemental oxygen on quality of life.<br/><sup>g</sup>The result is likely BF times more compatible with the null‐hypothesis of a RR increase of 0% than the alternative hypothesis of a RR reduction of 20% for an effect of higher vs lower supplemental oxygen on lung injuries.<br/><sup>h</sup>The result is likely BF times more compatible with the null‐hypothesis of a RR increase of 0% than the alternative hypothesis of a RR increase of 20% for an effect of higher vs lower supplemental oxygen on lung injuries.<br/><sup>i</sup>The result is likely BF<sup>−1</sup> times more compatible with the alternative hypothesis of a RR reduction of 20% than the null‐hypothesis of a RR reduction of 0% for an effect of higher vs lower supplemental oxygen on acute myocardial infarction.<br/><sup>j</sup>The result is likely BF times more compatible with the null‐hypothesis of a RR increase of 0% than the alternative hypothesis of a RR increase of 20% for an effect of higher vs lower supplemental oxygen on acute myocardial infarction.<br/><sup>k</sup>The result is likely BF times more compatible with the null‐hypothesis of a RR increase of 0% than the alternative hypothesis of a RR reduction of 20% for an effect of higher vs lower supplemental oxygen on stroke.<br/><sup>l</sup>The result is likely BF times more compatible with the null‐hypothesis of a RR increase of 0% than the alternative hypothesis of a RR increase of 20% for an effect of higher vs lower supplemental oxygen on stroke.<br/><sup>m</sup>The result is likely BF times more compatible with the null‐hypothesis of a RR increase of 0% than the alternative hypothesis of a RR reduction of 20% for an effect of higher vs lower supplemental oxygen on severe sepsis.<br/><sup>n</sup>The result is likely BF<sup>‐1</sup> times more compatible with the alternative hypothesis of a RR increase of 20% than the null‐hypothesis of a RR increase of 0% for an effect of higher vs lower supplemental oxygen on severe sepsis. </p> </div> </div> </section> <section id="CD012631-sec-0093"> <h6 class="title">Subgroup analyses</h6> <p>We found no evidence of a difference in the subgroup analyses according to risk of bias (<a href="./references#CD012631-fig-0031" title="">Analysis 2.2</a>), different types of oxygen interventions (<a href="./references#CD012631-fig-0032" title="">Analysis 2.3</a>), oxygenation target in the higher oxygen‐administration group (<a href="./references#CD012631-fig-0033" title="">Analysis 2.4</a>), FiO<sub>2</sub> or oxygenation target in the lower oxygen‐administration group (<a href="./references#CD012631-fig-0034" title="">Analysis 2.5</a>), or oxygen delivery system (<a href="./references#CD012631-fig-0036" title="">Analysis 2.7</a>). When considering effects according to ICU population only subtotals are presented as more than one trial is represented in more than one subgroup (<a href="./references#CD012631-fig-0035" title="">Analysis 2.6</a>). </p> </section> <section id="CD012631-sec-0094"> <h6 class="title">Sensitivity analyses</h6> <p>The sensitivity analysis excluding trials comparing two low oxygenation strategies or two high oxygenation strategies indicated no evidence of a difference in the effect of higher versus lower oxygenation strategies on all‐cause mortality (RR 1.00, 95% CI 0.87 to 1.14; I<sup>2</sup> = 34%; 3873 participants; 6 trials; <a href="./references#CD012631-fig-0037" title="">Analysis 2.8</a>). </p> <p>Results from the best‐worst (<a href="./references#CD012631-fig-0038" title="">Analysis 2.9</a>) and worst‐best case (<a href="./references#CD012631-fig-0039" title="">Analysis 2.10</a>) scenarios are presented in <a href="./appendices#CD012631-sec-0186">Appendix 11</a>. </p> </section> </section> <section id="CD012631-sec-0095"> <h5 class="title">Proportion of participants with one or more SAEs</h5> <p>Seventeen of the 19 trials included (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>), with a total of 10,248 participants randomised, reported on the occurrence of any SAE reported on outcomes categorised by us as an SAE according to the ICH‐GCP definition (<a href="./references#CD012631-bbs2-0130" title="International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH) adopts consolidated guideline on good clinical practice in the conduct of clinical trials on medicinal products for human use. International Digest of Health Legislation1997;48(2):231-4. [PMID: 11656783]">ICH‐GCP 1997</a>). Three of the 19 trials (3944 participants) reported the proportion of participants with one or more SAEs as a composite outcome (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>), but only one trial included death in this composite (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>) in accordance to the ICH‐GCP recommendation. </p> <p>A list of serious adverse events (SAEs only reported by a single trial is provided in <a href="#CD012631-tbl-0002">Table 1</a>. Individual SAEs are analysed below. </p> <p>As the reporting of SAEs as a combined outcome was only carried out strictly according to the ICH‐GCP recommendation in one trial (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>), we estimated the reported proportion of participants with one or more SAEs in two ways: </p> <p> <ol id="CD012631-list-0013"> <li> <p>By choosing the one specific SAE with the highest proportion reported in each trial that addresses the lowest possible proportion of participants with one or more SAEs, assuming that all other SAEs were included in this proportion (somehow a best‐case scenario); </p> </li> <li> <p>By cumulating all reported SAEs, assuming that participants only experience one SAE (the number of participants in each group will constitute a maximum), address the highest possible reported proportion of participants with one or more SAE (somehow a worst‐case scenario). </p> </li> </ol> </p> <p>Meta‐analysis of the highest proportion of specific SAEs in trials at overall low risk of bias indicated no evidence of a difference in the effect of higher versus lower oxygenation strategies (fixed‐effect model RR 1.01, 95% CI 0.95 to 1.07; I<sup>2</sup> = 33%; 5733 participants; 9 trials; <a href="./references#CD012631-fig-0025" title="">Analysis 1.2</a>). </p> <p>Meta‐analysis of the cumulated number of SAEs in trials at overall low risk of bias indicated no evidence of a difference in the effect of higher versus lower oxygenation strategies (fixed‐effect model RR 1.02, 95% CI 0.99 to 1.05; I<sup>2</sup> = 0%; 4212 participants; 5 trials; <a href="./references#CD012631-fig-0026" title="">Analysis 1.3</a>). </p> <p>Meta‐analysis of all trials indicated no difference in the effect of higher versus lower oxygenation strategies when assessing the highest reported proportion of specific SAEs in each trial (fixed‐effect model RR 1.01, 95% CI 0.96 to 1.06; I<sup>2</sup> = 36%; 9466 participants; 17 trials; <a href="./references#CD012631-fig-0040" title="">Analysis 3.1</a>; <a href="./full#CD012631-tbl-0001">summary of findings Table 1</a>). Individual types of SAEs included mortality (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>); proportion of participants with one or more SAE (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>); mechanical ventilation (reported as a poor outcome) (<a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>); and myocardial infarction (<a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>). </p> <p>Meta‐analysis of all trials indicated evidence of a difference between higher versus lower oxygenation strategies when assessing the cumulated number of SAEs (fixed‐effect model RR 1.04, 95% CI 1.02 to 1.07; I<sup>2</sup> = 75%; 9489 participants; 17 trials; <a href="./references#CD012631-fig-0041" title="">Analysis 3.2</a>; <a href="./full#CD012631-tbl-0001">summary of findings Table 1</a>). Individual types of SAEs included mortality; ARDS; pneumonia; sepsis; respiratory failure; cardiovascular failure; liver failure; renal failure; bloodstream infection; respiratory infection; surgical site infection; peripheral arterial thrombosis, pneumothorax; ventricular arrhythmias; new infections; haemodynamic instability; mechanical ventilation; severe hypercapnia and respiratory acidosis (PaCO<sub>2</sub> &gt; 10 kPa (75 mmHg) and pH &lt; 7.15); intestinal ischaemia; coma; digestive haemorrhage; acute myocardial infarction; seizures; stroke; cardiac arrhythmia, haemodynamic instability; bleeding; cardiac arrest; haemoptysis; and unexplained brain oedema on computed tomography (CT) scan. </p> <p>Meta‐analysis of trials reporting on the occurrence of SAEs as a composite outcome indicated no difference in the effect of higher versus lower oxygenation strategies (fixed‐effect model RR 1.05, 95% CI 0.98 to 1.13; I<sup>2</sup> = 27%; 3744 participants; 3 trials; <a href="./references#CD012631-fig-0042" title="">Analysis 3.3</a>). </p> <section id="CD012631-sec-0096"> <h6 class="title">Publication bias</h6> <p>Funnel plots of the highest reported proportion of SAEs and the cumulated number of SAEs at maximum follow‐up are presented in <a href="#CD012631-fig-0007">Figure 7</a> and <a href="#CD012631-fig-0008">Figure 8</a>. </p> <div class="figure" id="CD012631-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Funnel plot of the highest reported proportion of serious adverse events at maximum follow‐up. A relative risk (RR) &lt; 1 indicates benefit of higher oxygenation strategies, whilst an RR &gt; 1 indicate benefit of lower. Each circle represents the point estimate of the trials. The black dashed line represent the point estimate for the RR of the highest reported proportion of serious adverse events at maximum follow‐up (1.01).Abbreviations: log: natural logarithm; SE: standard error; RR: relative risk." data-id="CD012631-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of the highest reported proportion of serious adverse events at maximum follow‐up. A relative risk (RR) &lt; 1 indicates benefit of higher oxygenation strategies, whilst an RR &gt; 1 indicate benefit of lower. Each circle represents the point estimate of the trials. The black dashed line represent the point estimate for the RR of the highest reported proportion of serious adverse events at maximum follow‐up (1.01). </p> <p><b>Abbreviations: log:</b> natural logarithm; <b>SE:</b> standard error; <b>RR:</b> relative risk. </p> </div> </div> </div> <div class="figure" id="CD012631-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Funnel plot of the cumulated number of serious adverse events at maximum follow‐up. A relative risk (RR) &lt; 1 indicates benefit of higher oxygenation strategies, whilst an RR &gt; 1 indicate benefit of lower. Each circle represents the point estimate of the trials. The black dashed line represent the point estimate for the RR of the cumulated number of serious adverse events at maximum follow‐up (1.04).Abbreviations: log: natural logarithm; SE: standard error; RR: relative risk." data-id="CD012631-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-08.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of the cumulated number of serious adverse events at maximum follow‐up. A relative risk (RR) &lt; 1 indicates benefit of higher oxygenation strategies, whilst an RR &gt; 1 indicate benefit of lower. Each circle represents the point estimate of the trials. The black dashed line represent the point estimate for the RR of the cumulated number of serious adverse events at maximum follow‐up (1.04). </p> <p><b>Abbreviations: log:</b> natural logarithm; <b>SE:</b> standard error; <b>RR:</b> relative risk. </p> </div> </div> </div> <p>We found no indications of any small‐study effect by the Harbord test (P = 0.58) or Begg's test (P = 0.97) for the highest reported proportion of SAEs. </p> <p>We found no indications of any small‐study effect by the Harbord test (P = 0.98) or Begg's test (P = 0.43) for the cumulated number of SAEs. </p> </section> <section id="CD012631-sec-0097"> <h6 class="title">Heterogeneity</h6> <p>We found significant heterogeneity for the cumulated number of SAEs (I<sup>2</sup> = 74%; Chi<sup>2</sup> = 62.52; P &lt; 0.001), but not for the reported highest proportion (I<sup>2</sup> = 36%; Chi<sup>2</sup> = 28.89; P = 0.07). Neither visual inspection of the forest plot nor inconsistency factor (I<sup>2</sup> = 27%; Chi<sup>2</sup> = 2.73; P = 0.25) indicated statistical heterogeneity for trials reporting on one or more SAEs as a composite outcome. </p> </section> <section id="CD012631-sec-0098"> <h6 class="title">Trial Sequential Analyses</h6> <section id="CD012631-sec-0099"> <p><b>Highest reported proportion of serious adverse events</b></p> <p>Trial Sequential Analysis of the estimated highest reported proportion of SAEs showed that with an anticipated RRI of 20%, SAEs in the control group of 41.1%, a type 1 error of 2.5%, a type 2 error of 10%, and a diversity of 64.0%, the required information size was 5057 participants. The cumulated Z‐curve crossed the trial sequential monitoring boundaries for futility, and with 9466 participants in the analysis the required information size was exceeded. This indicated that, considering repetitive testing, the evidence was sufficient to refute a 20% RRI or a 20% RRR for the benefit or harm of higher versus lower oxygenation strategies (<a href="#CD012631-fig-0009">Figure 9</a>). The TSA CI was 0.93 to 1.08. </p> <div class="figure" id="CD012631-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the highest reported proportion of specific serious adverse events. The analysis was based on a proportion of participants with one or more serious adverse events in the control group (control event proportion = CEP) of 41.1%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 64.0%. The cumulative Z‐curve crossed the boundaries for trial sequential monitoring boundaries for futility, and the required information size (RIS) was exceeded." data-id="CD012631-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the highest reported proportion of specific serious adverse events. The analysis was based on a proportion of participants with one or more serious adverse events in the control group (control event proportion = CEP) of 41.1%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 64.0%. The cumulative Z‐curve crossed the boundaries for trial sequential monitoring boundaries for futility, and the required information size (RIS) was exceeded.</b> </p> </div> </div> </div> <p>Trial Sequential Analysis of the estimated highest reported proportion of SAes showed that with an anticipated RRI of 10%, SAEs in the control group of 41.1%, a type 1 error of 2.5%, a type 2 error of 10%, and a diversity of 64.0%, the required information size was 20,035 participants. The cumulated Z‐curve crossed the trial sequential monitoring boundaries for futility. This indicated that, considering repetitive testing, the evidence was sufficient to refute a 10% RRI or a 10% RRR the for benefit or harm of higher versus lower oxygenation strategies (<a href="#CD012631-fig-0010">Figure 10</a>). The TSA CI was 0.93 to 1.08. </p> <div class="figure" id="CD012631-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the highest reported proportion of specific serious adverse events. The analysis was based on a proportion of participants with one or more serious adverse events in the control group (control event proportion = CEP) of 41.1%, a relative risk increase (RRI) of 10%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 64.0%. RIS = required information size. The cumulative Z‐curve crossed the boundaries for trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the highest reported proportion of specific serious adverse events. The analysis was based on a proportion of participants with one or more serious adverse events in the control group (control event proportion = CEP) of 41.1%, a relative risk increase (RRI) of 10%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 64.0%. RIS = required information size. The cumulative Z‐curve crossed the boundaries for trial sequential monitoring boundaries for futility.</b> </p> </div> </div> </div> </section> <section id="CD012631-sec-0100"> <p><b>Cumulated number of serious adverse events</b></p> <p>Trial Sequential Analysis of the cumulated number of SAEs showed that with an anticipated RRI of 20%, SAEs in the control group of 71.4%, a type 1 error of 2.5%, a type 2 error of 10%, and a diversity of 87.4%, the required information size was 3266 participants. The cumulated Z‐curve crossed the trial sequential monitoring boundaries for futility, and with 9489 participants in the analysis the required information size was exceeded. This indicated that, considering repetitive testing, the evidence was sufficient to refute a 20% RRI or a 20% RRR for benefit or harm of higher versus lower oxygenation strategies (<a href="#CD012631-fig-0011">Figure 11</a>). The TSA CI was 1.00 to 1.06. </p> <div class="figure" id="CD012631-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the cumulated number of serious adverse events. The analysis was based on a proportion of participants with one or more serious adverse events in the control group (control event proportion = CEP) of 71.4%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 87.4%. The cumulative Z‐curve crossed the boundaries for trial sequential monitoring boundaries for futility, and the required information size (RIS) was exceeded." data-id="CD012631-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the cumulated number of serious adverse events. The analysis was based on a proportion of participants with one or more serious adverse events in the control group (control event proportion = CEP) of 71.4%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 87.4%. The cumulative Z‐curve crossed the boundaries for trial sequential monitoring boundaries for futility, and the required information size (RIS) was exceeded.</b> </p> </div> </div> </div> <p>Trial Sequential Analysis of the cumulated number of SAEs showed that with an anticipated RRI of 10%, SAEs in the control group of 71.4%, a type 1 error of 2.5%, a type 2 error of 10%, and a diversity of 87.4%, the required information size was 14,527 participants. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility. This indicated that considering sparse data and repetitive testing, evidence was insufficient to confirm or refute a 10% RRI or a 10% RRR for the benefit or harm of higher versus lower oxygenation strategies (<a href="#CD012631-fig-0012">Figure 12</a>). The TSA CI was 0.90 to 1.06. </p> <div class="figure" id="CD012631-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the cumulated number of serious adverse events. The analysis was based on a proportion of participants with one or more serious adverse events in the control group (control event proportion = CEP) of 71.4%, a relative risk increase (RRI) of 10%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 87.4%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-12.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the cumulated number of serious adverse events. The analysis was based on a proportion of participants with one or more serious adverse events in the control group (control event proportion = CEP) of 71.4%, a relative risk increase (RRI) of 10%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 87.4%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility.</b> </p> </div> </div> </div> </section> </section> <section id="CD012631-sec-0101"> <h6 class="title">Bayes factor</h6> <p>Bayes factors for all outcomes are presented in <a href="#CD012631-tbl-0004">Table 3</a>. </p> </section> <section id="CD012631-sec-0102"> <h6 class="title">Subgroup analyses</h6> <p>No subgroup analyses were performed as the reporting of serious adverse events as a composite outcome was only carried out in one trial according to the ICH‐GCP recommendation. </p> </section> </section> <section id="CD012631-sec-0103"> <h5 class="title">Quality of life</h5> <p>Two included trials, with a total of 3928 participants randomised, reported data on quality of life (<a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>). One trial was judged to be of low risk of bias (<a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>), and one at high risk of bias (<a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>) for this outcome due to missing data. Data on quality of life from <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a> was reported in <a href="./references#CD012631-bbs2-0094" title="CrescioliE , KlitgaardTL , PoulsenLM , BrandBA , SiegemundM , GrøfteT , et al. Long‑term mortality and health‑related quality of life of lower versus higher oxygenation targets in ICU patients with severe hypoxaemia. Intensive Care Medicine2022;48(6):714-22. [DOI: 10.1007/s00134-022-06695-0] [PMID: 35441849]">Crescioli 2022a</a>. </p> <p>The reported mean difference (MD) in health state scores (EQ‐VAS) was ‐0.50 points (fixed‐effect model 95% CI ‐2.75 to 1.75; I<sup>2</sup> = 34%, 1649 participants; 2 trials; <a href="./references#CD012631-fig-0043" title="">Analysis 4.1</a>; <a href="./full#CD012631-tbl-0001">summary of findings Table 1</a>). </p> <section id="CD012631-sec-0104"> <h6 class="title">Publication bias</h6> <p>No evaluation of publication bias was performed as less than ten trials reported on quality of life. </p> </section> <section id="CD012631-sec-0105"> <h6 class="title">Heterogeneity</h6> <p>Neither visual inspection of the forest plot nor inconsistency factor (I<sup>2</sup> = 34%; Chi<sup>2</sup> = 1.52; P = 0.22) indicated statistical heterogeneity for trials reporting on quality of life at longest follow‐up. </p> </section> <section id="CD012631-sec-0106"> <h6 class="title">Trial Sequential Analyses</h6> <p>The minimum important difference in the EQ‐VAS score has been estimated to be between 7 and 12 (<a href="./references#CD012631-bbs2-0167" title="PatronaSD , ZaniniA , AielloM , AdamoD , CasaleS , CherubinoF , et al. Estimation of minimum clinically important difference in EQ-VAS score after pulmonary rehabilitation in COPD patients. European Respiratory Journal2014;44(Suppl 58):P3669.">Patrona 2014</a>; <a href="./references#CD012631-bbs2-0169" title="PickardAS , NearyMP , CellaD . Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health and Quality of Life Outcomes2007;5:70. [DOI: 10.1186/1477-7525-5-70]">Pickard 2007</a>; <a href="./references#CD012631-bbs2-0212" title="ZaniniA , AielloM , AdamoD , CasaleS , CherubinoF , PatronaSD , et al. Estimation of minimal clinically important difference in EQ-5D visual analog scale score after pulmonary rehabilitation in subjects with COPD. Respiratory Care2015;60(1):88-95. [DOI: 10.4187/respcare.03272] [PMID: 25336531]">Zanini 2015</a>). We chose the smallest effect size for reference of analysis. </p> <p>Trial Sequential Analysis of quality of life showed that with an anticipated mean difference of ‐7 points, a type 1 error level of 2.5%, a type 2 error level of 10%, and a diversity of 0%, the required information size was 550 participants. The cumulated Z‐curve crossed the trial sequential monitoring boundaries for futility, and with 1649 participants in the analysis the required information size was exceeded. This indicated that, considering repetitive testing, the evidence was sufficient to refute a 7 point increase or a 7‐point decrease benefit or harm of higher versus lower oxygenation strategies (<a href="#CD012631-fig-0013">Figure 13</a>). The TSA CI was ‐3.89 to 1.56. </p> <div class="figure" id="CD012631-fig-0013"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 13</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on quality of life. The analysis was based on an observed mean difference of ‐0.5 points, a minimal clinical relevance of ‐7 points, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve crossed the trial sequential monitoring boundaries for futility and the required information size was exceeded." data-id="CD012631-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-13.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on quality of life. The analysis was based on an observed mean difference of ‐0.5 points, a minimal clinical relevance of ‐7 points, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve crossed the trial sequential monitoring boundaries for futility and the required information size was exceeded.</b> </p> </div> </div> </div> <p>As the diversity for the Trial Sequential Analysis of the quality of life was 0%, we performed a sensitivity analysis with diversity defined as 20%, as described in the protocol (<a href="./references#CD012631-bbs2-0214" title="BarbateskovicM , SchjørringOL , JakobsenJC , MeyhoffCS , DahlRM , RasmussenBS , et al. Higher versus lower inspiratory oxygen fraction or targets of arterial oxygenation for adult intensive care patients. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD012631. [DOI: 10.1002/14651858.CD012631]">Barbateskovic 2017</a>). With an anticipated mean difference of ‐7, a type 1 error level of 2.5%, a type 2 error level of 10%, and a diversity of 20%, the required information size was 687 participants. The cumulated Z‐curve crossed the trial sequential monitoring boundaries for futility, and with 1649 participants in the analysis the required information size was exceeded. This indicated that, considering repetitive testing, the evidence was sufficient to refute a 7‐point increase or a 7‐point decrease benefit or harm of higher versus lower oxygenation strategies (<a href="#CD012631-fig-0014">Figure 14</a>). The TSA CI, adjusted for multiple outcomes, sparse data, and repetitive testing, for the intervention effect was ‐4.27 to 1.94. </p> <div class="figure" id="CD012631-fig-0014"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 14</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on quality of life. The analysis was based on an observed mean difference of ‐0.5 points, a minimal clinical relevance of ‐7 points, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 20%. RIS = required information size. The cumulated Z‐curve crossed the trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-14.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on quality of life. The analysis was based on an observed mean difference of ‐0.5 points, a minimal clinical relevance of ‐7 points, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 20%. RIS = required information size. The cumulated Z‐curve crossed the trial sequential monitoring boundaries for futility.</b> </p> </div> </div> </div> <p>For the Trial Sequential Analysis using an RRR or RRI based on the conventional 95% confidence interval of the analysis of quality of life closest to the null‐effect (1.6 point increase), a type 1 error of 2.5%, a type 2 error of 10%, and a diversity of 0%, required information size was 10,513 participants. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility. This indicated that considering sparse data and repetitive testing, evidence was insufficient to confirm or refute a 7‐point increase or a 7‐point decrease benefit or harm of higher versus lower oxygenation strategies (<a href="#CD012631-fig-0015">Figure 15</a>). The TSA CI, adjusted for multiple outcomes, sparse data, and repetitive testing, for the intervention effect was ‐10.34 to 8.01. </p> <div class="figure" id="CD012631-fig-0015"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 15</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on quality of life. The analysis was based on an observed mean difference of ‐0.5 points, a difference of 1.6 points, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-15.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on quality of life. The analysis was based on an observed mean difference of ‐0.5 points, a difference of 1.6 points, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility.</b> </p> </div> </div> </div> </section> <section id="CD012631-sec-0107"> <h6 class="title">Bayes factor</h6> <p>Bayes factors for all outcomes are presented in <a href="#CD012631-tbl-0004">Table 3</a>. </p> </section> <section id="CD012631-sec-0108"> <h6 class="title">Subgroup analyses</h6> <p>No significant subgroup differences were found according to overall risk of bias (<a href="./references#CD012631-fig-0044" title="">Analysis 4.2</a>), types of oxygen interventions (<a href="./references#CD012631-fig-0045" title="">Analysis 4.3</a>), level of FiO<sub>2</sub>/target in the higher group (<a href="./references#CD012631-fig-0046" title="">Analysis 4.4</a>), level of FiO<sub>2</sub>/target in the lower group (<a href="./references#CD012631-fig-0047" title="">Analysis 4.5</a>), or oxygen delivery system (<a href="./references#CD012631-fig-0049" title="">Analysis 4.7</a>). When considering effects according to ICU population only subtotals are presented as more than one trial is represented in more than one subgroup (<a href="./references#CD012631-fig-0048" title="">Analysis 4.6</a>). </p> </section> <section id="CD012631-sec-0109"> <h6 class="title">Sensitivity analyses</h6> <p>No sensitivity analysis excluding trials comparing two low‐oxygenation strategies or two high‐oxygenation strategies was performed, as only one trial reporting on quality of life satisfied the criteria for this analysis (<a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>). </p> <p>Results from the best‐worst (<a href="./references#CD012631-fig-0050" title="">Analysis 4.8</a>) and worst‐best case (<a href="./references#CD012631-fig-0051" title="">Analysis 4.9</a>) scenarios are presented in <a href="./appendices#CD012631-sec-0186">Appendix 11</a>. </p> </section> </section> </section> <section id="CD012631-sec-0110"> <h4 class="title">Secondary outcomes</h4> <section id="CD012631-sec-0111"> <h5 class="title">Lung injury</h5> <p>None of the 19 included trials reported any data on lung injury as a composite outcome (defined as either acute respiratory distress syndrome (ARDS), pulmonary fibrosis, or pneumonia) at any time‐point. Eight of the 18 trials reported on specific lung outcomes during index admission: three trials reported on ARDS (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>); four trials reported on pneumonia (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>), one trial reported on both ARDS and pneumonia (<a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>); none reported on pulmonary fibrosis. </p> <p>We estimated the reported proportion of participants with one or more lung injuries in two ways. </p> <p> <ol id="CD012631-list-0014"> <li> <p>By choosing the one specific lung injury event with the highest proportion reported in each trial that addresses the lowest possible proportion of participants with one or more lung injuries (somehow a best‐case scenario); </p> </li> <li> <p>By cumulating all reported lung injury events, assuming that participants only experience one lung injury event (the number of participants in each group will constitute a maximum), address the highest possible reported proportion of participants with one or more lung injuries (somehow a worst‐case scenario). </p> </li> </ol> </p> <p>Three trials reporting on lung injury were judged to be at overall low risk of bias (432 participants) (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>). </p> <p>Meta‐analysis of the highest proportion of participants with lung injury as a composite outcome in trials at overall low risk of bias indicated no evidence of a difference in the effect of higher versus lower oxygenation strategies (random‐effects model RR 1.16, 95% CI 0.74 to 1.81; I<sup>2</sup> = 0%; 424 participants; 3 trials; <a href="./references#CD012631-fig-0027" title="">Analysis 1.4</a>; very low‐certainty evidence). </p> <p>Meta‐analysis of the cumulated number of participants with lung injury as a composite outcome in trials at overall low risk of bias indicated no evidence of a difference in the effect of higher versus lower oxygenation strategies (random‐effects model RR 1.16, 95% CI 0.74 to 1.81; I<sup>2</sup> = 0%; 424 participants; 3 trials; <a href="./references#CD012631-fig-0028" title="">Analysis 1.5</a>; very low‐certainty evidence). </p> <p>Meta‐analysis of all trials indicated no evidence of a difference between higher versus lower oxygenation strategies when assessing the highest reported proportion of lung injury (random‐effects model RR 1.08, 95% CI 0.85 to 1.38; I<sup>2</sup> = 0%; 2048 participants; 8 trials; <a href="./references#CD012631-fig-0052" title="">Analysis 5.1</a>; very low‐certainty evidence; <a href="./full#CD012631-tbl-0001">summary of findings Table 1</a>). </p> <p>Meta‐analysis of all trials indicated no evidence of a difference between higher versus lower oxygenation strategies when assessing the cumulated number of lung injury events (fixed‐effect model RR 1.04, 95% CI 0.82 to 1.33; I<sup>2</sup> = 0%; 2048 participants; 8 trials; <a href="./references#CD012631-fig-0053" title="">Analysis 5.2</a>; very low‐certainty evidence; <a href="./full#CD012631-tbl-0001">summary of findings Table 1</a>). </p> <section id="CD012631-sec-0112"> <h6 class="title">Individual components of lung injury</h6> <section id="CD012631-sec-0113"> <p><b>Acute respiratory distress syndrome</b></p> <p>Four trials, with a total of 871 participants randomised, reported on ARDS (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>). A total of 2.7% in the higher group versus 3.8% in the lower group had ARDS. Meta‐analysis indicated no evidence of a difference between higher versus lower oxygenation strategies when assessing the occurrence of ARDS (random‐effects model RR 0.86, 95% CI 0.43 to 1.69; I<sup>2</sup> = 0%; 862 participants; 4 trials; <a href="./references#CD012631-fig-0054" title="">Analysis 5.3</a>; very low‐certainty evidence). </p> </section> <section id="CD012631-sec-0114"> <p><b>Pneumonia</b></p> <p>Five trials, with a total of 1197 participants randomised, reported on pneumonia (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>). A total of 16.4% in the higher group versus 14.9% in the lower group had pneumonia. Meta‐analysis indicated no evidence of a difference between higher versus lower oxygenation strategies when assessing the occurrence of pneumonia (fixed‐effect model RR 1.10, 95% CI 0.85 to 1.42; I<sup>2</sup> = 0%; 1251 participants; 5 trials; <a href="./references#CD012631-fig-0055" title="">Analysis 5.4</a>; very low‐certainty evidence). </p> </section> </section> <section id="CD012631-sec-0115"> <h6 class="title">Publication bias</h6> <p>No evaluation of publication bias was performed as less than ten10 trials reported on lung injury (as a composite outcome defined as either ARDS, pulmonary fibrosis, or pneumonia) at any time‐point. </p> </section> <section id="CD012631-sec-0116"> <h6 class="title">Heterogeneity</h6> <p>Neither visual inspection of the forest plot nor inconsistency factor indicated statistical heterogeneity when assessing the highest reported number of lung injuries (I<sup>2</sup> = 0%; Chi<sup>2</sup> = 2.39; P = 0.93) or the cumulated number of lung injuries (I<sup>2</sup> = 0%; Chi<sup>2</sup> = 4.84; P = 0.68). </p> </section> <section id="CD012631-sec-0117"> <h6 class="title">Trial Sequential Analyses</h6> <p>As no trial reported on lung injury as a composite outcome no TSA was performed of this outcome. </p> <section id="CD012631-sec-0118"> <p><b>Highest reported proportion of lung injuries</b></p> <p>Trial Sequential Analysis of all trials of the highest reported proportion of lung injuries showed that with an anticipated RRI of 20%, lung injury in the control group of 10.4%, a type 1 error of 2%, a type 2 error of 10%, and a diversity of 0%, the required information size was 12,193 participants. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility. This indicated that considering sparse data and repetitive testing, evidence was insufficient to confirm or refute a 20% RRR or a 20% RRI for the benefit or harm of higher versus lower oxygenation strategies (<a href="#CD012631-fig-0016">Figure 16</a>). The TSA CI, adjusted for multiple outcomes, sparse data, and repetitive testing, for the intervention effect was 0.40 to 2.89. </p> <div class="figure" id="CD012631-fig-0016"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 16</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the highest reported proportion of lung injuries. The analysis was based on the highest reported proportion of lung injuries in the control group (control event proportion = CEP) of 10.4%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-16.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the highest reported proportion of lung injuries. The analysis was based on the highest reported proportion of lung injuries in the control group (control event proportion = CEP) of 10.4%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility.</b> </p> </div> </div> </div> <p>Trial Sequential Analysis of all trials of the highest reported proportion of lung injuries with an anticipated RRI of 10%, lung injury in the control group of 10.3%, a type 1 error of 2%, a type 2 error of 10%, and a diversity of 0% was not conducted as only 4.37% of the required information size reached for this outcome. The required information size was 46,828 participants. </p> <p>As the diversity for the Trial Sequential Analysis of the highest reported proportion of lung injuries was 0%, we performed a sensitivity analysis with diversity defined as 20%, described in the protocol (<a href="./references#CD012631-bbs2-0214" title="BarbateskovicM , SchjørringOL , JakobsenJC , MeyhoffCS , DahlRM , RasmussenBS , et al. Higher versus lower inspiratory oxygen fraction or targets of arterial oxygenation for adult intensive care patients. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD012631. [DOI: 10.1002/14651858.CD012631]">Barbateskovic 2017</a>). With an anticipated RRI of 20%, lung injury in the control group of 10.4%, a type 1 error of 2%, a type 2 error of 10%, and a diversity of 20%, the required information size was 15,241 participants. This indicated that considering sparse data and repetitive testing, evidence was insufficient to confirm or refute a 20% RRR or a 20% RRI for the benefit or harm of higher versus lower oxygenation strategies (<a href="#CD012631-fig-0017">Figure 17</a>). The TSA CI, adjusted for multiple outcomes, sparse data, and repetitive testing, for the intervention effect was 0.40 to 2.89. </p> <div class="figure" id="CD012631-fig-0017"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 17</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of the effects of higher versus oxygenation strategies on the highest reported proportion of lung injuries. The analysis was based on the highest reported proportion of lung injuries in the control group (control event proportion = CEP) of 10.4%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 20%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-17.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus oxygenation strategies on the highest reported proportion of lung injuries. The analysis was based on the highest reported proportion of lung injuries in the control group (control event proportion = CEP) of 10.4%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 20%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility.</b> </p> </div> </div> </div> <p>For the Trial Sequential Analysis of all trials using an RRR or RRI based on the conventional 95% confidence interval of the analysis of the highest reported proportion of lung injuries closest to the null‐effect (RRR of 15%), lung injury in the control group of 10.4%, a type 1 error level of 2%, a type two error level of 10%, and a diversity of 0%, the required information size was 18,603 participants. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility. This indicated that considering sparse data and repetitive testing, evidence was insufficient to confirm or refute a 15% RRR or a 15% RRI for the benefit or harm of higher versus lower oxygenation strategies (<a href="#CD012631-fig-0018">Figure 18</a>). The TSA CI, adjusted for multiple outcomes, sparse data, and repetitive testing, for the intervention effect was 0.40 to 2.89. </p> <div class="figure" id="CD012631-fig-0018"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 18</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the highest reported proportion of lung injuries. The analysis was based on the highest reported proportion of lung injuries in the control group (control event proportion = CEP) of 10.4%, a relative risk reduction (RRR) of 15%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-18.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the highest reported proportion of lung injuries. The analysis was based on the highest reported proportion of lung injuries in the control group (control event proportion = CEP) of 10.4%, a relative risk reduction (RRR) of 15%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility.</b> </p> </div> </div> </div> </section> <section id="CD012631-sec-0119"> <p><b>Cumulated number of lung injuries</b></p> <p>Trial Sequential Analysis of all trials of the cumulated number of lung injuries showed that with an anticipated RRI of 20%, lung injury in the control group of 10.7%, a type 1 error of 2%, a type 2 error of 10%, and a diversity of 0%, the required information size was 11,807 participants. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility. This indicated that considering sparse data and repetitive testing, evidence was insufficient to confirm or refute a 20% RRR or a 20% RRI the for benefit or harm of higher versus lower oxygenation strategies (<a href="#CD012631-fig-0019">Figure 19</a>). The TSA CI, adjusted for multiple outcomes, sparse data, and repetitive testing, for the intervention effect was 0.33 to 3.38. </p> <div class="figure" id="CD012631-fig-0019"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 19</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the cumulated number of lung injuries. The analysis was based on a cumulated number (control event proportion = CEP) of 10.7%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-19.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the cumulated number of lung injuries. The analysis was based on a cumulated number (control event proportion = CEP) of 10.7%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility.</b> </p> </div> </div> </div> <p>Trial Sequential Analysis of all trials of the cumulated number of lung injuries with an anticipated RRI of 10%, lung injury in the control group of 10.7%, a type 1 error of 2%, a type 2 error of 10%, and a diversity of 0% was not conducted as only 4.5% of the required information size reached for this outcome. The required information size was 45,355 participants. </p> <p>As the diversity for the Trial Sequential Analysis of the cumulated number of lung injuries was 0%, we performed a sensitivity analysis with diversity defined as 20%, as described in the protocol (<a href="./references#CD012631-bbs2-0214" title="BarbateskovicM , SchjørringOL , JakobsenJC , MeyhoffCS , DahlRM , RasmussenBS , et al. Higher versus lower inspiratory oxygen fraction or targets of arterial oxygenation for adult intensive care patients. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD012631. [DOI: 10.1002/14651858.CD012631]">Barbateskovic 2017</a>). With an anticipated RRI of 20%, lung injury in the control group of 10.7%, a type 1 error of 2%, a type 2 error of 10%, and a diversity of 20%, the required information size was 14,758 participants. This indicated that considering sparse data and repetitive testing, evidence was insufficient to confirm or refute a 20% RRR or a 20% RRI for benefit or harm of higher versus lower oxygenation strategies (<a href="#CD012631-fig-0020">Figure 20</a>). The TSA CI, adjusted for multiple outcomes, sparse data, and repetitive testing, for the intervention effect was 0.33 to 3.38. </p> <div class="figure" id="CD012631-fig-0020"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 20</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the cumulated number of lung injuries. The analysis was based on a cumulated number of lung injuries in the control group (control event proportion = CEP) of 10.7%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 20%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-20.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the cumulated number of lung injuries. The analysis was based on a cumulated number of lung injuries in the control group (control event proportion = CEP) of 10.7%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 20%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility.</b> </p> </div> </div> </div> <p>For the Trial Sequential Analysis using an RRR or RRI based on the conventional 95% confidence interval of the cumulated number of lung injuries at longest follow‐up closest to the null‐effect (RRR of 21%), lung injury in the control group of 10.7%, a type 1 error level of 2%, a type two error level of 10%, and a diversity of 0%, the required information size was 8905 participants. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility. This indicated that considering sparse data and repetitive testing, evidence was insufficient to confirm or refute a 21% RRR or a 21% RRI the for benefit or harm of higher versus lower oxygenation strategies (<a href="#CD012631-fig-0021">Figure 21</a>). The TSA CI, adjusted for multiple outcomes, sparse data, and repetitive testing, for the intervention effect was 0.33 to 3.38. </p> <div class="figure" id="CD012631-fig-0021"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 21</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the cumulated number of lung injuries. The analysis was based on a cumulated number of lung injuries in the control group (control event proportion = CEP) of 10.7%, a relative risk reduction (RRR) of 20%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-21.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the cumulated number of lung injuries. The analysis was based on a cumulated number of lung injuries in the control group (control event proportion = CEP) of 10.7%, a relative risk reduction (RRR) of 20%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility.</b> </p> </div> </div> </div> </section> </section> <section id="CD012631-sec-0120"> <h6 class="title">Bayes factor</h6> <p>Bayes factors for all outcomes are presented in <a href="#CD012631-tbl-0004">Table 3</a>. </p> </section> <section id="CD012631-sec-0121"> <h6 class="title">Subgroup analyses</h6> <p>As none of the 19 included trials reported on lung injury as a composite outcome (defined as either ARDS, pulmonary fibrosis, or pneumonia) at any time‐point, none of the prespecified subgroup analyses were performed (<a href="./references#CD012631-bbs2-0214" title="BarbateskovicM , SchjørringOL , JakobsenJC , MeyhoffCS , DahlRM , RasmussenBS , et al. Higher versus lower inspiratory oxygen fraction or targets of arterial oxygenation for adult intensive care patients. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD012631. [DOI: 10.1002/14651858.CD012631]">Barbateskovic 2017</a>). </p> </section> </section> <section id="CD012631-sec-0122"> <h5 class="title">Myocardial infarction</h5> <p>Four of the 19 trials included, with a total of 6576 participants randomised, reported on the occurrence of myocardial infarction (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>). </p> <p>No meta‐analysis of trials judged at overall low risk of bias was performed, as only one trial reporting on this outcome was judged to be at overall low risk of bias (<a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>). In this trial 8 of 1457 participants in the higher group and 14 of 1453 participants in the lower group had an acute myocardial infarction (random‐effects model RR 0.57, 95% CI 0.24 to 1.35; 2910 participants; very low‐certainty evidence). </p> <p>In all trials, a total of 2.1% in the higher group versus 2.1% in the lower group had a myocardial infarction. Meta‐analysis indicated no evidence of a difference between higher versus lower oxygenation strategies when assessing the occurrence of myocardial infarction (fixed‐effect model RR 0.77, 95% CI 0.51 to 1.15; I<sup>2</sup> = 37%; 5002 participants; 4 trials; <a href="./references#CD012631-fig-0056" title="">Analysis 6.1</a>; very low‐certainty evidence; <a href="./full#CD012631-tbl-0001">summary of findings Table 1</a>). </p> <section id="CD012631-sec-0123"> <h6 class="title">Publication bias</h6> <p>No evaluation of publication bias was performed as less than ten trials reported on acute myocardial infarction. </p> </section> <section id="CD012631-sec-0124"> <h6 class="title">Heterogeneity</h6> <p>Neither visual inspection of the forest plot nor inconsistency factor (I<sup>2</sup> = 37%; Chi<sup>2</sup> = 4.79; P = 0.19) indicated statistical heterogeneity for trials reporting on acute myocardial infarction. </p> </section> <section id="CD012631-sec-0125"> <h6 class="title">Trial Sequential Analyses</h6> <p>Trial Sequential Analysis of all trials reporting on the occurrence of myocardial infarction with an anticipated RRI of 20%, myocardial infarction in the control group of 2.1%, a type 1 error of 2%, a type 2 error of 10%, and a diversity of 47.7% was not conducted as only 3.2% of the required information size reached for this outcome. The required information size was 157,860 participants. </p> <p>Trial Sequential Analysis of all trials reporting on the occurrence of myocardial infarction with an anticipated RRI of 10%, myocardial infarction in the control group of 2.1%, a type 1 error of 2%, a type 2 error of 10%, and a diversity of 47.7% was not conducted as only 0.8% of the required information size reached for this outcome. The required information size was 603,258 participants. </p> <p>Trial Sequential Analysis of all trials reporting on the occurrence of myocardial infarction, using an RRR or RRI based on the conventional 95% confidence interval of all trials reporting on the occurrence of myocardial infarction closest to the null‐effect (RRR of 15%), myocardial infarction in the control group of 2.1%, a type 1 error of 2%, a type 2 error of 10%, and a diversity of 47.7% was not conducted as only 2.0% of the required information size reached for this outcome. The required information size was 246,656 participants. </p> </section> <section id="CD012631-sec-0126"> <h6 class="title">Bayes factor</h6> <p>Bayes factors for all outcomes are presented in <a href="#CD012631-tbl-0004">Table 3</a>. </p> </section> <section id="CD012631-sec-0127"> <h6 class="title">Subgroup analyses</h6> <p>No significant subgroup differences were found according to overall risk of bias (<a href="./references#CD012631-fig-0057" title="">Analysis 6.2</a>), level of FiO<sub>2</sub>/target in the lower group (<a href="./references#CD012631-fig-0060" title="">Analysis 6.5</a>), or oxygen delivery system (<a href="./references#CD012631-fig-0062" title="">Analysis 6.7</a>). No test for subgroup differences could be performed according to the level of FiO<sub>2</sub>/target in the higher group (<a href="./references#CD012631-fig-0059" title="">Analysis 6.4</a>). When considering effects according to ICU population only subtotals are presented as more than one trial is represented in more than one subgroup (<a href="./references#CD012631-fig-0061" title="">Analysis 6.6</a>). A subgroup effect was suggested when considering types of oxygen interventions (<a href="./references#CD012631-fig-0058" title="">Analysis 6.3</a>). </p> </section> <section id="CD012631-sec-0128"> <h6 class="title">Sensitivity analyses</h6> <p>No sensitivity analysis excluding trials comparing two low‐oxygenation strategies or two high‐oxygenation strategies was performed, as only one trial reporting on acute myocardial infarction satisfied the criteria for this analysis (<a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>). </p> <p>Results from the best‐worst (<a href="./references#CD012631-fig-0063" title="">Analysis 6.8</a>) and worst‐best case (<a href="./references#CD012631-fig-0064" title="">Analysis 6.9</a>) scenarios are presented in <a href="./appendices#CD012631-sec-0186">Appendix 11</a>. </p> </section> </section> <section id="CD012631-sec-0129"> <h5 class="title">Stroke</h5> <p>Five of the 19 trials included (7694 participants) reported on the occurrence of stroke (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>). Two trials were judged to be at overall low risk of bias (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>). Meta‐analysis of trials at overall low risk of bias indicated no evidence of a difference in the effect of higher versus lower oxygenation strategies (fixed‐effect model RR 1.04, 95% CI 0.59 to 1.83; I<sup>2</sup> = 49%; 3111 participants; 2 trials; <a href="./references#CD012631-fig-0029" title="">Analysis 1.6</a>; very low‐certainty evidence) </p> <p>In all included trials, a total of 1.8% in the higher group versus 1.3% in the lower group had a stroke. Meta‐analysis of all trials showed no evidence of a difference between higher versus lower oxygenation strategies when assessing the occurrence of stroke (fixed‐effect model RR 1.08, 95% CI 0.72 to 1.64; I<sup>2</sup> = 0; 6110 participants; 5 trials; <a href="./references#CD012631-fig-0065" title="">Analysis 7.1</a>; very low‐certainty evidence; <a href="./full#CD012631-tbl-0001">summary of findings Table 1</a>). </p> <section id="CD012631-sec-0130"> <h6 class="title">Publication bias</h6> <p>No evaluation of publication bias was performed as less than ten trials reported on the occurrence of stroke. </p> </section> <section id="CD012631-sec-0131"> <h6 class="title">Heterogeneity</h6> <p>Neither visual inspection of the forest plot nor inconsistency factor (I<sup>2</sup> = 0%; Chi<sup>2</sup> = 2.65; P = 0.62) indicated statistical heterogeneity for trials reporting on the occurrence of stroke. </p> </section> <section id="CD012631-sec-0132"> <h6 class="title">Trial Sequential Analyses</h6> <p>Trial Sequential Analysis of all trials reporting on the occurrence of stroke showed that with an anticipated RRI of 20%, stroke in the control group of 1.3%, a type 1 error of 2%, a type 2 error of 10%, and a diversity of 0%, the required information size was 108,569 participants. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility. This indicated that considering sparse data and repetitive testing, evidence was insufficient to confirm or refute a 20% RRR or a 20% RRI for benefit or harm of higher versus lower oxygenation strategies (<a href="#CD012631-fig-0022">Figure 22</a>). The TSA CI, adjusted for multiple outcomes, sparse data, and repetitive testing, for the intervention effect was 0.20 to 5.92. </p> <div class="figure" id="CD012631-fig-0022"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 22</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the occurrence of stroke. The analysis was based on stroke in the control group (control event proportion = CEP) of 1.7%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-22.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the occurrence of stroke. The analysis was based on stroke in the control group (control event proportion = CEP) of 1.7%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility.</b> </p> </div> </div> </div> <p>Trial Sequential Analysis of all trials reporting on the occurrence of stroke with an anticipated RRI of 10%, stroke in the control group of 1.3%, a type 1 error of 2%, a type 2 error of 10%, and a diversity of 0% was not conducted as only 1.5% of the required information size reached for this outcome. The required information size was 414,807 participants. </p> <p>As the diversity for the Trial Sequential Analysis of the occurence of stroke was 0%, we performed a sensitivity analysis with diversity defined as 20%, as described in the protocol (<a href="./references#CD012631-bbs2-0214" title="BarbateskovicM , SchjørringOL , JakobsenJC , MeyhoffCS , DahlRM , RasmussenBS , et al. Higher versus lower inspiratory oxygen fraction or targets of arterial oxygenation for adult intensive care patients. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD012631. [DOI: 10.1002/14651858.CD012631]">Barbateskovic 2017</a>). With an anticipated RRI of 20%, stroke in the control group of 1.3%, a type 1 error of 2%, a type 2 error of 10%, and a diversity of 20%, the required information size was 135,711 participants. As only 4.5% of the required information sizes was reached for this outcome the analysis could not be conducted. </p> <p>For the Trial Sequential Analysis using an RRR or RRI based on the conventional 95% confidence interval of all trials reporting on the occurrence of stroke closest to the null‐effect (RRR of 28%), stroke in the control group of 1.3%, a type 1 error level of 2%, a type two error level of 10%, and a diversity of 0%, the required information size was 58581. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility. This indicated that considering sparse data and repetitive testing, evidence was insufficient to confirm or refute a 35% RRR or a 35% RRI for the benefit or harm of higher versus lower oxygenation strategies (<a href="#CD012631-fig-0023">Figure 23</a>). The TSA CI, adjusted for multiple outcomes, sparse data, and repetitive testing, for the intervention effect was 0.20 to 5.92. </p> <div class="figure" id="CD012631-fig-0023"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 23</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the occurrence of stroke. The analysis was based on stroke in the control group (control event proportion = CEP) of 1.3%, a relative risk reduction (RRR) of 28%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-23.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the occurrence of stroke. The analysis was based on stroke in the control group (control event proportion = CEP) of 1.3%, a relative risk reduction (RRR) of 28%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility.</b> </p> </div> </div> </div> </section> <section id="CD012631-sec-0133"> <h6 class="title">Bayes factor</h6> <p>Bayes factors for all outcomes are presented in <a href="#CD012631-tbl-0004">Table 3</a>. </p> <section id="CD012631-sec-0134"> <p><b>Subgroup analyses</b></p> <p>No significant subgroup differences were found according to overall risk of bias (<a href="./references#CD012631-fig-0066" title="">Analysis 7.2</a>), level of FiO<sub>2</sub>/target in the lower group (<a href="./references#CD012631-fig-0069" title="">Analysis 7.5</a>), or oxygen delivery system (<a href="./references#CD012631-fig-0071" title="">Analysis 7.7</a>). No test of subgroup differences could be performed according to types of oxygen interventions (<a href="./references#CD012631-fig-0067" title="">Analysis 7.3</a>) or level of FiO<sub>2</sub>/target in the higher group (<a href="./references#CD012631-fig-0068" title="">Analysis 7.4</a>). When considering effects according to ICU population only subtotals are presented as one trial is represented in more than one subgroup (<a href="./references#CD012631-fig-0070" title="">Analysis 7.6</a>). </p> </section> </section> <section id="CD012631-sec-0135"> <h6 class="title">Sensitivity analyses</h6> <p>The sensitivity analysis excluding trials comparing two low oxygenation strategies or two high oxygenation strategies indicated no evidence of a difference in the effect of higher versus lower oxygenation strategies on the occurrence of stroke (RR 1.04, 95% CI 0.59 to 1.83; I<sup>2</sup> = 49%; 3111 participants; 2 trials; <a href="./references#CD012631-fig-0072" title="">Analysis 7.8</a>). </p> <p>Results from the best‐worst (<a href="./references#CD012631-fig-0073" title="">Analysis 7.9</a>) and worst‐best case (<a href="./references#CD012631-fig-0074" title="">Analysis 7.10</a>) scenarios are presented in <a href="./appendices#CD012631-sec-0186">Appendix 11</a>. </p> </section> </section> <section id="CD012631-sec-0136"> <h5 class="title">Sepsis</h5> <p>Three of the 19 trials included, with a total of 795 participants randomised, reported on the occurrence of sepsis at any time‐point (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>). Sepsis was reported as septicaemia (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>), bacteraemia (<a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>), or new bloodstream infection (<a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>). No sensitivity analysis was performed for sepsis according to risk of bias, as only one trial reporting on this outcome was judged to be at overall low risk of bias (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>). In this trial, 19 of 102 participants in the higher group and 11 of 99 participants in the control group experienced a new episode of sepsis (fixed‐effect RR 1.68, 95% 0.84 to 3.34, 201 participants). </p> <p>In all included trials, a total of 12.4% in the higher group versus 6.7% in the lower group had sepsis. Meta‐analysis indicated evidence of benefit from lower oxygenation strategies compared with higher when assessing the occurrence of sepsis (random‐effects model RR 1.85, 95% CI 1.17 to 2.93; I<sup>2</sup> = 0%; 752 participants; 3 trials; <a href="./references#CD012631-fig-0075" title="">Analysis 8.1</a>; very low‐certainty evidence; <a href="./full#CD012631-tbl-0001">summary of findings Table 1</a>). </p> <section id="CD012631-sec-0137"> <h6 class="title">Publication bias</h6> <p>No evaluation of publication bias was performed as less than ten trials reported on the occurrence of sepsis at any time point. </p> </section> <section id="CD012631-sec-0138"> <h6 class="title">Heterogeneity</h6> <p>Neither visual inspection of the forest plot nor inconsistency factor (I<sup>2</sup> = 0%; Chi<sup>2</sup> = 0.15; P = 0.93) indicated statistical heterogeneity for trials reporting on the occurrence of sepsis. </p> </section> <section id="CD012631-sec-0139"> <h6 class="title">Trials Sequential Analyses</h6> <p>Trial Sequential Analysis of all trials reporting on the occurrence of sepsis with an anticipated RRI of 20%, sepsis in the control group of 6.7%, a type 1 error of 2%, a type 2 error of 10%, and a diversity of 0% was not conducted as only 3.3% of the required information size reached for this outcome. The required information size was 19,797 participants. </p> <p>Trial Sequential Analysis of all trials reporting on the occurrence of sepsis with an anticipated RRI of 10%, sepsis in the control group of 6.7%, a type 1 error of 2%, a type 2 error of 10%, and a diversity of 0% was not conducted as only 0.9% of the required information size reached for this outcome. The required information size was 75,859 participants. </p> <p>As the diversity for the Trial Sequential Analysis of the occurrence of sepsis was 0%, we performed a sensitivity analysis with diversity defined as 20%, as described in the protocol (<a href="./references#CD012631-bbs2-0214" title="BarbateskovicM , SchjørringOL , JakobsenJC , MeyhoffCS , DahlRM , RasmussenBS , et al. Higher versus lower inspiratory oxygen fraction or targets of arterial oxygenation for adult intensive care patients. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD012631. [DOI: 10.1002/14651858.CD012631]">Barbateskovic 2017</a>). With an anticipated RRI of 20%, sepsis in the control group of 6.7%, a type 1 error of 2%, a type 2 error of 10%, and a diversity of 20%, the required information size was 24,352 participants. As only 2.6% of the required information sizes was reached for this outcome the analysis could not be conducted. </p> <p>For the Trial Sequential Analysis using an RRR or RRI based on the conventional 95% confidence interval of the analysis of the occurrence of sepsis closest to the null‐effect (RRI of 17%), sepsis in the control group of 6.7%, a type 1 error level of 2%, a type two error level of 10%, and a diversity of 0% was not conducted as only 2.4% of the required information sizes was reached. The required information size was 27,010 participants. </p> </section> <section id="CD012631-sec-0140"> <h6 class="title">Bayes factor</h6> <p>Bayes factors for all outcomes are presented in <a href="#CD012631-tbl-0004">Table 3</a>. </p> </section> <section id="CD012631-sec-0141"> <h6 class="title">Subgroup analyses</h6> <p>No significant subgroup differences were found according to overall risk of bias (<a href="./references#CD012631-fig-0076" title="">Analysis 8.2</a>), or oxygen delivery system (<a href="./references#CD012631-fig-0081" title="">Analysis 8.7</a>). No test of subgroup differences could be performed according to types of oxygen interventions (<a href="./references#CD012631-fig-0077" title="">Analysis 8.3</a>), level of FiO<sub>2</sub>/target in the higher group (<a href="./references#CD012631-fig-0078" title="">Analysis 8.4</a>), level of FiO<sub>2</sub>/target in the lower group (<a href="./references#CD012631-fig-0079" title="">Analysis 8.5</a>), or according to ICU‐population (<a href="./references#CD012631-fig-0080" title="">Analysis 8.6</a>). </p> </section> <section id="CD012631-sec-0142"> <h6 class="title">Sensitivity analyses</h6> <p>No sensitivity analysis excluding trials comparing two low targets or two high targets was performed, as only one trial reporting on the occurrence of sepsis satisfied the criteria for this analysis (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>). </p> <p>Results from the best‐worst (<a href="./references#CD012631-fig-0082" title="">Analysis 8.8</a>) and worst‐best case (<a href="./references#CD012631-fig-0083" title="">Analysis 8.9</a>) scenarios are presented in <a href="./appendices#CD012631-sec-0186">Appendix 11</a>. </p> </section> </section> <section id="CD012631-sec-0143"> <h5 class="title">Additional serious adverse events</h5> <section id="CD012631-sec-0144"> <h6 class="title">Serious adverse events only reported in a single trial</h6> <p>SAEs only reported in a single trial are presented in <a href="#CD012631-tbl-0002">Table 1</a>. </p> </section> <section id="CD012631-sec-0145"> <h6 class="title">Specific serious adverse events reported in two or more trials</h6> <p>The following SAEs were reported in two or more trials.</p> <section id="CD012631-sec-0146"> <p><b>Delirium</b></p> <p>Two of the 19 trials included, with a total of 239 participants randomised, reported on the occurrence of delirium (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>). A total of 10.9% in the higher group versus 10.3% in the lower group had delirium. Meta‐analysis indicated no evidence of a difference between higher versus lower oxygenation strategies when assessing the occurrence of delirium (random‐effects model RR 1.05, 95% CI 0.50 to 2.21; I<sup>2</sup> = 0%; 235 participants; 2 trials; <a href="./references#CD012631-fig-0089" title="">Analysis 9.6</a>). </p> </section> <section id="CD012631-sec-0147"> <p><b>Pneumothorax</b></p> <p>Three of the 19 trials included, with a total of 3634 participants randomised, reported on pneumothorax (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>). One trial reported the combined proportion of participants with either pneumothorax or pneumomediastinum (<a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>). A total of 5.0% in the higher group versus 3.7% in the lower group had a pneumothorax. Meta‐analysis indicated no evidence of a difference between higher versus lower oxygenation strategies when assessing the occurrence of pneumothorax (fixed‐effect model RR 1.33, 95% CI 0.86 to 2.05; I<sup>2</sup> = 0%; 2269 participants; 3 trials; <a href="./references#CD012631-fig-0090" title="">Analysis 9.7</a>). </p> </section> <section id="CD012631-sec-0148"> <p><b>Intestinal ischaemia</b></p> <p>Three of the 19 trials included, with a total of 3575 participants randomised, reported on intestinal ischaemia (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>). A total of 2.0% in the higher group versus 2.3% in the lower group had intestinal ischaemia. Meta‐analysis indicated no evidence of a difference between higher versus lower oxygenation strategies when assessing the occurrence of intestinal ischaemia (random‐effects model RR 0.90, 95% CI 0.35 to 2.30; I<sup>2</sup> = 46%; 3545 participants; 3 trials; <a href="./references#CD012631-fig-0091" title="">Analysis 9.8</a>). </p> </section> <section id="CD012631-sec-0149"> <p><b>Cardiovascular failure including shock</b></p> <p>Two of the 19 trials included, with a total of 3408 participants randomised, reported on cardiovascular failure including shock (<a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>). A total of 3.2% in the higher group versus 3.0% in the lower group had cardiovascular failure including shock. Meta‐analysis indicated no evidence of a difference between higher versus lower oxygenation strategies when assessing the occurrence of cardiovascular failure including shock (fixed‐effect model RR 1.09, 95% CI 0.98 to 1.20; I<sup>2</sup> = 85%; 3355 participants; 2 trials; <a href="./references#CD012631-fig-0092" title="">Analysis 9.9</a>). </p> </section> <section id="CD012631-sec-0150"> <p><b>Cardiac arrhythmia</b></p> <p>Six of the 19 trials included, with a total of 4486 participants randomised, reported on cardiac arrhythmia (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>). One trial reported both the proportion of participants with atrial and ventricular arrhythmias, and these were combined in the analysis (<a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>). A total of 1.0% in the higher group versus 1.2% in the lower group had cardiac arrhythmia. Meta‐analysis indicated no evidence of a difference between higher versus lower oxygenation strategies when assessing the occurrence of cardiac arrhythmia (random‐effects model RR 0.98, 95% CI 0.82 to 1.16; I<sup>2</sup> = 0%; 3216 participants; 6 trials; <a href="./references#CD012631-fig-0093" title="">Analysis 9.10</a>). </p> </section> <section id="CD012631-sec-0151"> <p><b>Liver failure</b></p> <p>Three of the 19 trials included, with a total of 1164 participants randomised, reported on liver failure (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>). A total of 4.5% in the higher group versus 2.5% in the lower group had liver failure. Meta‐analysis indicated no evidence of a difference between higher versus lower oxygenation strategies when assessing the occurrence of liver failure (random‐effects model RR 1.65, 95% CI 0.29 to 9.23; I<sup>2</sup> = 73%; 951 participants; 3 trials; <a href="./references#CD012631-fig-0094" title="">Analysis 9.11</a>). </p> </section> <section id="CD012631-sec-0152"> <p><b>Renal failure</b></p> <p>Five of the 19 trials included, with a total of 4877 participants randomised, reported on renal failure (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>). A total of 12.1% in the higher group versus 19.8% in the lower group had renal failure. Meta‐analysis indicated no evidence of a difference between higher versus lower oxygenation strategies when assessing the occurrence of renal failure (fixed‐effect model RR 1.03, 95% CI 0.92 to 1.16; I<sup>2</sup> = 0%; 4072 participants; 5 trials; <a href="./references#CD012631-fig-0095" title="">Analysis 9.12</a>). </p> </section> <section id="CD012631-sec-0153"> <p><b>Seizure</b></p> <p>Two of the 19 trials included, with a total of 1007 participants randomised, reported on the occurrence of seizures (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>). A total of 16.7% in the higher group versus 16.7% in the lower group had a new occurrence of seizure. Meta‐analysis indicated no evidence of a difference between higher versus lower oxygenation strategies when assessing the occurrence of seizure (random‐effects model RR 1.00, 95% CI 0.76 to 1.31; I<sup>2</sup> = 0%; 990 participants; 2 trials; <a href="./references#CD012631-fig-0096" title="">Analysis 9.13</a>). </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012631-sec-0154" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012631-sec-0154"></div> <section id="CD012631-sec-0155"> <h3 class="title" id="CD012631-sec-0155">Summary of main results</h3> <p>We included 19 trials that randomised a total of 10,385 participants in this updated systematic review, of which 17 trials, with a total of 10,248 randomised participants, contributed with data to the analyses. Sixteen trials reported on mortality; serious adverse events (SAEs) were reported in 17 trials, however only three of these trials reported the proportion of participants with one or more SAE as a composite outcome; two trials reported on quality of life; no trial reported on lung injury as a composite outcome (defined as acute respiratory distress syndrome (ARDS), pneumonia, or lung fibrosis), but eight trials reported on the individual components; three trials reported on acute myocardial infarction; four trials reported on stroke, and three trials reported on sepsis. </p> <p>Overall, we found no evidence for a beneficial or harmful effect of higher versus lower oxygenation strategies for adults admitted to the intensive care unit (ICU). Also, the certainty of evidence for all outcomes was low or very low, thus limiting the ability to draw clear conclusions. </p> <p>Analysis of all‐cause mortality at maximum follow‐up showed no difference between higher versus lower oxygenation strategies for neither trials judged to being at overall low risk of bias, nor when considering all included trials. Trial Sequential Analysis (TSA), considering multiple outcomes, sparse data, and repetitive testing, revealed that a relative risk increase (RRI) of 10% could be refused as the trial sequential monitoring border for futility was crossed (<a href="#CD012631-fig-0004">Figure 4</a>). </p> <p>Analysis of the highest reported proportion of participants with any specific SAE at maximum follow‐up showed no difference between higher versus lower oxygenation strategies when considering trials at overall low risk of bias, or when considering all included trials. When analysing the cumulated number of SAEs in all trials we found indication of a benefit of a lower oxygenation strategy. Trial Sequential Analysis, considering multiple outcomes, sparse data, and repetitive testing, revealed that an RRI of 10% on the highest reported proportion of participants with any SAE at maximum follow‐up could be refused as the trial sequential monitoring border for futility was crossed (<a href="#CD012631-fig-0010">Figure 10</a>). </p> <p>Two trials reported on quality of life at any time post‐randomisation, with no indications of a difference between higher versus lower oxygenation strategies. </p> <p>We found no evidence of a difference in the occurrence of lung injury at maximum follow‐up with higher versus lower oxygenation strategies when analysed as the highest proportion, the cumulated number, or as individual components. However, the evidence is very uncertain due to serious risk of bias and imprecision. Additionally, Trial Sequential Analysis considering multiple outcomes, sparse data, and repetitive testing, revealed that only 13% of the required information size was reached to detect or reject a 20% RRI, and that neither conventional nor trial sequential monitoring boundaries for benefit, harm, or futility had been crossed (<a href="#CD012631-fig-0016">Figure 16</a>). </p> <p>We found no evidence of a difference in the occurrence of myocardial infarction at maximum follow‐up when comparing higher versus lower oxygenation strategies in all included trials. Only one of three trials reporting on acute myocardial infarction was judged to be at overall low risk of bias. </p> <p>We found no evidence of a difference in the occurrence of stroke at maximum follow‐up when comparing higher versus lower oxygenation strategies in trials judged to be at overall low risk of bias, nor in all included trials. </p> <p>Three trials reported on the occurrence of sepsis at maximum follow‐up, indicating potential harm from higher versus lower oxygenation strategies. Only one trial reporting on severe sepsis was judged to be at overall low risk of bias for this outcome. </p> </section> <section id="CD012631-sec-0156"> <h3 class="title" id="CD012631-sec-0156">Overall completeness and applicability of evidence</h3> <p>In this updated review we reran the literature search and included randomised controlled trials (RCTs) up until November 2022 and identified 10 additional trials (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>) in addition to the ten trials (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0006" title="IshiiK , MorimatsuH , HyodoT , OnoK , HidakaH , KoyamaY , et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e]">Ishii 2018</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>; <a href="./references#CD012631-bbs2-0209" title="YoungPJ , MackleDM , BaileyMJ , BeasleyRW , BennettVL , DeaneAM , et al, The ICU-ROX pilot investigators, The Australian and New Zealand Intensive Care Society Clinical Trials Group. Intensive care unit randomised trial comparing two approaches to oxygen therapy (ICU-ROX): results of the pilot phase. Critical Care and Resuscitation2017;19(4):344-54. [PMID: 29202261]">Young 2017</a>) included up to December 2018 in the previous version of this review (<a href="./references#CD012631-bbs2-0215" title="BarbateskovicM , SchjørringOL , KraussSR , JakobsenJC , MeyhoffCS , DahlRM , et al. Higher versus lower fraction of inspired oxygen or targets of arterial oxygenation for adults admitted to the intensive care unit. Cochrane Database of Systematic Reviews2019, Issue 11. Art. No: CD012631. [DOI: 10.1002/14651858.CD012631.pub2] [PMID: 31773728]">Barbateskovic 2019</a>). One previously identified trial was excluded (<a href="./references#CD012631-bbs2-0209" title="YoungPJ , MackleDM , BaileyMJ , BeasleyRW , BennettVL , DeaneAM , et al, The ICU-ROX pilot investigators, The Australian and New Zealand Intensive Care Society Clinical Trials Group. Intensive care unit randomised trial comparing two approaches to oxygen therapy (ICU-ROX): results of the pilot phase. Critical Care and Resuscitation2017;19(4):344-54. [PMID: 29202261]">Young 2017</a>) due to overlap in trial population with a new report (<a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>). One‐year follow‐up in <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a> was reported by <a href="./references#CD012631-bbs2-0094" title="CrescioliE , KlitgaardTL , PoulsenLM , BrandBA , SiegemundM , GrøfteT , et al. Long‑term mortality and health‑related quality of life of lower versus higher oxygenation targets in ICU patients with severe hypoxaemia. Intensive Care Medicine2022;48(6):714-22. [DOI: 10.1007/s00134-022-06695-0] [PMID: 35441849]">Crescioli 2022a</a>. </p> <p>We identified a high risk of clinical diversity/heterogeneity amongst the identified trials. See <a href="./references#CD012631-sec-0202" title="">Characteristics of included studies</a>. This was especially evident in relation to the applied interventions, as the trials did not use the same definitions of higher and lower oxygenation strategies. Some trials used a fixed fraction of inspired oxygen (FiO<sub>2</sub>), whilst others used oxygenation targets of arterial or peripheral oxygen saturation (SaO<sub>2</sub> or SaO<sub>2</sub>) or partial pressure of arterial oxygen (PaO<sub>2</sub>) or combinations of such. Thus, the achieved oxygen level may end up being high when compared to other trials, even though participants were allocated to the lower FiO<sub>2</sub> or oxygenation target group; only six of 19 trials assessed strategies categorised by us as true higher versus true lower (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>). This is reflected in the sensitivity analyses excluding high versus high strategies and low versus low strategies (<a href="./references#CD012631-fig-0037" title="">Analysis 2.8</a>; <a href="./references#CD012631-fig-0072" title="">Analysis 7.8</a>). Additionally, some trials were designed with an overlap between interventions (<a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>) thus challenging inferences on outcome effects. Also, the duration of the interventions varied substantially, ranging from a few hours (<a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>) to the entirety of the ICU admission for up to 90 days including any ICU readmissions (<a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>). A summary of interventions used in the included trials is presented in <a href="#CD012631-tbl-0003">Table 2</a>. </p> <p>Clinical diversity/heterogeneity in trial settings and the studied populations and was also present. The identified trials were conducted from 1994 (<a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>) to 2022 (<a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>). Nine trials were conducted in Europe (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>); three in China (<a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>); two in Iran (<a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>; <a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>); one in Australia and New Zealand (<a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>); one in Australia, New Zealand, and France (<a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>); one in Hong Kong (<a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>); one in Japan (<a href="./references#CD012631-bbs2-0006" title="IshiiK , MorimatsuH , HyodoT , OnoK , HidakaH , KoyamaY , et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e]">Ishii 2018</a>); and one in the USA (<a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>). The mean or median age of participants spanned from 44 years (<a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>) to 70 years (<a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>), and the percentage of males ranged from 49% (<a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>) to 84% (<a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>). The severity of disease was reported in various manners; five trials reported Acute Physiology and Chronic Health Evaluation II (APACHE II) (<a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>); two trials reported Simplified Acute Physiology Score (SAPS II) (<a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>); two trials reported SAPS III (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>); two trials reported <b>:</b> sequential organ failure assessment (SOFA) scores (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>); two trials reported SOFA scores excluding the respiratory component (<a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>); one trial reported APACHE III (<a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>); one trial reported Bartel index (<a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>); two trials reported Glasgow Coma Scale (<a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>); and three trials did not report any score (<a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0006" title="IshiiK , MorimatsuH , HyodoT , OnoK , HidakaH , KoyamaY , et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e]">Ishii 2018</a>; <a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>). Moreover, the severity of disease differed also amongst the included trials as illustrated by the median APACHE II score spanning from 17 (<a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>) to 28 (<a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>). </p> <p>All participants were admitted to an ICU prior to randomisation, but the inclusion criteria differed substantially; 11 trials included multidisciplinary ICU patients (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>); 11 trials restricted inclusion to patients receiving invasive mechanical ventilation (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0006" title="IshiiK , MorimatsuH , HyodoT , OnoK , HidakaH , KoyamaY , et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e]">Ishii 2018</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>; <a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>); five trials included only participants with respiratory failure, but with varying definitions of such (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a>; <a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>); four trials included only medical ICU patients (<a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>); three trials included only surgical ICU patients (<a href="./references#CD012631-bbs2-0006" title="IshiiK , MorimatsuH , HyodoT , OnoK , HidakaH , KoyamaY , et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e]">Ishii 2018</a>; <a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>); two trials included only participants with traumatic brain injury (<a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a>; <a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a>); one trial included only participants with<b>:</b> chronic obstructive pulmonary disease (COPD) (<a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a>), three additional trials allowed patients with COPD to be randomised (<a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>; <a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a>), whilst seven trials excluded patients with COPD (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a>; <a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a>; <a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a>; <a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a>); two trials included only adults resuscitated from out‐of‐hospital cardiac arrest (<a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a>; <a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a>); and one trial included only adults with acute stroke (<a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a>). These obvious differences in inclusion criteria may have caused potentially different effect sizes of the applied interventions. Consequently, the overall generalisability of the findings to all types of ICU patients may be impeded. Statistical heterogeneity, however, was evaluated as being low or moderate, except when considering the estimated cumulated number of participants with one or more SAEs, number of participants with a new episode of liver failure, and number of participants with a new episode of cardiovascular failure including shock. </p> <p>Missing or incomplete outcome data, as evaluated by the sensitivity analyses exploring best‐worst and worst‐best case scenarios, could potentially influence the effect estimates for several outcomes (<a href="./appendices#CD012631-sec-0186">Appendix 11</a>). </p> <p>The Trial Sequential Analyses on all‐cause mortality and highest reported proportion of SAEs could both reject a 20% and a 10% RRR or RRI, when accounting for multiple outcomes and sparse data. Trial Sequential Analysis on SAEs revealed that the boundaries for futility was crossed in both analyses (<a href="#CD012631-fig-0004">Figure 4</a>; <a href="#CD012631-fig-0010">Figure 10</a>). The TSA on quality of life revealed that the required information size to reject an 7‐point increase of decrease in EQ‐VAS was reached (<a href="#CD012631-fig-0013">Figure 13</a>). The TSA on lung injuries revealed that the required information size to detect or reject an RRR or RRI of 20% was not reached (<a href="#CD012631-fig-0016">Figure 16</a>). This was also the case for myocardial infarction, stroke, and sepsis. However, further data for all outcomes are needed to establish more precise effect estimates. </p> </section> <section id="CD012631-sec-0157"> <h3 class="title" id="CD012631-sec-0157">Quality of the evidence</h3> <p>We used <a href="./references#CD012631-bbs2-0114" title="GRADEpro GDT. Version accessed 25 March 2019. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a> to assess the certainty of the evidence for the results on all‐cause mortality, serious adverse events (SAEs), quality of life, lung injury, acute myocardial infarction, stroke, and sepsis both in trials judged to be at overall low risk of bias and in all included trials (<a href="./full#CD012631-tbl-0001">summary of findings Table 1</a>). </p> <p>We found no indications of publication bias when considering all‐cause mortality, the estimated highest reported proportion of SAEs, or the estimated cumulated number of SAEs. For all other outcomes, we were unable to assess publication bias due to limited data. </p> <p>The GRADE assessment showed that the certainty of the evidence for an effect on mortality in trials at overall low risk of bias was low due to indirectness. The certainty was very low when considering all trials included due to the risk of bias and indirectness. Trial Sequential Analysis showed that the trial sequential monitoring borders for futility were crossed. Thus, even when considering repetitive testing and disregarding the risk of bias, the evidence was sufficient to refute a 10% RRI or RRR for benefit or harm from higher versus lower oxygenation strategies. </p> <p>The certainty of the evidence for an effect on the proportion of SAEs in trials at overall low risk of bias was low due to indirectness and very low when considering all trials due to the added risk of bias. Trial Sequential Analysis showed that the boundary for futility was crossed and the required information size was reached; hence, evidence was sufficient to reject an RRI of at least 20%. </p> <p>The certainty of the evidence was very low for quality of life due to inconsistency, risk of bias, and imprecision. </p> <p>The certainty of the evidence was very low for lung injury in both trials at low risk of bias due to indirectness, and imprecision, but also in all identified trials due to risk of bias, indirectness, and imprecision. </p> <p>The certainty of the evidence was very low for acute myocardial infarction, stroke, and sepsis in both trials at low risk of bias due to indirectness, and imprecision, but also in all identified trials due to risk of bias, indirectness, and imprecision. </p> </section> <section id="CD012631-sec-0158"> <h3 class="title" id="CD012631-sec-0158">Potential biases in the review process</h3> <section id="CD012631-sec-0159"> <h4 class="title">Strengths</h4> <p>For this updated review we used a predefined (<a href="./references#CD012631-bbs2-0214" title="BarbateskovicM , SchjørringOL , JakobsenJC , MeyhoffCS , DahlRM , RasmussenBS , et al. Higher versus lower inspiratory oxygen fraction or targets of arterial oxygenation for adult intensive care patients. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD012631. [DOI: 10.1002/14651858.CD012631]">Barbateskovic 2017</a>), rigorous, up to date, systematic review methodology, and made only minor changes to the methods during the updating process (<a href="#CD012631-sec-0200">Differences between protocol and review</a>). In addition, we expanded the search strategy and screened a vast volume of reports. </p> <p>As is now recommended, we used the RoB‐2 tool to evaluate the risk of bias (systematic errors) for all outcomes, and GRADEpro GDT to assess the certainty of evidence (<a href="./references#CD012631-bbs2-0126" title="HigginsJPT , SterneJAC , SavovićJ , PageMJ , HróbjartssonA , BoutronI , et al. A revised tool for assessing risk of bias in randomized trials. In: Chandler J, McKenzie J, Boutron I, Welch V (editors). Cochrane Methods. Cochrane Database of Systematic Reviews, 2016. Available from cochranelibrary.com/cdsr/doi/10.1002/14651858.CD201601/full. [DOI: dx.doi.org/10.1002/14651858.CD201601]">Higgins 2016</a>; <a href="./references#CD012631-bbs2-0189" title="SterneJAC , SavovićJ , PageMJ , ElbersRG , BlencoweNS , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. British Medical Journal2019;366:l4898. [DOI: 10.1136/bmj.l4898] [PMID: 31462531]">Sterne 2019</a>). We complemented the conventional meta‐analyses with Trial Sequential Analyses, incorporating adjusted thresholds for significance as a sensitivity analysis and as means to rigorously control the risk of random errors. To further investigate the magnitude of effects we post‐hoc performed Trial Sequential Analyses assessing an RRI or RRR of 10%. Additionally, we used the eight‐step procedure as suggested by <a href="./references#CD012631-bbs2-0135" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [DOI: 10.1186/1471-2288-14-120] [PMID: 25416419]">Jakobsen 2014a</a> when assessing if the thresholds or statistical and clinical significance were crossed. </p> <p>We have provided detailed summaries of all included trials, as well as of all identified ongoing trials. </p> <p>Post‐hoc, we increased the power in the meta‐analyses from 80% to 90% as meta‐analyses should use the same or higher power as the included trials, to communicate the best available evidence. </p> <p>Our findings were also supplemented by sensitivity analyses to assess the robustness.</p> <p>Trials were included regardless of publication type, publication status, language, and outcomes reported. We contacted relevant trial authors if additional information was required. </p> <p>We conducted two post‐hoc analyses that estimated the effects of higher versus lower oxygenation strategies on the risk of having one or more SAE, and lung injury, respectively. </p> <p>We performed analyses of publication bias on all‐cause mortality, and detected no indications of publication bias for this estimate. </p> </section> <section id="CD012631-sec-0160"> <h4 class="title">Limitations</h4> <p>To the best of our knowledge, we have identified all relevant trials for this review. Screening of reports has been carried out in two rounds with different review authors. TLK and FMN did the screening for the update and were assisted by the primary review authors OLS and MB. </p> <p>Five review authors (TLK, OLS, JW, AP, and BSR) were investigators of one of the included trials (<a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>). Assessment of this trial and data extraction was validated by another review author (FMN), not involved in this trial, to avoid bias in the process. </p> <p>We identified 13 ongoing trials (<a href="./references#CD012631-bbs2-0055" title="ACTRN12620000391976. The mega randomised registry trial comparing conservative vs. liberal oxygenation targets [A randomised, registry-embedded, single blinded clinical trial comparing conservative oxygen therapy to liberal oxygen therapy in mechanically ventilated adults in the intensive care unit]. anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379432&amp;isReview=true (first received 10 March 2020). ">ACTRN12620000391976</a>; <a href="./references#CD012631-bbs2-0056" title="ChiCTR-INR-17012800. The effect of conservative oxygen therapy in the mechanical ventilation patients. chictr.org.cn/showproj.html?proj=21892 (first received 26 September 2017). ">ChiCTR‐INR‐17012800</a>; <a href="./references#CD012631-bbs2-0057" title="ChiCTR-IOR-17011717. Comparing the effects of conservative oxygen therapy vs conventional oxygen therapy on outcomes in critically ill patients [The effects of conservative oxygen therapy vs conventional oxygen therapy on outcomes in critically ill patients: a randomised controlled trial]. chictr.org.cn/showproj.html?proj=19990 (first received 21 June 2017). ">ChiCTR‐IOR‐17011717</a>; <a href="./references#CD012631-bbs2-0058" title="CTRI/2020/12/029614. Liberal use of oxygen in early stage of COVID-19 patients [Early liberal oxygen therapy in COVID-19: an open-labeled randomised control trial]. ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=49680&amp;EncHid=&amp;modid=&amp;compid=%27,%2749680det%27 (first received 2 November 2020). ">CTRI/2020/12/029614</a>; <a href="./references#CD012631-bbs2-0059" title="ISRCTN13384956. Intensive care unit randomised trial comparing two approaches to oxygen therapy (UK-ROX). isrctn.com/ISRCTN13384956 (first received 8 December 2020). ">ISRCTN13384956</a>; <a href="./references#CD012631-bbs2-0060" title="JPRN-UMIN000046914. Early restricted oxygen therapy after resuscitation from cardiac arrest trial [Early restricted oxygen therapy after resuscitation from cardiac arrest trial – ER-OXYTRAC trial]. trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000046914 (first received 14 February 2022). ">JPRN‐UMIN000046914</a>; <a href="./references#CD012631-bbs2-0061" title="NCT02999932. Pulse Oxygen Saturation (SpO2) Directed Oxygen Therapy (POSDOT) [Effect of low vs high peripheral oxygen saturation (SpO 2 ) directed oxygen therapy on mortality among critically ill patients]. clinicaltrials.gov/show/NCT02999932 (first received 14 December 2016). ">NCT02999932</a>; <a href="./references#CD012631-bbs2-0062" title="NCT04144868. Safety and efficacy of NBO in acute intracerebral hemorrhage. clinicaltrials.gov/show/NCT04144868 (first received 30 December 2019). ">NCT04144868</a>; <a href="./references#CD012631-bbs2-0063" title="NCT04198077. Conservative versus conventional oxygen administration in critically ill patients [Conservative vs conventional oxygen administration in critically ill patients: effects on ICU mortality. A multicentre randomized open label clinical trial]. clinicaltrials.gov/show/NCT04198077 (first received 10 December 2019). ">NCT04198077</a>; <a href="./references#CD012631-bbs2-0064" title="NCT04425031. Handling oxygenation targets in COVID-19 (HOT-COVID) [Handling oxygenation targets in COVID-19 patients with acute hypoxaemic respiratory failure in the intensive care unit: a randomised clinical trial of a lower versus a higher oxygenation target]. clinicaltrials.gov/show/NCT04425031 (first received 5 June 2020). ">NCT04425031</a>; <a href="./references#CD012631-bbs2-0065" title="NCT04824703. Comparative study between liberal and conservative oxygen therapy in mechanically ventilated intensive care patients. clinicaltrials.gov/show/NCT04824703 (first received 26 March 2021). ">NCT04824703</a>; <a href="./references#CD012631-bbs2-0066" title="NCT05404373. Treatment duration on normobaric hyperoxia in acute ischemic stroke [The efficacy and safety of normobaric hyperoxia on treatment duration for acute ischemic stroke patients with endovascular treatment]. clinicaltrials.gov/show/NCT05404373 (first received 3 June 2022). ">NCT05404373</a>; <a href="./references#CD012631-bbs2-0067" title="NL7185. Arterial oxygenation targets in intensive care patients [ICONIC study − conservative versus conventional oxygenation targets in intensive care patients: study protocol for a randomized clinical trial]. onderzoekmetmensen.nl/en/trial/19970 (first received 20 July 2018). ">NL7185</a>) comparing higher versus lower oxygenation strategies in adult ICU patients. Publication of these trials will increase the precision of the estimates of effects. </p> <p>We made several post‐hoc changes to the analyses pre‐planned in the protocol to improve the quality of the final updated review. All changes are listed in the section <a href="#CD012631-sec-0200">Differences between protocol and review</a>. </p> <p>When evaluating the risk of bias we judged several trials to be at overall low risk of bias for several outcomes, despite none of the identified trials being fully blinded (i.e. blinding of participants/relatives, staff, and outcome assessors). Even though data should be included from trials where blinding of participants and/or personnel is not possible (<a href="./references#CD012631-bbs2-0170" title="PocockSJ , ClaytonTC , StoneGW . Design of major randomized trials: part 3 of a 4-part series on statistics for clinical trials. Journal of the American College of Cardiology2015;66(24):2757-66. [DOI: 10.1016/j.jacc.2015.10.036] [PMID: 26700838]">Pocock 2015</a>), inadequate blinding may still represent a limitation since it has been associated with underestimation of adverse intervention effects and amplifications of positive effects (<a href="./references#CD012631-bbs2-0129" title="HróbjartssonA , EmanuelssonF , Skou ThomsenAS , HildenJ , BrorsonS . Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies. International Journal of Epidemiology2014;43(4):1272-83. [DOI: 10.1093/ije/dyu115] [PMID: 24881045]">Hróbjartsson 2014</a>; <a href="./references#CD012631-bbs2-0181" title="SavovićJ , TurnerRM , MawdsleyD , JonesHE , BeynonR , HigginsJPT , et al. Association between risk-of-bias assessments and results of randomized trials in Cochrane Reviews: the ROBES meta-epidemiologic study. American Journal of Epidemiology2018;187(5):1113-22. [DOI: 10.1093/aje/kwx344] [PMID: 29126260]">Savović 2018</a>). On this basis, a biassed effect estimate can not be precluded based on the included trials. However, according to the updated RoB‐2 tool, we did not downgrade the certainty of the evidence on mortality on this basis (<a href="./references#CD012631-bbs2-0189" title="SterneJAC , SavovićJ , PageMJ , ElbersRG , BlencoweNS , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. British Medical Journal2019;366:l4898. [DOI: 10.1136/bmj.l4898] [PMID: 31462531]">Sterne 2019</a>). </p> <p>We analysed the individual components of 'serious adverse events', because each component of a composite outcome may not be equally severe and therefore could distort the result of the outcome (<a href="./references#CD012631-bbs2-0111" title="GarattiniS , JakobsenJC , WetterslevJ , BerteléV , BanziR , RathA , et al. Evidence-based clinical practice: overview of threats to the validity of evidence and how to minimise them. European Journal of Internal Medicine2016;32:13-21. [DOI: 10.1016/j.ejim.2016.03.020] [PMID: 27160381]">Garattini 2016</a>). If more serious adverse events occur in one group than in the other, there is a risk of ignoring the actual differences in severity when a composite outcome is used. We identified three trials reporting on SAEs as a composite outcome of 'participants with one or more serious adverse events' (<a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a>; <a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a>; <a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a>). As we did not identify any trials that reported on the composite outcome of 'lung injury', we analysed each component separately here as well. When analysing the 'highest reported proportion of serious adverse events' and 'highest reported proportion of lung injuries' the analyses included both participants from the event with the highest proportion, but the same participants may also have had other SAEs or lung injuries. If mortality, for example, was the highest proportion of SAEs, the analysis would imply that all participants that survived did not experience another SAE. Thus, the analysis necessarily underestimates the 'proportion of participants with one or more SAE', as it would be reasonable to expect participants who are not included in the highest reported proportion to experience other SAEs not included in the highest reported proportion. On the contrary, the analyses ascertaining the 'cumulated proportion of SAEs' and 'cumulated number of lung injuries' inadvertently risk overestimating the intervention effect, as it implies that all participants who experience an SAE or lung injury only had this one specific event. Again, it is reasonable to expect at least one participant to experience more than one SAE. Thus, the 'true' effect is expected to reside in between these two extremes. </p> </section> </section> <section id="CD012631-sec-0161"> <h3 class="title" id="CD012631-sec-0161">Agreements and disagreements with other studies or reviews</h3> <p>Several systematic reviews of randomised clinical trials on oxygenation strategies in critically ill patients have been published in recent years. For this review, we included only trials assessing adults admitted to and randomised within the ICU without limiting findings to specific patients categories, whereas other reviews also included other settings, e.g. ARDS, trauma, surgery, or pre‐hospital initiated oxygen supplementation (<a href="./references#CD012631-bbs2-0089" title="CabelloJB , BurlsA , EmparanzaJI , BaylissS , QuinnT . Oxygen therapy for acute myocardial infarction. Cochrane Database of Systematic Reviews2016, Issue 12. Art. No: CD007160. [DOI: 10.1002/14651858.CD007160.pub4] [PMID: 27991651]">Cabello 2016</a>; <a href="./references#CD012631-bbs2-0091" title="ChuDK , KimLH , YoungPJ , ZamiriN , AlmenawerSA , JaeschkeR , et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet2018;391(10131):1693-705. [DOI: 10.1016/S0140-6736(18)30479-3] [PMID: 29726345]">Chu 2018</a>; <a href="./references#CD012631-bbs2-0096" title="CumpsteyAF , OldmanAH , SmithAF , MartinD , GrocottMP . Oxygen targets in the intensive care unit during mechanical ventilation for acute respiratory distress syndrome: a rapid review. Cochrane Database of Systematic Reviews2020, Issue 9. Art. No: CD013708. [DOI: 10.1002/14651858.CD013708] [PMID: 32870512]">Cumpstey 2020</a>; <a href="./references#CD012631-bbs2-0110" title="EskesenTG , BaekgaardJS , SteinmetzJ , RasmussenLS . Initial use of supplementary oxygen for trauma patients: a systematic review. BMJ Open2018;8(7):e020880. [DOI: 10.1136/bmjopen-2017-020880] [PMID: 29982208]">Eskesen 2018</a>; <a href="./references#CD012631-bbs2-0183" title="SepehrvandN , JamesSK , StubD , KhoshnoodA , EzekowitzJA , HofmannR . Effects of supplemental oxygen therapy in patients with suspected acute myocardial infarction: a meta-analysis of randomised clinical trials. Heart2018;104(20):1694-8. [DOI: 10.1136/heartjnl-2018-313089] [PMID: 29599378]">Sepehrvand 2018</a>; <a href="./references#CD012631-bbs2-0207" title="YouJ , FanX , BiX , XianY , XieD , FanM , et al. Association between arterial hyperoxia and mortality in critically ill patients: a systematic review and meta-analysis. Journal of Critical Care2018;47:260-8. [DOI: 10.1016/j.jcrc.2018.07.014] [PMID: 30077082]">You 2018</a>; <a href="./references#CD012631-bbs2-0079" title="BarbateskovicM , SchjørringOL , KraussSR , MeyhoffCS , JakobsenJC , RasmussenBS , et al. Higher vs lower oxygenation strategies in acutely ill adults: a systematic review with meta-analysis and trial sequential analysis. Chest2021;159(1):154-73. [DOI: 10.1016/j.chest.2020.07.015] [PMID: 32687907]">Barbateskovic 2021a</a>; <a href="./references#CD012631-bbs2-0147" title="LiL , ZhangY , WangP , ChongW , HaiY , XuP , et al. Conservative versus liberal oxygen therapy for acutely ill medical patients: a systematic review and meta-analysis. International Journal of Nursing Studies2021;118:103924. [DOI: 10.1016/j.ijnurstu.2021.103924] [PMID: 33774265]">Li 2021a</a>; <a href="./references#CD012631-bbs2-0117" title="HansenTE , ChristensenRE , BaekgaardJ , SteinmetzJ , RasmussenLS . Supplemental oxygen for traumatic brain injury: a systematic review. Acta Anaesthesiologica Scandinavica2022;66(3):307-16. [DOI: 10.1111/aas.14019] [PMID: 34907522]">Hansen 2021</a>). Meta‐analyses report conflicting findings, with some reporting that higher levels of supplemental oxygen may be harmful or not beneficial (<a href="./references#CD012631-bbs2-0089" title="CabelloJB , BurlsA , EmparanzaJI , BaylissS , QuinnT . Oxygen therapy for acute myocardial infarction. Cochrane Database of Systematic Reviews2016, Issue 12. Art. No: CD007160. [DOI: 10.1002/14651858.CD007160.pub4] [PMID: 27991651]">Cabello 2016</a>; <a href="./references#CD012631-bbs2-0091" title="ChuDK , KimLH , YoungPJ , ZamiriN , AlmenawerSA , JaeschkeR , et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet2018;391(10131):1693-705. [DOI: 10.1016/S0140-6736(18)30479-3] [PMID: 29726345]">Chu 2018</a>; <a href="./references#CD012631-bbs2-0183" title="SepehrvandN , JamesSK , StubD , KhoshnoodA , EzekowitzJA , HofmannR . Effects of supplemental oxygen therapy in patients with suspected acute myocardial infarction: a meta-analysis of randomised clinical trials. Heart2018;104(20):1694-8. [DOI: 10.1136/heartjnl-2018-313089] [PMID: 29599378]">Sepehrvand 2018</a>; <a href="./references#CD012631-bbs2-0198" title="van derWalLI , GrimCCA , vanWesterlooDJ , SchultzMJ , deJongeE , HelmerhorstHJF . Higher versus lower oxygenation strategies in the general intensive care unit population: a systematic review, meta-analysis and meta-regression of randomized controlled trials. Journal of Critical Care2022;72:154151. [DOI: 10.1016/j.jcrc.2022.154151] [PMID: 36182731]">van der Wal 2022</a>; <a href="./references#CD012631-bbs2-0207" title="YouJ , FanX , BiX , XianY , XieD , FanM , et al. Association between arterial hyperoxia and mortality in critically ill patients: a systematic review and meta-analysis. Journal of Critical Care2018;47:260-8. [DOI: 10.1016/j.jcrc.2018.07.014] [PMID: 30077082]">You 2018</a>), whilst others report insufficient evidence to support beneficial or harmful effects of higher versus lower oxygenation strategies (<a href="./references#CD012631-bbs2-0079" title="BarbateskovicM , SchjørringOL , KraussSR , MeyhoffCS , JakobsenJC , RasmussenBS , et al. Higher vs lower oxygenation strategies in acutely ill adults: a systematic review with meta-analysis and trial sequential analysis. Chest2021;159(1):154-73. [DOI: 10.1016/j.chest.2020.07.015] [PMID: 32687907]">Barbateskovic 2021a</a>; <a href="./references#CD012631-bbs2-0096" title="CumpsteyAF , OldmanAH , SmithAF , MartinD , GrocottMP . Oxygen targets in the intensive care unit during mechanical ventilation for acute respiratory distress syndrome: a rapid review. Cochrane Database of Systematic Reviews2020, Issue 9. Art. No: CD013708. [DOI: 10.1002/14651858.CD013708] [PMID: 32870512]">Cumpstey 2020</a>; <a href="./references#CD012631-bbs2-0097" title="CumpsteyAF , OldmanAH , MartinDS , SmithA , GrocottMPW . Oxygen targets during mechanical ventilation in the ICU: a systematic review and meta-analysis. Critical Care Explorations 25 March 2022;4(4):e0652. [DOI: 10.1097/CCE.0000000000000652] [PMID: 35506014]">Cumpstey 2022</a>; <a href="./references#CD012631-bbs2-0110" title="EskesenTG , BaekgaardJS , SteinmetzJ , RasmussenLS . Initial use of supplementary oxygen for trauma patients: a systematic review. BMJ Open2018;8(7):e020880. [DOI: 10.1136/bmjopen-2017-020880] [PMID: 29982208]">Eskesen 2018</a>; <a href="./references#CD012631-bbs2-0147" title="LiL , ZhangY , WangP , ChongW , HaiY , XuP , et al. Conservative versus liberal oxygen therapy for acutely ill medical patients: a systematic review and meta-analysis. International Journal of Nursing Studies2021;118:103924. [DOI: 10.1016/j.ijnurstu.2021.103924] [PMID: 33774265]">Li 2021a</a>; <a href="./references#CD012631-bbs2-0148" title="LiX , LiuD , LiuC , MaoZ , LiuY , YiH , et al. Conservative versus liberal oxygen therapy in relation to all-cause mortality among patients in the intensive care unit: a systematic review of randomized controlled trials with meta-analysis and trial sequential analysis. Medicina Intensiva2023;47(2):73-83. [DOI: 10.1016/j.medin.2021.08.006] [PMID: 34526060]">Li 2021b</a>; <a href="./references#CD012631-bbs2-0117" title="HansenTE , ChristensenRE , BaekgaardJ , SteinmetzJ , RasmussenLS . Supplemental oxygen for traumatic brain injury: a systematic review. Acta Anaesthesiologica Scandinavica2022;66(3):307-16. [DOI: 10.1111/aas.14019] [PMID: 34907522]">Hansen 2021</a>). However, only a few of these meta‐analyses included proper risk of bias assessment to support their conclusions/recommendations. Additionally, we did not find the available evidence to be of high certainty, as has previously been suggested (<a href="./references#CD012631-bbs2-0091" title="ChuDK , KimLH , YoungPJ , ZamiriN , AlmenawerSA , JaeschkeR , et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet2018;391(10131):1693-705. [DOI: 10.1016/S0140-6736(18)30479-3] [PMID: 29726345]">Chu 2018</a>). Generally, reports on long‐term outcomes after targeted oxygen therapy is limited (<a href="./references#CD012631-bbs2-0095" title="CrescioliE , KrejbergKU , KlitgaardTL , NielsenFM , BarbateskovicM , SkrubbeltrangC , et al. Long-term effects of lower versus higher oxygenation levels in adult ICU patients – a systematic review. Acta Anaesthesiologica Scandinavica2022;66(8):910-22. [DOI: 10.1111/aas.14107] [PMID: 35749059]">Crescioli 2022b</a>). Higher versus lower oxygenation strategies in patients with ARDS has also been evaluated in a recent Cochrane Review (<a href="./references#CD012631-bbs2-0096" title="CumpsteyAF , OldmanAH , SmithAF , MartinD , GrocottMP . Oxygen targets in the intensive care unit during mechanical ventilation for acute respiratory distress syndrome: a rapid review. Cochrane Database of Systematic Reviews2020, Issue 9. Art. No: CD013708. [DOI: 10.1002/14651858.CD013708] [PMID: 32870512]">Cumpstey 2020</a>), but the authors only identified a single trial on this matter (<a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a>), thus making inferences difficult. Young and colleagues also investigated conservative versus liberal oxygen therapy in the ICU in patients with cardiac arrest in an individual‐level data meta‐analysis, indicating a benefit of a conservative oxygenation strategy (<a href="./references#CD012631-bbs2-0210" title="YoungPJ , BaileyM , BellomoR , BernardS , BrayJ , JakkulaP , et al. Conservative or liberal oxygen therapy in adults after cardiac arrest: an individual-level patient data meta-analysis of randomised controlled trials. Resuscitation2020;157:15-22. [DOI: 10.1016/j.resuscitation.2020.09.036.] [PMID: 33058991]">Young 2021</a>). Limitations due to clinical diversity/heterogeneity are to a greater or lesser extent highlighted in these reviews, but seem only to be partly reflected in the conclusions. For this review, we have in greater detail summarised the differences in the included trials and incorporated some of these aspects in our subgroup and sensitivity analyses. Most importantly the applied interventions in the identified trials varied substantially, thus making direct comparison of the trials difficult. This factor could also potentially contribute to imprecision in the overall effect estimate. </p> <p>Despite low estimates of statistical heterogeneity for most of the effect estimates presented in this review, such estimates may not adequately account for the potentially extensive clinical diversity/heterogeneity. A novel tool for systematically assessing clinical diversity/heterogeneity in meta‐analyses of intervention has been proposed (<a href="./references#CD012631-bbs2-0078" title="BarbateskovicM , KosterTM , EckRJ , MaagaardM , AfshariA , BlokzijlF , et al. A new tool to assess clinical diversity in meta-analyses (CDIM) of interventions. Journal of Clinical Epidemiology2021;135:29-41. [DOI: 10.1016/j.jclinepi.2021.01.023] [PMID: 33561529]">Barbateskovic 2021b</a>). By systematically identifying and quantifying domains of clinical diversity/heterogeneity the authors of systematic reviews and meta‐analyses may incorporate these levels of information to conduct for example meta‐regression analyses, which allows for adjustment according to important imbalances between identified trials. However, this was not performed as it was beyond the scope of this review. </p> <p>We performed Trial Sequential Analyses to control the risk of random errors in a cumulative meta‐analysis and to prevent premature statements regarding the superiority of higher versus lower oxygenation strategies. This was also used by Chu and colleagues but without adjusting for multiple outcomes and using a potentially inadequate power of 80% (<a href="./references#CD012631-bbs2-0091" title="ChuDK , KimLH , YoungPJ , ZamiriN , AlmenawerSA , JaeschkeR , et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet2018;391(10131):1693-705. [DOI: 10.1016/S0140-6736(18)30479-3] [PMID: 29726345]">Chu 2018</a>). Trial Sequential Analyses with adjustment for multiple outcomes, and with proper power, were conducted by Barbateskovic and colleagues when considering the harms or benefits of higher or lower oxygenation strategies in a broader population of acutely ill adult patients (<a href="./references#CD012631-bbs2-0079" title="BarbateskovicM , SchjørringOL , KraussSR , MeyhoffCS , JakobsenJC , RasmussenBS , et al. Higher vs lower oxygenation strategies in acutely ill adults: a systematic review with meta-analysis and trial sequential analysis. Chest2021;159(1):154-73. [DOI: 10.1016/j.chest.2020.07.015] [PMID: 32687907]">Barbateskovic 2021a</a>) equivalent of the population in the review by Chu and colleagues (<a href="./references#CD012631-bbs2-0091" title="ChuDK , KimLH , YoungPJ , ZamiriN , AlmenawerSA , JaeschkeR , et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet2018;391(10131):1693-705. [DOI: 10.1016/S0140-6736(18)30479-3] [PMID: 29726345]">Chu 2018</a>). </p> <p>Despite methodological discrepancies between our review and other reviews and meta‐analyses, we agree with recently published reviews that the amount of data on this matter is still insufficient. However, based on the available data, large intervention effects from oxygen therapy appear unlikely, as we could reject an overall RRI or RRR of 10% for mortality, and 20% for SAEs, and on quality of life in the ICU population. Correspondingly, Barbateskovic and colleagues could reject an RRI or RRR of 15% for mortality and 20% for SAEs in acutely ill patients in general (<a href="./references#CD012631-bbs2-0079" title="BarbateskovicM , SchjørringOL , KraussSR , MeyhoffCS , JakobsenJC , RasmussenBS , et al. Higher vs lower oxygenation strategies in acutely ill adults: a systematic review with meta-analysis and trial sequential analysis. Chest2021;159(1):154-73. [DOI: 10.1016/j.chest.2020.07.015] [PMID: 32687907]">Barbateskovic 2021a</a>). However, even smaller effect sizes are relevant to patients given the widespread use of oxygen supplementation in the ICU. </p> <p>Several large‐scale trials are currently being conducted. With their completion, the combined number of participants will exceed an estimated 60,000. Thus, the amount of information will potentially aid in answering the questions laid out in this review. However, the difficulties with aggregating data based on methodologically very diverse trials, as explored in this review, are still to be considered carefully when drawing conclusions. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012631-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-FIG-01" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD012631-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of the risk of mortality at maximum follow‐up. A relative risk (RR) &lt; 1 indicates benefit of higher oxygenation strategies, whilst an RR &gt; 1 indicate benefit of lower. Each circle represents the point estimate of the trials. The black dashed line represent the point estimate for the RR of all‐cause mortality at maximum follow‐up (1.01).Abbreviations: log: natural logarithm; SE: standard error; RR: relative risk." data-id="CD012631-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Funnel plot of the risk of mortality at maximum follow‐up. A relative risk (RR) &lt; 1 indicates benefit of higher oxygenation strategies, whilst an RR &gt; 1 indicate benefit of lower. Each circle represents the point estimate of the trials. The black dashed line represent the point estimate for the RR of all‐cause mortality at maximum follow‐up (1.01). </p> <p><b>Abbreviations: log:</b> natural logarithm; <b>SE:</b> standard error; <b>RR:</b> relative risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the risk of mortality in trials judged to be at overall low risk of bias. The analysis was based on a mortality in the control group (control event proportion = CEP) of 41.9%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 27.9%. The cumulative Z‐curve crossed the trial sequential monitoring boundaries for futility, and the required information size (RIS) was exceeded." data-id="CD012631-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-03.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the risk of mortality in trials judged to be at overall low risk of bias. The analysis was based on a mortality in the control group (control event proportion = CEP) of 41.9%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 27.9%. The cumulative Z‐curve crossed the trial sequential monitoring boundaries for futility, and the required information size (RIS) was exceeded.</b> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the risk of mortality. The analysis was based on a mortality in the control group (control event proportion = CEP) 38.7%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 41.1%. The cumulative Z‐curve crossed the trial sequential monitoring boundaries for futility, and the required information size (RIS) was exceeded." data-id="CD012631-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-04.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the risk of mortality. The analysis was based on a mortality in the control group (control event proportion = CEP) 38.7%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 41.1%. The cumulative Z‐curve crossed the trial sequential monitoring boundaries for futility, and the required information size (RIS) was exceeded.</b> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the risk of mortality. The analysis was based on a mortality in the control group (control event proportion = CEP) of 38.7%, a relative risk increase (RRI) of 10%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 41.1%. Required information size = RIS. The cumulative Z‐curve crossed the trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-05.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the risk of mortality. The analysis was based on a mortality in the control group (control event proportion = CEP) of 38.7%, a relative risk increase (RRI) of 10%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 41.1%. Required information size = RIS. The cumulative Z‐curve crossed the trial sequential monitoring boundaries for futility.</b> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the risk of mortality. The analysis was based on a mortality in the control group (control event proportion = CEP) of 38.7%, a relative risk reduction (RRR) of 4%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 41.1%. Required information size = RIS. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-06.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the risk of mortality. The analysis was based on a mortality in the control group (control event proportion = CEP) of 38.7%, a relative risk reduction (RRR) of 4%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 41.1%. Required information size = RIS. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility.</b> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of the highest reported proportion of serious adverse events at maximum follow‐up. A relative risk (RR) &lt; 1 indicates benefit of higher oxygenation strategies, whilst an RR &gt; 1 indicate benefit of lower. Each circle represents the point estimate of the trials. The black dashed line represent the point estimate for the RR of the highest reported proportion of serious adverse events at maximum follow‐up (1.01).Abbreviations: log: natural logarithm; SE: standard error; RR: relative risk." data-id="CD012631-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Funnel plot of the highest reported proportion of serious adverse events at maximum follow‐up. A relative risk (RR) &lt; 1 indicates benefit of higher oxygenation strategies, whilst an RR &gt; 1 indicate benefit of lower. Each circle represents the point estimate of the trials. The black dashed line represent the point estimate for the RR of the highest reported proportion of serious adverse events at maximum follow‐up (1.01). </p> <p><b>Abbreviations: log:</b> natural logarithm; <b>SE:</b> standard error; <b>RR:</b> relative risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of the cumulated number of serious adverse events at maximum follow‐up. A relative risk (RR) &lt; 1 indicates benefit of higher oxygenation strategies, whilst an RR &gt; 1 indicate benefit of lower. Each circle represents the point estimate of the trials. The black dashed line represent the point estimate for the RR of the cumulated number of serious adverse events at maximum follow‐up (1.04).Abbreviations: log: natural logarithm; SE: standard error; RR: relative risk." data-id="CD012631-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Funnel plot of the cumulated number of serious adverse events at maximum follow‐up. A relative risk (RR) &lt; 1 indicates benefit of higher oxygenation strategies, whilst an RR &gt; 1 indicate benefit of lower. Each circle represents the point estimate of the trials. The black dashed line represent the point estimate for the RR of the cumulated number of serious adverse events at maximum follow‐up (1.04). </p> <p><b>Abbreviations: log:</b> natural logarithm; <b>SE:</b> standard error; <b>RR:</b> relative risk. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the highest reported proportion of specific serious adverse events. The analysis was based on a proportion of participants with one or more serious adverse events in the control group (control event proportion = CEP) of 41.1%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 64.0%. The cumulative Z‐curve crossed the boundaries for trial sequential monitoring boundaries for futility, and the required information size (RIS) was exceeded." data-id="CD012631-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-09.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the highest reported proportion of specific serious adverse events. The analysis was based on a proportion of participants with one or more serious adverse events in the control group (control event proportion = CEP) of 41.1%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 64.0%. The cumulative Z‐curve crossed the boundaries for trial sequential monitoring boundaries for futility, and the required information size (RIS) was exceeded.</b> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-FIG-10" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the highest reported proportion of specific serious adverse events. The analysis was based on a proportion of participants with one or more serious adverse events in the control group (control event proportion = CEP) of 41.1%, a relative risk increase (RRI) of 10%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 64.0%. RIS = required information size. The cumulative Z‐curve crossed the boundaries for trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-10.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-FIG-10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the highest reported proportion of specific serious adverse events. The analysis was based on a proportion of participants with one or more serious adverse events in the control group (control event proportion = CEP) of 41.1%, a relative risk increase (RRI) of 10%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 64.0%. RIS = required information size. The cumulative Z‐curve crossed the boundaries for trial sequential monitoring boundaries for futility.</b> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-FIG-11" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the cumulated number of serious adverse events. The analysis was based on a proportion of participants with one or more serious adverse events in the control group (control event proportion = CEP) of 71.4%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 87.4%. The cumulative Z‐curve crossed the boundaries for trial sequential monitoring boundaries for futility, and the required information size (RIS) was exceeded." data-id="CD012631-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-11.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-FIG-11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the cumulated number of serious adverse events. The analysis was based on a proportion of participants with one or more serious adverse events in the control group (control event proportion = CEP) of 71.4%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 87.4%. The cumulative Z‐curve crossed the boundaries for trial sequential monitoring boundaries for futility, and the required information size (RIS) was exceeded.</b> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-FIG-12" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the cumulated number of serious adverse events. The analysis was based on a proportion of participants with one or more serious adverse events in the control group (control event proportion = CEP) of 71.4%, a relative risk increase (RRI) of 10%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 87.4%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-12.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-FIG-12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the cumulated number of serious adverse events. The analysis was based on a proportion of participants with one or more serious adverse events in the control group (control event proportion = CEP) of 71.4%, a relative risk increase (RRI) of 10%, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 87.4%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility.</b> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-FIG-13" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on quality of life. The analysis was based on an observed mean difference of ‐0.5 points, a minimal clinical relevance of ‐7 points, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve crossed the trial sequential monitoring boundaries for futility and the required information size was exceeded." data-id="CD012631-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-13.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-FIG-13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on quality of life. The analysis was based on an observed mean difference of ‐0.5 points, a minimal clinical relevance of ‐7 points, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve crossed the trial sequential monitoring boundaries for futility and the required information size was exceeded.</b> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-FIG-14" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on quality of life. The analysis was based on an observed mean difference of ‐0.5 points, a minimal clinical relevance of ‐7 points, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 20%. RIS = required information size. The cumulated Z‐curve crossed the trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-14.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-FIG-14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 14</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on quality of life. The analysis was based on an observed mean difference of ‐0.5 points, a minimal clinical relevance of ‐7 points, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 20%. RIS = required information size. The cumulated Z‐curve crossed the trial sequential monitoring boundaries for futility.</b> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-FIG-15" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on quality of life. The analysis was based on an observed mean difference of ‐0.5 points, a difference of 1.6 points, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-15.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-FIG-15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 15</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on quality of life. The analysis was based on an observed mean difference of ‐0.5 points, a difference of 1.6 points, a type 1 error level (alpha) of 2.5%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility.</b> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-FIG-16" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the highest reported proportion of lung injuries. The analysis was based on the highest reported proportion of lung injuries in the control group (control event proportion = CEP) of 10.4%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-16.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-FIG-16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 16</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the highest reported proportion of lung injuries. The analysis was based on the highest reported proportion of lung injuries in the control group (control event proportion = CEP) of 10.4%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility.</b> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-FIG-17" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of the effects of higher versus oxygenation strategies on the highest reported proportion of lung injuries. The analysis was based on the highest reported proportion of lung injuries in the control group (control event proportion = CEP) of 10.4%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 20%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-17.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-FIG-17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 17</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus oxygenation strategies on the highest reported proportion of lung injuries. The analysis was based on the highest reported proportion of lung injuries in the control group (control event proportion = CEP) of 10.4%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 20%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility.</b> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-FIG-18" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the highest reported proportion of lung injuries. The analysis was based on the highest reported proportion of lung injuries in the control group (control event proportion = CEP) of 10.4%, a relative risk reduction (RRR) of 15%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-18.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-FIG-18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 18</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the highest reported proportion of lung injuries. The analysis was based on the highest reported proportion of lung injuries in the control group (control event proportion = CEP) of 10.4%, a relative risk reduction (RRR) of 15%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility.</b> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-FIG-19" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the cumulated number of lung injuries. The analysis was based on a cumulated number (control event proportion = CEP) of 10.7%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-19.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-FIG-19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 19</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the cumulated number of lung injuries. The analysis was based on a cumulated number (control event proportion = CEP) of 10.7%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility.</b> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-FIG-20" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the cumulated number of lung injuries. The analysis was based on a cumulated number of lung injuries in the control group (control event proportion = CEP) of 10.7%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 20%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-20.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-FIG-20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 20</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the cumulated number of lung injuries. The analysis was based on a cumulated number of lung injuries in the control group (control event proportion = CEP) of 10.7%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 20%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility.</b> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-FIG-21" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the cumulated number of lung injuries. The analysis was based on a cumulated number of lung injuries in the control group (control event proportion = CEP) of 10.7%, a relative risk reduction (RRR) of 20%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-21.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-FIG-21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 21</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the cumulated number of lung injuries. The analysis was based on a cumulated number of lung injuries in the control group (control event proportion = CEP) of 10.7%, a relative risk reduction (RRR) of 20%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility.</b> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-FIG-22" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the occurrence of stroke. The analysis was based on stroke in the control group (control event proportion = CEP) of 1.7%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-22.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-FIG-22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 22</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the occurrence of stroke. The analysis was based on stroke in the control group (control event proportion = CEP) of 1.7%, a relative risk increase (RRI) of 20%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility.</b> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-FIG-23" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the occurrence of stroke. The analysis was based on stroke in the control group (control event proportion = CEP) of 1.3%, a relative risk reduction (RRR) of 28%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility." data-id="CD012631-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-23.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-FIG-23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 23</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis of the effects of higher versus lower oxygenation strategies on the occurrence of stroke. The analysis was based on stroke in the control group (control event proportion = CEP) of 1.3%, a relative risk reduction (RRR) of 28%, a type 1 error level (alpha) of 2.0%, a type 2 error level (beta) of 10%, and a diversity of 0%. RIS = required information size. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility.</b> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-FIG-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Trials at overall low risk of bias, Outcome 1: All‐cause mortality ‐ trials at overall low risk of bias" data-id="CD012631-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Trials at overall low risk of bias, Outcome 1: All‐cause mortality ‐ trials at overall low risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Trials at overall low risk of bias, Outcome 2: Highest proportion of specific serious adverse events ‐ trials at overall low risk of bias" data-id="CD012631-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Trials at overall low risk of bias, Outcome 2: Highest proportion of specific serious adverse events ‐ trials at overall low risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Trials at overall low risk of bias, Outcome 3: Cumulated number of serious adverse events ‐ trials at overall low risk of bias" data-id="CD012631-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Trials at overall low risk of bias, Outcome 3: Cumulated number of serious adverse events ‐ trials at overall low risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Trials at overall low risk of bias, Outcome 4: Highest reported proportion of lung injury ‐ trials at overall low risk of bias" data-id="CD012631-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Trials at overall low risk of bias, Outcome 4: Highest reported proportion of lung injury ‐ trials at overall low risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Trials at overall low risk of bias, Outcome 5: Cumulated number of lung injury ‐ trials at overall low risk of bias" data-id="CD012631-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Trials at overall low risk of bias, Outcome 5: Cumulated number of lung injury ‐ trials at overall low risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Trials at overall low risk of bias, Outcome 6: Stroke ‐ trials at overall low risk of bias" data-id="CD012631-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Trials at overall low risk of bias, Outcome 6: Stroke ‐ trials at overall low risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: All‐cause mortality, Outcome 1: All‐cause mortality" data-id="CD012631-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: All‐cause mortality, Outcome 1: All‐cause mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: All‐cause mortality, Outcome 2: Subgroup analysis: all‐cause mortality ‐ overall risk of bias" data-id="CD012631-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: All‐cause mortality, Outcome 2: Subgroup analysis: all‐cause mortality ‐ overall risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: All‐cause mortality, Outcome 3: Subgroup analysis: all‐cause mortality ‐ types of oxygen interventions" data-id="CD012631-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: All‐cause mortality, Outcome 3: Subgroup analysis: all‐cause mortality ‐ types of oxygen interventions </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: All‐cause mortality, Outcome 4: Subgroup analysis: all‐cause mortality ‐ level of FiO2/target in higher group" data-id="CD012631-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: All‐cause mortality, Outcome 4: Subgroup analysis: all‐cause mortality ‐ level of FiO<sub>2</sub>/target in higher group </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: All‐cause mortality, Outcome 5: Subgroup analysis: all‐cause mortality ‐ level of FiO2/target in lower group" data-id="CD012631-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: All‐cause mortality, Outcome 5: Subgroup analysis: all‐cause mortality ‐ level of FiO<sub>2</sub>/target in lower group </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: All‐cause mortality, Outcome 6: Subgroup analysis: all‐cause mortality ‐ ICU‐population" data-id="CD012631-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: All‐cause mortality, Outcome 6: Subgroup analysis: all‐cause mortality ‐ ICU‐population </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: All‐cause mortality, Outcome 7: Subgroup analysis: all‐cause mortality ‐ oxygen delivery system" data-id="CD012631-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: All‐cause mortality, Outcome 7: Subgroup analysis: all‐cause mortality ‐ oxygen delivery system </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: All‐cause mortality, Outcome 8: Sensitivity analysis: all‐cause mortality ‐ high vs high oxygenation strategies and low vs low oxygenation strategies excluded" data-id="CD012631-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: All‐cause mortality, Outcome 8: Sensitivity analysis: all‐cause mortality ‐ high vs high oxygenation strategies and low vs low oxygenation strategies excluded </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: All‐cause mortality, Outcome 9: Sensitivity analysis: all‐cause mortality ‐ best‐worst‐case scenario" data-id="CD012631-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: All‐cause mortality, Outcome 9: Sensitivity analysis: all‐cause mortality ‐ best‐worst‐case scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: All‐cause mortality, Outcome 10: Sensitivity analysis: all‐cause mortality ‐ worst‐best‐case scenario" data-id="CD012631-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: All‐cause mortality, Outcome 10: Sensitivity analysis: all‐cause mortality ‐ worst‐best‐case scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Proportion of patients with one or more serious adverse events, Outcome 1: Highest proportion of specific serious adverse events reported" data-id="CD012631-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Proportion of patients with one or more serious adverse events, Outcome 1: Highest proportion of specific serious adverse events reported </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Proportion of patients with one or more serious adverse events, Outcome 2: Cumulated number of serious adverse events" data-id="CD012631-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Proportion of patients with one or more serious adverse events, Outcome 2: Cumulated number of serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Proportion of patients with one or more serious adverse events, Outcome 3: Proportion of patients with one or more serious adverse event (as defined by trialists)" data-id="CD012631-fig-0042" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Proportion of patients with one or more serious adverse events, Outcome 3: Proportion of patients with one or more serious adverse event (as defined by trialists) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Quality of life, Outcome 1: Quality of life" data-id="CD012631-fig-0043" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Quality of life, Outcome 1: Quality of life</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Quality of life, Outcome 2: Subgroup analysis: quality of life ‐ risk of bias" data-id="CD012631-fig-0044" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Quality of life, Outcome 2: Subgroup analysis: quality of life ‐ risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Quality of life, Outcome 3: Subgroup analysis: quality of life ‐ types of oxygen intervention" data-id="CD012631-fig-0045" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Quality of life, Outcome 3: Subgroup analysis: quality of life ‐ types of oxygen intervention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Quality of life, Outcome 4: Subgroup analysis: quality of life ‐ level of FiO2/target in higher group" data-id="CD012631-fig-0046" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Quality of life, Outcome 4: Subgroup analysis: quality of life ‐ level of FiO<sub>2</sub>/target in higher group </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Quality of life, Outcome 5: Subgroup analysis: quality of life ‐ level of FiO2/target in lower group" data-id="CD012631-fig-0047" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Quality of life, Outcome 5: Subgroup analysis: quality of life ‐ level of FiO<sub>2</sub>/target in lower group </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Quality of life, Outcome 6: Subgroup analysis: quality of life ‐ ICU‐population" data-id="CD012631-fig-0048" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Quality of life, Outcome 6: Subgroup analysis: quality of life ‐ ICU‐population</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Quality of life, Outcome 7: Subgroup analysis: quality of life ‐ oxygen delivery system" data-id="CD012631-fig-0049" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Quality of life, Outcome 7: Subgroup analysis: quality of life ‐ oxygen delivery system </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Quality of life, Outcome 8: Sensitivity analysis: quality of life ‐ best‐worst‐case scenario" data-id="CD012631-fig-0050" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Quality of life, Outcome 8: Sensitivity analysis: quality of life ‐ best‐worst‐case scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-004.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Quality of life, Outcome 9: Sensitivity analysis: quality of life ‐ worst‐best‐case scenario" data-id="CD012631-fig-0051" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-004.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-004.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4: Quality of life, Outcome 9: Sensitivity analysis: quality of life ‐ worst‐best‐case scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-004.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Lung injury, Outcome 1: Lung injury ‐ highest proportion reported" data-id="CD012631-fig-0052" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Lung injury, Outcome 1: Lung injury ‐ highest proportion reported</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Lung injury, Outcome 2: Lung injury ‐ cumulated number" data-id="CD012631-fig-0053" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Lung injury, Outcome 2: Lung injury ‐ cumulated number</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Lung injury, Outcome 3: Acute respiratory distress syndrome" data-id="CD012631-fig-0054" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Lung injury, Outcome 3: Acute respiratory distress syndrome</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Lung injury, Outcome 4: Pneumonia" data-id="CD012631-fig-0055" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Lung injury, Outcome 4: Pneumonia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Myocardial infartion, Outcome 1: Myocardial infarction" data-id="CD012631-fig-0056" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Myocardial infartion, Outcome 1: Myocardial infarction</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Myocardial infartion, Outcome 2: Subgroup analysis: myocardial infarction ‐ overall risk of bias" data-id="CD012631-fig-0057" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Myocardial infartion, Outcome 2: Subgroup analysis: myocardial infarction ‐ overall risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Myocardial infartion, Outcome 3: Subgroup analysis: myocardial infarction ‐ types of oxygen interventions" data-id="CD012631-fig-0058" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Myocardial infartion, Outcome 3: Subgroup analysis: myocardial infarction ‐ types of oxygen interventions </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Myocardial infartion, Outcome 4: Subgroup analysis: myocardial infarction ‐ level of FiO2/target in higher group" data-id="CD012631-fig-0059" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Myocardial infartion, Outcome 4: Subgroup analysis: myocardial infarction ‐ level of FiO<sub>2</sub>/target in higher group </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Myocardial infartion, Outcome 5: Subgroup analysis: myocardial infarction ‐ level of FiO2/target in lower group" data-id="CD012631-fig-0060" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Myocardial infartion, Outcome 5: Subgroup analysis: myocardial infarction ‐ level of FiO<sub>2</sub>/target in lower group </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-006.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Myocardial infartion, Outcome 6: Subgroup analysis: myocardial infarction ‐ ICU‐population" data-id="CD012631-fig-0061" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-006.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-006.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6: Myocardial infartion, Outcome 6: Subgroup analysis: myocardial infarction ‐ ICU‐population </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-006.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-006.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Myocardial infartion, Outcome 7: Subgroup analysis: myocardial infarction ‐ oxygen delivery system" data-id="CD012631-fig-0062" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-006.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-006.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6: Myocardial infartion, Outcome 7: Subgroup analysis: myocardial infarction ‐ oxygen delivery system </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-006.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-006.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Myocardial infartion, Outcome 8: Sensitivity analysis: myocardial infarction ‐ best‐worst‐case scenario" data-id="CD012631-fig-0063" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-006.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-006.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6: Myocardial infartion, Outcome 8: Sensitivity analysis: myocardial infarction ‐ best‐worst‐case scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-006.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-006.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Myocardial infartion, Outcome 9: Sensitivity analysis: myocardial infarction ‐ worst‐best‐case scenario" data-id="CD012631-fig-0064" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-006.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-006.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6: Myocardial infartion, Outcome 9: Sensitivity analysis: myocardial infarction ‐ worst‐best‐case scenario </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-006.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Stroke, Outcome 1: Stroke" data-id="CD012631-fig-0065" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Stroke, Outcome 1: Stroke</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Stroke, Outcome 2: Subgroup analysis: stroke ‐ overall risk of bias" data-id="CD012631-fig-0066" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Stroke, Outcome 2: Subgroup analysis: stroke ‐ overall risk of bias</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Stroke, Outcome 3: Subgroup analysis: stroke ‐ types of oxygen interventions" data-id="CD012631-fig-0067" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Stroke, Outcome 3: Subgroup analysis: stroke ‐ types of oxygen interventions</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Stroke, Outcome 4: Subgroup analysis: stroke ‐ level of FiO2/target in the higher group" data-id="CD012631-fig-0068" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Stroke, Outcome 4: Subgroup analysis: stroke ‐ level of FiO<sub>2</sub>/target in the higher group </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Stroke, Outcome 5: Subgroup analysis: stroke ‐ level of FiO2/target in lower group" data-id="CD012631-fig-0069" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: Stroke, Outcome 5: Subgroup analysis: stroke ‐ level of FiO<sub>2</sub>/target in lower group </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-007.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Stroke, Outcome 6: Subgroup analysis: stroke ‐ ICU‐population" data-id="CD012631-fig-0070" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-007.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-007.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7: Stroke, Outcome 6: Subgroup analysis: stroke ‐ ICU‐population</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-007.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-007.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Stroke, Outcome 7: Subgroup analysis: stroke ‐ oxygen delivery system" data-id="CD012631-fig-0071" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-007.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-007.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7: Stroke, Outcome 7: Subgroup analysis: stroke ‐ oxygen delivery system</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-007.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-007.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Stroke, Outcome 8: Sensitivity analysis: stroke ‐ high vs high oxygenation strategies and low vs low oxygenation strategies excluded" data-id="CD012631-fig-0072" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-007.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-007.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7: Stroke, Outcome 8: Sensitivity analysis: stroke ‐ high vs high oxygenation strategies and low vs low oxygenation strategies excluded </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-007.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-007.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Stroke, Outcome 9: Sensitivity analysis: stroke ‐ best‐worst‐case scenario" data-id="CD012631-fig-0073" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-007.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-007.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.9</div> <div class="figure-caption"> <p>Comparison 7: Stroke, Outcome 9: Sensitivity analysis: stroke ‐ best‐worst‐case scenario</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-007.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-007.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Stroke, Outcome 10: Sensitivity analysis: stroke ‐ worst‐best‐case scenario" data-id="CD012631-fig-0074" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-007.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-007.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.10</div> <div class="figure-caption"> <p>Comparison 7: Stroke, Outcome 10: Sensitivity analysis: stroke ‐ worst‐best‐case scenario</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-007.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sepsis, Outcome 1: Sepsis" data-id="CD012631-fig-0075" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Sepsis, Outcome 1: Sepsis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sepsis, Outcome 2: Subgroup analysis: sepsis ‐ overall risk of bias" data-id="CD012631-fig-0076" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Sepsis, Outcome 2: Subgroup analysis: sepsis ‐ overall risk of bias</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sepsis, Outcome 3: Subgroup analysis: sepsis ‐ types of oxygen interventions" data-id="CD012631-fig-0077" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Sepsis, Outcome 3: Subgroup analysis: sepsis ‐ types of oxygen interventions</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-008.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sepsis, Outcome 4: Subgroup analysis: sepsis ‐ level of FiO2/target in higher group" data-id="CD012631-fig-0078" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-008.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-008.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8: Sepsis, Outcome 4: Subgroup analysis: sepsis ‐ level of FiO<sub>2</sub>/target in higher group </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-008.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-008.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sepsis, Outcome 5: Subgroup analysis: sepsis ‐ level of FiO2/target in lower group" data-id="CD012631-fig-0079" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-008.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-008.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8: Sepsis, Outcome 5: Subgroup analysis: sepsis ‐ level of FiO<sub>2</sub>/target in lower group </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-008.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-008.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sepsis, Outcome 6: Subgroup analysis: sepsis ‐ ICU‐population" data-id="CD012631-fig-0080" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-008.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-008.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8: Sepsis, Outcome 6: Subgroup analysis: sepsis ‐ ICU‐population</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-008.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-008.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sepsis, Outcome 7: Subgroup analysis: sepsis ‐ oxygen delivery system" data-id="CD012631-fig-0081" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-008.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-008.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8: Sepsis, Outcome 7: Subgroup analysis: sepsis ‐ oxygen delivery system</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-008.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-008.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sepsis, Outcome 8: Sensitivity analysis: sepsis ‐ best‐worst‐case scenario" data-id="CD012631-fig-0082" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-008.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-008.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8: Sepsis, Outcome 8: Sensitivity analysis: sepsis ‐ best‐worst‐case scenario</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-008.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-008.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sepsis, Outcome 9: Sensitivity analysis: sepsis ‐ worst‐best‐case scenario" data-id="CD012631-fig-0083" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-008.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-008.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.9</div> <div class="figure-caption"> <p>Comparison 8: Sepsis, Outcome 9: Sensitivity analysis: sepsis ‐ worst‐best‐case scenario</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-008.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Specific serious adverse events, Outcome 1: Myocardial infarction" data-id="CD012631-fig-0084" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Specific serious adverse events, Outcome 1: Myocardial infarction</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Specific serious adverse events, Outcome 2: Stroke" data-id="CD012631-fig-0085" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Specific serious adverse events, Outcome 2: Stroke</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Specific serious adverse events, Outcome 3: Sepsis" data-id="CD012631-fig-0086" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Specific serious adverse events, Outcome 3: Sepsis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-009.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Specific serious adverse events, Outcome 4: Acute respiratory distress syndrome" data-id="CD012631-fig-0087" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-009.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9: Specific serious adverse events, Outcome 4: Acute respiratory distress syndrome </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-009.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Specific serious adverse events, Outcome 5: Pneumonia" data-id="CD012631-fig-0088" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-009.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9: Specific serious adverse events, Outcome 5: Pneumonia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-009.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Specific serious adverse events, Outcome 6: Delirium" data-id="CD012631-fig-0089" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-009.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9: Specific serious adverse events, Outcome 6: Delirium</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-009.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Specific serious adverse events, Outcome 7: Pneumothorax" data-id="CD012631-fig-0090" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-009.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.7</div> <div class="figure-caption"> <p>Comparison 9: Specific serious adverse events, Outcome 7: Pneumothorax</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-009.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Specific serious adverse events, Outcome 8: Intestinal ischaemia" data-id="CD012631-fig-0091" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-009.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.8</div> <div class="figure-caption"> <p>Comparison 9: Specific serious adverse events, Outcome 8: Intestinal ischaemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-009.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Specific serious adverse events, Outcome 9: Cardiovascular failure including shock" data-id="CD012631-fig-0092" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-009.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.9</div> <div class="figure-caption"> <p>Comparison 9: Specific serious adverse events, Outcome 9: Cardiovascular failure including shock </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-009.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Specific serious adverse events, Outcome 10: Cardiac arrhythmia" data-id="CD012631-fig-0093" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-009.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.10</div> <div class="figure-caption"> <p>Comparison 9: Specific serious adverse events, Outcome 10: Cardiac arrhythmia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-009.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Specific serious adverse events, Outcome 11: Liver failure" data-id="CD012631-fig-0094" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-009.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.11</div> <div class="figure-caption"> <p>Comparison 9: Specific serious adverse events, Outcome 11: Liver failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-009.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Specific serious adverse events, Outcome 12: Renal failure" data-id="CD012631-fig-0095" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-009.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.12</div> <div class="figure-caption"> <p>Comparison 9: Specific serious adverse events, Outcome 12: Renal failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012631-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/urn:x-wiley:14651858:media:CD012631:CD012631-CMP-009.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Specific serious adverse events, Outcome 13: Seizure" data-id="CD012631-fig-0096" src="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_t/tCD012631-CMP-009.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.13</div> <div class="figure-caption"> <p>Comparison 9: Specific serious adverse events, Outcome 13: Seizure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/media/CDSR/CD012631/image_n/nCD012631-CMP-009.13.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012631-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Higher vs lower FiO2 or targets of arterial oxygenation for adults admitted to the ICU</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Higher vs lower FiO<sub>2</sub> or targets of arterial oxygenation for adults admitted to the ICU</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Participant or population:</b> adults admitted to the ICU<br/><b>Setting:</b> trials were conducted in ICU departments in Europe (n = 9); China (n = 3); Iran (n = 2); Australia, New Zealand (n = 1); Australia, New Zealand, and France (n = 1); Hong Kong (n = 1); Japan (n = 1); and United States of America (n = 1).<br/><b>Intervention:</b> higher FiO<sub>2</sub> or targets of arterial oxygenation<br/><b>Comparison:</b> lower FiO<sub>2</sub> or targets of arterial oxygenation </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>a</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with lower FiO<sub>2</sub> or targets of arterial oxygenation (№ of events per 1000 participants)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with higher FiO<sub>2</sub> or targets of arterial oxygenation (№ of events per 1000 participants)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality: range 1 mo to 1 y</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.96 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>9408<br/>(16 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Very low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Meta‐analysis from the analysis of trials at overall low risk of bias showed a RR of 1.01 (95% CI 0.94 to 1.08; I<sup>2</sup> = 7%; 5733 participants; 9 RCTs). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>387 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>390 per 1000<br/>(371 to 410) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Proportion of participants with ≥ 1 serious adverse events according to International Conference on Harmonisation Good Clinical Practice: range 3 d to 180 d </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.96 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>9466<br/>(17 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Very low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Reported results are derived by taking the highest proportion reported in each trial, which addresses the lowest possible proportion of participants with ≥ 1 serious adverse events. </p> <p>The following outcomes and numbers of trials and participants have been included:</p> <p> <ol id="CD012631-list-0001"> <li> <p>mortality: 13 trials, 8540 participants;</p> </li> <li> <p>proportion of participants with ≥ 1 serious adverse events: 2 trials, 834 participants;</p> </li> <li> <p>acute myocardial infarction: 1 trial, 58 participants; and</p> </li> <li> <p>mechanical ventilation (reported as a poor outcome): 1 trials, 34 participants.</p> </li> </ol> </p> <p>Meta‐analysis from the analysis of cumulating all reported serious adverse events, which address the highest possible reported proportion of participants with ≥ 1 serious adverse events, showed a RR of 1.04 (95% CI 1.02 to 1.07; I<sup>2</sup> = 75%; 9489 participants; 17 RCTs). </p> <p>Meta‐analysis from the analysis of trials at overall low risk of bias showed a RR of 1.01 (95% CI 0.95 to 1.07; I<sup>2</sup> = 33%; 5733 participants; 9 RCTs). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>411 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>415 per 1000<br/>(394 to 436) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (any measure): range 180 d to 1 y</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 points lower in participants assigned to a higher oxygenation strategy (2.75 points lower to 1.75 points higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1649 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Lung injury diagnosed after randomisation (composite outcome): range 4 d to 23 d</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.08<br/>(0.85 to 1.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2048<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Very low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Reported results are derived by taking the highest proportion reported in each trial, which addresses the lowest possible proportion of participants with ≥ 1 lung injuries. </p> <p>The following outcomes and numbers of trials and participants have been included:</p> <p> <ol id="CD012631-list-0002"> <li> <p>ARDS: 4 trials, 862 participants; and</p> </li> <li> <p>pneumonia: 5 trials, 1251 participants.</p> </li> </ol> </p> <p>Meta‐analysis from the analysis cumulating all reported lung injuries, which address the highest possible reported proportion of participants with ≥ 1 lung injuries, showed a RR of 1.04 (95% CI 0.82 to 1.33; I<sup>2</sup> = 0%; 2048 participants; 8 RCTs). </p> <p>Meta‐analysis from the analysis of ARDS showed a RR of 0.86 (95% CI 0.43 to 1.69; I² = 0%; 862 participants; 4 RCTs). </p> <p>Meta‐analysis from the analysis of pneumonia showed a RR of 1.10 (95% CI 0.85 to 1.42; I<sup>2</sup> = 0%; 1251 participants; 5 RCTs). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>104 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>112 per 1000<br/>(88 to 143) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Myocardial infarction diagnosed after randomisation: range ≤ 90 d</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.77 (0.51 to 1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5002 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Very low<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>–</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> <p>(11 to 24)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Stroke diagnosed after randomisation: range 1 mo to 3 mo</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.08 (0.72 to 1.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6110 (5</p> <p>RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Very low<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Meta‐analysis from the analysis of trials at overall low risk of bias showed a RR of 1.04 (95% CI 0.59 to 1.83; I<sup>2</sup> = 49%; 3111 participants; 2 RCTs). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> <p>(10 to 22)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Sepsis diagnosed after randomisation: range 28 d to 60 d</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.85 (1.17 to 2.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>752 (3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Very low<sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>–</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>124 per 1000</p> <p>(78 to 196)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ARDS:</b> acute respiratory distress syndrome; <b>CI:</b> confidence interval; <b>FiO<sub>2</sub>:</b> fraction of inspired oxygen; <b>GRADE:</b> grading of recommendations, assessment, development, and evaluations; <b>ICU:</b> intensive care unit; <b>OIS:</b> Optimal information size; <b>RCT:</b> randomised controlled trial; <b>RIS:</b> required information size; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE working group grades of evidence:</p> <p> <ol id="CD012631-list-0003"> <li> <p>High certainty: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low certainty: our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low certainty: we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </li> </ol> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The risk in the intervention (higher) group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). The risk in the control (lower) group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/><sup>b</sup>Downgraded 3 levels: 1 level owing to risk of bias because only 10 trials of 16 trials were judged to be at overall low risk of bias; 2 levels owing to indirectness because of differences in the inspiratory oxygen fraction and the target of arterial oxygenation in the experimental and control groups amongst trials and owing to differences in inclusion criteria amongst trials. The RIS is 2026 participants. The RIS = OIS when I<sup>2</sup> = 0 and alpha is adjusted for multiple outcomes.<br/><sup>c</sup>Downgraded 3 levels: 1 level owing to risk of bias because 9 trials of 17 trials were judged to be at overall high risk of bias; 2 levels owing to indirectness because of differences in inspiratory oxygen fraction and target of arterial oxygenation in the experimental and control groups amongst trials and owing to differences in inclusion criteria amongst trials. The RIS is 1820 participants. The RIS = OIS when I<sup>2</sup> = 0 and alpha is adjusted for multiple outcomes.<br/><sup>d</sup>Downgraded 3 levels: 2 levels owing to indirectness because of differences in inspiratory oxygen fraction and target of arterial oxygenation in the experimental and control groups amongst trials and owing to differences in inclusion criteria amongst trials; 1 level because risk of bias. The RIS is 550 participants. The RIS = OIS when I<sup>2</sup> = 0 and alpha is adjusted for multiple outcomes.<br/><sup>e</sup>Downgraded 3 levels: 1 level owing to risk of bias because only 3 trials of 8 trials were judged to be at overall low risk of bias; 2 levels owing to indirectness because of differences in inspiratory oxygen fraction and target of arterial oxygenation in the experimental and control groups amongst trials and owing to differences in inclusion criteria amongst trials. The RIS is 12,193 participants. The RIS = OIS when I<sup>2</sup> = 0 and alpha is adjusted for multiple outcomes.<br/><sup>f</sup>Downgraded 3 levels: 1 level owing to risk of bias because only 1 trial of 4 trials was judged to be at overall low risk of bias; 1 level owing to indirectness because of differences in inspiratory oxygen fraction and target of arterial oxygenation in the experimental and control groups amongst trials; and 1 level owing to imprecision because the RIS was not reached (127,218 participants). The RIS = OIS when I<sup>2</sup> = 0 and alpha is adjusted for multiple outcomes.<br/><sup>g</sup>Downgraded 3 levels: 1 level owing to risk of bias because only 2 trials of 5 trials were judged to be at overall low risk of bias; 1 level owing to indirectness because of differences in inspiratory oxygen fraction and target of arterial oxygenation in the experimental and control groups amongst trials; and 1 level owing to imprecision because the RIS was not reached (108,569 participants). The RIS = OIS when I<sup>2</sup> = 0 and alpha is adjusted for multiple outcomes.<br/><sup>h</sup>Downgraded 3 levels: 1 level owing to risk of bias because only 1 trial of 3 trials was judged to be at overall low risk of bias; 1 level owing to indirectness because of differences in inspiratory oxygen fraction and target of arterial oxygenation in the experimental and control groups amongst trials; and 1 level owing to imprecision because the RIS was not reached (19,797 participants). The RIS = OIS when I<sup>2</sup> = 0 and alpha is adjusted for multiple outcomes. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Higher vs lower FiO2 or targets of arterial oxygenation for adults admitted to the ICU</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012631-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Outcomes reported only in a single trial</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Serious adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. of higher group events/analysed</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No. of lower group events/analysed</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92/395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82/394</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac arrest not resulting in death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57/1187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/447</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Digestive haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/99</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Digital ischaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/217</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haemoptysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/99</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Respiratory failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/220</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe hypercapnia and respiratory acidosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgical site infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/142</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unexplained brain oedema on CT scan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/61</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><b>CT:</b> computerised tomography </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Outcomes reported only in a single trial</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012631-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Interventions used in the higher and lower group</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="2" valign="bottom"></td> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Higher group</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Lower group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Duration of intervention</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>FiO<sub>2</sub> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>PaO<sub>2</sub> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SaO<sub>2</sub>/SpO<sub>2</sub> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>FiO<sub>2</sub> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>PaO<sub>2</sub> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SaO<sub>2</sub>/SpO<sub>2</sub> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0001" title="AsfarP , SchortgenF , Boisramé-HelmsJ , CharpentierJ , GuérotE , MegarbaneB , et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respiratory Medicine2017;5(3):180-90. [DOI: 10.1016/S2213-2600(17)30046-2] [PMID: 28219612]">Asfar 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88% to 95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximum 24 h after randomisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0002" title="BarrotL , AsfarP , MaunyF , WiniszewskiH , MontiniF , BadieJ , et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. New England Journal of Medicine2020;382(11):999-1008. [DOI: 10.1056/NEJMoa1916431] [PMID: 32160661]">Barrot 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 mmHg to 105 mmHg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 96%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 mmHg to 70 mmHg (7.3 kPa to 9.3 kPa)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88% to 92%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until extubation, maximum 7 d of invasive mechanical ventilation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0003" title="GelissenH , deGroothHJ , SmuldersY , WilsE , deRuijterW , VinkR , et al. Effect of low-normal vs high-normal oxygenation targets on organ dysfunction in critically ill patients: a randomized clinical trial. Journal of American Medical Association2021;326(10):940-8. [DOI: 10.1001/jama.2021.13011] [PMID: 34463696]">Gelissen 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 kPa to 12 kPa (60 mmHg to 90 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 kPa to 18 kPa (105 mmHg to 135 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until ICU discharge or death, maximum 14 d</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0004" title="GirardisM , BusaniS , DamianiE , DonatiA , RinaldiL , MarudiA , et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen-ICU randomized clinical trial. Journal of American Medical Association2016;316(15):1583-9. [DOI: 10.1001/jama.2016.11993] [PMID: 27706466]">Girardis 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 20 kPa (150 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97% to 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.3 kPa to 13.3 kPa (70 mmHg to 100 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94% to 98%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Entire ICU admission, upper limit not explicitly stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0005" title="GomersallCD , JoyntGM , FreebairnRC , LaiCK , OhTE . Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine2002;30(1):113-6. [DOI: 10.1097/00003246-200201000-00018] [PMID: 11905405]">Gomersall 2002</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 9.0 kPa (67.5 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 6.6 kPa (50 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximum 48 h after randomisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0006" title="IshiiK , MorimatsuH , HyodoT , OnoK , HidakaH , KoyamaY , et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e]">Ishii 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 mmHg (13.3 kPa)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not explicitly stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0007" title="JakkulaP , ReinikainenM , HästbackaJ , LoisaP , TiainenM , PettiläV , et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine2018;44(12):2112-21. [DOI: 10.1007/s00134-018-5453-9] [PMID: 30430209]">Jakkula 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 kPa to 25 kPa (150 mmHg to 187.5 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 kPa to 15 kPa (75 mmHg to 112.5 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95% to 98%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of mechanical ventilation, maximum 14 d after randomisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0008" title="JunJ , SunL , WangY , LiuF , YangG , HanB . Invasive mechanical ventilation with high concentration oxygen therapy for AECOPD patients with acute myocardial infarction. Chest2019;156(4 Suppl):A958. [DOI: 10.1016/j.chest.2019.08.886]">Jun 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.40 to 0.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30 to 0.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not explicitly stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0009" title="LångM , SkrifvarsMB , SiironenJ , TanskanenP , Ala-PeijariM , KoivistoT , et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica2018;62(6):801-10. [DOI: 10.1111/aas.13093] [PMID: 29464691]">Lång 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of mechanical ventilation, maximum 14 d</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0010" title="MackleD , BellomoR , BaileyM , BeasleyR , DeaneA , EastwoodG , et al, The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy during mechanical ventilation in the ICU. New England Journal of Medicine2020;382(11):989-98. [DOI: https://doi.org/10.1056/NEJMoa1903297] [PMID: 31613432]">Mackle 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>No specific measures were taken to avoid high FiO<sub>2</sub> or SpO<sub>2</sub>. </p> <p>FiO<sub>2</sub> &lt; 0.30 discouraged </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90% to 96%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until ICU discharge, maximum 28 d</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0011" title="MartinDS , McNeilM , Brew-GravesC , FilipeH , O’DriscollR , StevensJL , et al. A feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients. Journal of the Intensive Care Society2021;22(4):280-7. [DOI: 10.1177/17511437211010031]">Martin 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 96%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88% to 92%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until extubation, formation of tracheostomy, transfer to other ICU, or death</p> <p>Maximum duration was not explicitly stated.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0012" title="MazdehM , TaherA , TorabianS , SeifiradS . Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica2015;53(11):676-80. [PMID: 26786987]">Mazdeh 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Supplemental oxygen not used.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximum 12 h after randomisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0013" title="PanwarR , HardieM , BellomoR , BarrotL , EastwoodGM , YoungPJ , et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients – a pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2016;193(1):43-51. [DOI: 10.1164/rccm.201505-1019OC] [PMID: 26334785]">Panwar 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 96%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88% to 92%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of mechanical ventilation</p> <p>Maximum duration was not explicitly stated.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0014" title="SchjørringOL , KlitgaardTL , PernerA , WetterslevJ , LangeT , SiegemundM , et al. Lower or higher oxygenation targets for acute hypoxemic respiratory failure. New England Journal of Medicine2021;384(14):1301-11. [DOI: 10.1056/NEJMoa2032510] [PMID: 33471452]">Schjørring 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 kPa (90 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 kPa (60 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Entire ICU admission, including re‐admissions</p> <p>Maximum 90 d after randomisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0015" title="SchmidtH , KjaergaardJ , HassagerC , MølstrømS , GrandJ , BorregaardB , et al. Oxygen targets in comatose survivors of cardiac arrest. New England Journal of Medicine2022;387(16):1467-76. [DOI: 10.1056/NEJMoa2208686] [PMID: 36027567]">Schmidt 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 kPa to 14 kPa (97.5 mmHg to 105 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 kPa to 10 kPa (67.5 mmHg to 75 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until discontinuation of mechanical ventilation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0016" title="SemlerMW , CaseyJD , LloydBD , HastingsPG , HaysMA , StollingsJL , et al. Oxygen-saturation targets for critically ill adults receiving mechanical ventilation. New England Journal of Medicine2022;387(19):1759-69. [DOI: 10.1056/NEJMoa2208415 Abstract] [PMID: 36278971]">Semler 2022</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94% (92% to 96%) or 98% (96% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90% (88% to 92%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until discontinuation of mechanical ventilation, transfer out of a participating unit, or the end of the 2‐months study period, whichever occurred first </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0017" title="TaherA , PilehvariZ , PoorolajalJ , AghajanlooM . Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly2016;21(1):e26772. [DOI: 10.5812/traumamon.26772] [PMID: 27218057]">Taher 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximum 6 h after randomisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0018" title="YangX , ShangY , YuanS. Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study. Journal of Thoracic Disease2019;11(10):4234-40. [DOI: 10.21037/jtd.2019.09.66] [PMID: 10.21037/jtd.2019.09.66]">Yang 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 0.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96% to 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90% to 95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not explicitly stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012631-bbs2-0019" title="YangW , ZhangL . Observation of the curative effect of conservative oxygen therapy in mechanical ventilation of patients with severe pneumonia [保守氧疗法在重症肺炎机械通气患者中的应用效果观察]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2021;33(9):1069-73. [DOI: 10.3760/cma.j.cn121430-20210617-00902] [PMID: 34839863]">Yang 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 150 mmHg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 96%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.3 kPa to 13.3 kPa (70 mmHg to 100 mmHg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90% to 92%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not explicitly stated</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><b>FiO<sub>2</sub>:</b> fraction of inspired oxygen; <b>PaO<sub>2</sub>:</b> partial pressure of arterial oxygen; <b>SaO<sub>2</sub>:</b> arterial oxygen saturation of haemoglobin; <b>SpO<sub>2</sub>:</b> peripheral oxygen saturation </p> <p><sup>a</sup>Patients in lower oxygenation group also received doxapram if they developed acidosis (pH &lt; 7.2). Patients in the higher oxygenation group received doxapram if they developed symptomatic acidosis.<br/><sup>b</sup>Intermediate‐ and higher‐target groups have been combined due to the 3‐arm design of the trial. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Interventions used in the higher and lower group</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012631-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Calculated Bayes factors for all predefined outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention effect hypothesised</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention effect shown by the meta‐analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>BF</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>All‐cause mortality<sup>a</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3 × 10<sup>17</sup> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>All‐cause mortality<sup>b</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 × 10<sup>9</sup> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Highest reported proportion of serious adverse events<sup>c</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0 × 10<sup>18</sup> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Highest reported proportion of serious adverse events<sup>d</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0 × 10<sup>10</sup> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cumulated number of serious adverse events<sup>c</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1 × 10<sup>96</sup> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cumulated number of serious adverse events<sup>d</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.01 × 10<sup>27</sup> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Quality of life<sup>e</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−7 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.5 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.8 × 10<sup>7</sup> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Quality of life<sup>f</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+7 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.5 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 × 10<sup>9</sup> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Highest reported proportion of lung injuries<sup>g</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.44</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Highest reported proportion of lung injuries<sup>h</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.17</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cumulated number of lung injuries<sup>g</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.33</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cumulated number of lung injuries<sup>h</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.82</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Myocardial infarction<sup>i</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.42</p> <p>(BF<sup>−1</sup> = 2.39) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Myocardial infarction<sup>j</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.34</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Stroke<sup>k</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.61</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Stroke<sup>l</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.07</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Sepsis<sup>m</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.14</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Sepsis<sup>n</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.18</p> <p>(BF<sup>−1</sup> = 5.51) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><b>BF:</b> Bayes factor; <b>RR:</b> risk ratio </p> <p><sup>a</sup>The result is likely BF times more compatible with the null‐hypothesis of a RR reduction of 0% than the alternative hypothesis of a RR reduction of 20% for an effect of higher vs lower supplemental oxygen on all‐cause mortality.<br/><sup>b</sup>The result is likely BF times more compatible with the null‐hypothesis of a RR increase of 0% than the alternative hypothesis of a RR increase of 20% for an effect of higher vs lower supplemental oxygen on all‐cause mortality.<br/><sup>c</sup>The result is likely BF times more compatible with the null‐hypothesis of a RR reduction of 0% than the alternative hypothesis of a RR reduction of 20% for an effect of higher vs lower supplemental oxygen on serious adverse events.<br/><sup>d</sup>The result is likely BF times more compatible with the null‐hypothesis of a RR increase of 0% than the alternative hypothesis of a RR increase of 20% for an effect of higher vs lower supplemental oxygen on serious adverse events.<br/><sup>e</sup>The result is likely BF times more compatible with the null‐hypothesis of no difference than the alternative hypothesis of a mean difference of −7 points (minimally clinical important difference) for an effect of higher vs lower supplemental oxygen on quality of life.<br/><sup>f</sup>The result is likely BF times more compatible with the null‐hypothesis of no difference than the alternative hypothesis of a mean difference of +7 points (minimally clinical important difference) for an effect of higher vs lower supplemental oxygen on quality of life.<br/><sup>g</sup>The result is likely BF times more compatible with the null‐hypothesis of a RR increase of 0% than the alternative hypothesis of a RR reduction of 20% for an effect of higher vs lower supplemental oxygen on lung injuries.<br/><sup>h</sup>The result is likely BF times more compatible with the null‐hypothesis of a RR increase of 0% than the alternative hypothesis of a RR increase of 20% for an effect of higher vs lower supplemental oxygen on lung injuries.<br/><sup>i</sup>The result is likely BF<sup>−1</sup> times more compatible with the alternative hypothesis of a RR reduction of 20% than the null‐hypothesis of a RR reduction of 0% for an effect of higher vs lower supplemental oxygen on acute myocardial infarction.<br/><sup>j</sup>The result is likely BF times more compatible with the null‐hypothesis of a RR increase of 0% than the alternative hypothesis of a RR increase of 20% for an effect of higher vs lower supplemental oxygen on acute myocardial infarction.<br/><sup>k</sup>The result is likely BF times more compatible with the null‐hypothesis of a RR increase of 0% than the alternative hypothesis of a RR reduction of 20% for an effect of higher vs lower supplemental oxygen on stroke.<br/><sup>l</sup>The result is likely BF times more compatible with the null‐hypothesis of a RR increase of 0% than the alternative hypothesis of a RR increase of 20% for an effect of higher vs lower supplemental oxygen on stroke.<br/><sup>m</sup>The result is likely BF times more compatible with the null‐hypothesis of a RR increase of 0% than the alternative hypothesis of a RR reduction of 20% for an effect of higher vs lower supplemental oxygen on severe sepsis.<br/><sup>n</sup>The result is likely BF<sup>‐1</sup> times more compatible with the alternative hypothesis of a RR increase of 20% than the null‐hypothesis of a RR increase of 0% for an effect of higher vs lower supplemental oxygen on severe sepsis. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Calculated Bayes factors for all predefined outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/full#CD012631-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012631-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Trials at overall low risk of bias</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All‐cause mortality ‐ trials at overall low risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.94, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Highest proportion of specific serious adverse events ‐ trials at overall low risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.95, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Cumulated number of serious adverse events ‐ trials at overall low risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.99, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Highest reported proportion of lung injury ‐ trials at overall low risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.74, 1.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Cumulated number of lung injury ‐ trials at overall low risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.74, 1.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Stroke ‐ trials at overall low risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.59, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Trials at overall low risk of bias</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012631-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">All‐cause mortality</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.96, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Subgroup analysis: all‐cause mortality ‐ overall risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.96, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.95, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 High risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3675</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.93, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Subgroup analysis: all‐cause mortality ‐ types of oxygen interventions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.96, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 PaO 2 (SaO 2 or SpO 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.95, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 FiO 2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.50, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 Difference between groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.94, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Subgroup analysis: all‐cause mortality ‐ level of FiO<sub>2</sub>/target in higher group <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.96, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Lower</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2626</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.86, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Higher</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5831</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.97, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Subgroup analysis: all‐cause mortality ‐ level of FiO<sub>2</sub>/target in lower group <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.96, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Lower</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.93, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Higher</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1958</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.99, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Subgroup analysis: all‐cause mortality ‐ ICU‐population <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Medical ICU‐population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2746</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.87, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 Surgical ICU‐population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.35, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.3 Mixed ICU‐population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.97, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.4 Any respiratory failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.90, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.5 Any cerebral disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1025</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.90, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.6 Any heart disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.90, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.7 Any trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.35, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.8 COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.91, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Subgroup analysis: all‐cause mortality ‐ oxygen delivery system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.96, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Invasive mechanical ventilation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.92, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 Any non‐invasive oxygen administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.37, 3.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.3 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4930</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.95, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Sensitivity analysis: all‐cause mortality ‐ high vs high oxygenation strategies and low vs low oxygenation strategies excluded <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3873</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.87, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Sensitivity analysis: all‐cause mortality ‐ best‐worst‐case scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.80, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Sensitivity analysis: all‐cause mortality ‐ worst‐best‐case scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.15, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">All‐cause mortality</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012631-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Proportion of patients with one or more serious adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Highest proportion of specific serious adverse events reported <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.96, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Cumulated number of serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [1.02, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Proportion of patients with one or more serious adverse event (as defined by trialists) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.98, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Proportion of patients with one or more serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012631-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Quality of life</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐2.75, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Subgroup analysis: quality of life ‐ risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐2.75, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [‐2.25, 3.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 High risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.50 [‐6.40, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Subgroup analysis: quality of life ‐ types of oxygen intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐2.75, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 PaO 2 (SaO 2 or SpO 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐2.75, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Subgroup analysis: quality of life ‐ level of FiO<sub>2</sub>/target in higher group <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐2.75, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Higher</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐2.75, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Subgroup analysis: quality of life ‐ level of FiO<sub>2</sub>/target in lower group <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐2.74, 1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 Lower</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐2.74, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Subgroup analysis: quality of life ‐ ICU‐population <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 Mixed ICU‐population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐2.75, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.2 Any respiratory failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [‐2.25, 3.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Subgroup analysis: quality of life ‐ oxygen delivery system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐2.75, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐2.75, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Sensitivity analysis: quality of life ‐ best‐worst‐case scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2093</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.91 [8.66, 23.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.9 Sensitivity analysis: quality of life ‐ worst‐best‐case scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2093</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐18.22 [‐20.21, ‐16.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Quality of life</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012631-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Lung injury</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Lung injury ‐ highest proportion reported <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2048</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.85, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Lung injury ‐ cumulated number <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2048</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.82, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Acute respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>862</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.43, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.85, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Lung injury</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012631-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Myocardial infartion</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.51, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Subgroup analysis: myocardial infarction ‐ overall risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.51, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.24, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 High risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2092</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.53, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Subgroup analysis: myocardial infarction ‐ types of oxygen interventions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.51, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.1 PaO 2 (SaO 2 or SpO 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4944</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.58, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.2 FiO 2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.05, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Subgroup analysis: myocardial infarction ‐ level of FiO<sub>2</sub>/target in higher group <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.51, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.1 Lower</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1634</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.56, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.2 Higher</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.33, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Subgroup analysis: myocardial infarction ‐ level of FiO<sub>2</sub>/target in lower group <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.51, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.1 Lower</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.46, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.2 Higher</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.42, 3.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.6 Subgroup analysis: myocardial infarction ‐ ICU‐population <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.1 Medical ICU‐population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1692</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.47, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.2 Mixed ICU‐population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.39, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.3 Any respiratory failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.21, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.7 Subgroup analysis: myocardial infarction ‐ oxygen delivery system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.51, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7.1 Invasive mechanical ventilation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1692</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.47, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7.2 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.39, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.8 Sensitivity analysis: myocardial infarction ‐ best‐worst‐case scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.04, 0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.9 Sensitivity analysis: myocardial infarction ‐ worst‐best‐case scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.48 [0.47, 25.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Myocardial infartion</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012631-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Stroke</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.72, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Subgroup analysis: stroke ‐ overall risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.72, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.59, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.2 Some concern</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>965</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.02 [0.12, 73.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.3 High risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2034</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.58, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Subgroup analysis: stroke ‐ types of oxygen interventions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.72, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.1 PaO 2 (SaO 2 or SpO 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.72, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Subgroup analysis: stroke ‐ level of FiO<sub>2</sub>/target in the higher group <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.70, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.1 Lower</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1634</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.54, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.2 Higher</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.62, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Subgroup analysis: stroke ‐ level of FiO<sub>2</sub>/target in lower group <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.72, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.1 Lower</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5710</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.69, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.2 Higher</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [0.19, 23.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.6 Subgroup analysis: stroke ‐ ICU‐population <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.1 Medical ICU‐population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1634</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.54, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.2 Mixed ICU‐population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.65, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6.3 Any respiratory failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.66, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.7 Subgroup analysis: stroke ‐ oxygen delivery system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.72, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.1 Invasive mechanical ventilation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.51, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7.2 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.70, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.8 Sensitivity analysis: stroke ‐ high vs high oxygenation strategies and low vs low oxygenation strategies excluded <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.59, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.9 Sensitivity analysis: stroke ‐ best‐worst‐case scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7694</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.04, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.10 Sensitivity analysis: stroke ‐ worst‐best‐case scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7694</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.69 [0.95, 79.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Stroke</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012631-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Sepsis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [1.17, 2.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Subgroup analysis: sepsis ‐ overall risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [1.17, 2.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [0.84, 3.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.2 High risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>551</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [1.08, 3.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Subgroup analysis: sepsis ‐ types of oxygen interventions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [1.17, 2.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.1 PaO 2 (SaO 2 or SpO 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [1.17, 2.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.4 Subgroup analysis: sepsis ‐ level of FiO<sub>2</sub>/target in higher group <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [1.17, 2.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4.1 Higher</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [1.17, 2.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.5 Subgroup analysis: sepsis ‐ level of FiO<sub>2</sub>/target in lower group <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [1.17, 2.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5.1 Lower</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [1.11, 2.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5.2 Higher</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.16 [0.57, 8.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.6 Subgroup analysis: sepsis ‐ ICU‐population <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [1.17, 2.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6.1 Mixed ICU‐population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [1.17, 2.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.7 Subgroup analysis: sepsis ‐ oxygen delivery system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [1.17, 2.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7.1 Invasive mechanical ventilation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [0.96, 3.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7.2 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [0.97, 3.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.8 Sensitivity analysis: sepsis ‐ best‐worst‐case scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>791</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.71, 1.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.9 Sensitivity analysis: sepsis ‐ worst‐best‐case scenario <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>791</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [1.53, 4.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Sepsis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012631-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Specific serious adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.25, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.72, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [1.17, 2.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.4 Acute respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>862</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.43, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.5 Pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.85, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.6 Delirium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.50, 2.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.7 Pneumothorax <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.86, 2.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.8 Intestinal ischaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.35, 2.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.9 Cardiovascular failure including shock <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.98, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.10 Cardiac arrhythmia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.82, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.11 Liver failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>951</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.29, 9.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.12 Renal failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.92, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.13 Seizure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.76, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Specific serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#CD012631-tbl-0013">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-1"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.1 All‐cause mortality</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Asfar 2017</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computer‐generated randomization list stratified by site and presence or absence of ARDS using permuted blocks of random sizes (nQuery Advisor 6.0). No significant differences between groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clear separation of oxygenation levels between the two groups at both 12 and 24 hours. Intention‐to‐treat. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>442 patients were randomly assigned to either normoxia (n= 223) or hyperoxia (n= 219), of which 217 from each group (98.2%) was included in the intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients, the research staff, the safety committee, and the writing committee were blinded to the treatment assignments.<br/>Not explicitly specified if outcome assessors are blinded. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered prior to randomisation (NCT01722422), and all pre‐specified outcomes were reported on. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Barrot 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computer randomization was performed in blocks of four. Comparable groups at baseline.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clear separation in oxygenation levels between the two groups. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>4 out of 205 patients were lost to follow‐up (2 due to withrawn consent, 2 excluded due to not meeting eligibility criteria), thus leaving 201 patients in the analysis (98.0 %). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Details on assesment blinding not provided. Assessment of outcome judged to not to be influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered (NCT02713451).</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concers of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Gelissen 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Web‐based randomizationwith randomlypermuted blocks of size 4 to 8, stratified by age, sex, and reason of admittance (medical, surgical, or trauma). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Achieved separation in oxygentation targets, but did not achieve the aimed oxygenation target in high group (achieved: 12.8 kPa (IQR 10.9‐14.9) vs aimed: 14‐18 kPa). 1 patient excluded post‐randomisation due to development of severe ARDS. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>574 randomized, 400 in the intention‐to‐treat population (69.7%).</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Assessment of outcome judged not to be influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered trial protocol (NCT02321072). 90‐day all‐cause mortality added as outcome post‐hoc. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High proportion of loss to follow‐up, one patient excluded post‐randomization. Not predefined outcome. </p> </td> </tr> <tr class="study-data"> <td> <p>Girardis 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col10" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computerized random‐number generator. The randomization sequence was concealed from the researchers by use of sequentially numbered, closed, opaque envelopes that were opened after patient study inclusion. Comparable groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label. Clear separation of oxygenation levels between the two groups. A modified, not predefined, intent‐to‐treat population, consisting of all randomized patients with an ICU length of stay of 72 hours or longer and for whom at least 1 arterial blood gas analysis had been performed per day, was the primary population for analysis. However, the primary and secondary outcomes were also evaluated in the intent‐to‐treat population, which included all randomized patients, excluding those who withdrew consent. No justification for modification of intention‐to‐treat population reported. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on intention‐to‐treat population (n = 478) is available in supplement; 1 patient in each group withdrew consent. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not described; however, blinding of outcome assessment was clarified by email.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Primary analysis changed from intention‐to‐treat population to modified intention‐to‐treat population consisting of all randomized patients with an ICU length of stay of 72 hours or longer and for whom at least 1 arterial blood gas analysis had been performed per day. The trial was by us judged being registrered retrospectively (NCT01319643). 90‐day mortality defined as secondary outcome in protocol, but not reported. No justification for change to modified intention‐to‐treat population is reported. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Concern of bias due to change of analysed population, retrospective registration, and failure to report all prespecified outcome data. </p> </td> </tr> <tr class="study-data"> <td> <p>Gomersall 2002</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomization was performed using unmarked, ordered, sealed envelopes. The randomization order was deter‐ mined using a computer‐generated list of random numbers. No significant differences between the two groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were blinded to the target oxygen tension. Clear separation of oxygenation levels between the two groups. <br/>Unjustified, modified intention‐to‐treat analysis. Two patients in the low oxygen group were excluded post‐randomisationen due to violation of inclusion criteria. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>36 patients were recruited, 34 were included in analysis (94.4%).</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Only patients were blinded.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol could be found.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No prospective registration. No justification for modified intention‐to‐treat analysis.</p> </td> </tr> <tr class="study-data"> <td> <p>Jakkula 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A cryptographically strong random number generator with modulo bias eliminated is used to generate random numbers and an unbiased Fisher‐Yates (Durstenfeld) algorithm is used to shuffle blocks. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The treating clinicians and nurses will be made aware of treatment targets using laminated signs at the patient’s bedside and on mechanical ventilators. Clear separation in oxygenation between the two groups. Intention‐to‐treat. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>123 patients randomized, 3 were excluded post‐randomization (2 due to no consent, 1 due to randomization error), 120 included in analysis (97.6%). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No specification of outcome assessor blinding reported. Outcome assessment judged to not be influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered (NCT02698917). Trial protocol published before recruitment of last patient. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Lång 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Stated that the trial was randomized, but the method of sequence generation was not described. Sealed, opaque envelopes were used. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open label. Clear separation in provided intervention and oxygenation levels between the two groups. 5 patients were excluded du to loss‐to follow‐up, not specified group allocation. Clarified by mail. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>70 patients were randomised, 5 lost to follow‐up, leaving 65 (92.9). No information on reasons for loss provided, and no information on group allocation for patients lost to follow‐up. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on assessment blinding provided. Outcome assessment judged not to be influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered prior to randomization (NCT01201291), however quality of life is not reported; trial authors are planning to publish these results. Originally planned to include 500 patients, but due to lack of funding and a slow recruitment rate the study was presented as a pilot study. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Concerns of missing reporting of group allocation and proportion of missing data.</p> </td> </tr> <tr class="study-data"> <td> <p>Mackle 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomly assigned using a secure, centralized, internet‐based interface. The trial statistician generated the assignment sequence using computer‐generated random numbers with variable‐block randomization in a 1:1 ratio and stratification according to trial center. Comparable groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial‐group assignment was known to clinical staff members but was not disclosed to the patients or their families.<br/>Clear separation in oxygenation levels between groups. Intention‐to‐treat. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1000 patients randomized, 49 lost to follow‐up, leaving 951 patients (95.1%) for the analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients and outcome assessors were blinded to group allocation, as stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered protocol (ACTRN12615000957594).</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Martin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomly assigned on a 1:1 basis (www. sealedenvelope.com) into either the conservative or control group, stratified by study site, using random permuted blocks of different sizes. Randomisation was balanced between the two treatment groups (17:17) and was also balanced at each site (10:10 at site one and 7:7 at site two). No details on baseline characteristics stratified by group is provided. Only baseline characteristics for the entire cohort is reported. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Unblinded trial. Clear separation of oxygenation levels in the two groups. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome reported for all patients.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Unblinded trial. Assessment of outcome judged to not be influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered protocol (NCT03287466). Protocol published prior to completion of recruitment. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Mazdeh 2015</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Stated that the trial was randomized, but the method of sequence generation was not described. Only limited baseline data provided. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. No information on protocol adherence or oxygenation levels. No information provided. No CONSORT diagram provided. Not per‐protocol analyses provided. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1 out of 52 (2%) randomized participants was lost to follow‐up, and this was not described in the manuscript. It is not stated to which group this person was allocated. Patients of the control group which oxygen therapy were inevitable for them were also excluded from this study. It is unclear how many patients are excluded on this basis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No details on outcome assessment blinding. Assessment of outcome judged not to be influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged the trial to be registered retrospectively (IRCT201212199647N2). It was registered 3 November 2013 and submitted to journal 30 December 2013. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>One patient lost to follow‐up, but not described in manuscript. Uncertain amount of patients excluded from trial. No CONSORT‐diagram. No information on protocol adherence. Judged to be prospectively registrered. </p> </td> </tr> <tr class="study-data"> <td> <p>Panwar 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomization was done in a masked fashion, using opaque sealed envelopes, with a unique computer‐generated, permuted block randomization method with random block sizes. Comparable groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were unaware of their assigned group but blinding of treating clinicians was not considered feasible.<br/>Clear separation in oxygenation levels between the two groups. One patient in the lower group was in error treated according to the higher group protocol. Results from per‐protocol analysis was consistent with intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1 lost to follow‐up in conservative group due to consent withdrawn.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were not blinded. Clarified by email. Assessment of outcome judged to not be influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A study protocol was registered prior to randomization (ACTRN12613000505707), and all outcomes were reported on. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Schjørring 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized randomization and a computer‐generated concealed assignment sequence, with permuted blocks of varying sizes. The trial groups had similar charcteristics at baseline, except for the presence of cardiac arrest. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label. Clear separation of oxygenation levels in the two groups. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>2887 out of 2928 enrolled patients included in final analysis (98.6%).</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Stated as outcome assessment blinded. Asessment of outcome judged not to be influence by knowledge of intervention recieved. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered protocol (NCT03174002). Protocol and statistical analysis plan published prior to inclusion of last patient. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Schmidt 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Web‐based system using random permuted block sizes of 2, 4, or 6 that were stratified according to site.<br/>Comparable groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Some separation of oxygenation targets. Intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>802 patients randomized. Consent declined in 12 patients, 1 patient randomized twice. Data provided for 789 (98.4%). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Assessment of outcome not likely to be influenced by knowledge of group allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered protocol (NCT03141099). Protocol and statistical analysis plan published prior to inclusion of last patient. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All domains at overall low risk of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Semler 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Radomly generated cluster‐level crossover. The order of trial group assignments for each 2‐month period was generated by computerized randomization with the use of permuted blocks of three to minimize the effect of seasonal variation and temporal changes. The allocation remain concealed until the start of each 2‐months period. Patients recruited prospectively. Sequence of the individual cluster‐periods were unknown. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Reasons for protocol deviations are listed in supplement. Clear separation between allocated targets. Exclusion of patients enrolled during washout periods, as predefined in the trial protocol, and those positive for COVID‐19 (not predefined). No supplemental sensitivity‐analysis of of all included patients performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>2541/2987 patients included in analysis (85.1%). No supplemental sensitivity‐analysis of all included patients performed. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is a hard, objective endpoint. Blinded study personnel.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered (NCT03537937). Mortality predefined as an outcome.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Two domains at high risk of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Yang 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomized by a computerized random‐number generator. The randomization sequence was concealed in sequentially numbered, closed, opaque envelopes that were opened after patient study inclusion. Comparable groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The treating team was aware of allocation, but the included patients were unaware of their treatment group.<br/>Clear separation of oxygenation levels in the two groups. Intention‐to‐treat. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No patients lost to follow‐up.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on assesment blinding. Assessment of outcome judged not to be influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Pilot trial of prospectively registered trial (NCT02999932).</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Yang 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random number table allocation method. No information on allocation concealment. Limitid baseline information provided. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Intended interventions not achieved. Intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>110 patientens included, 4 were excluded. Complete data on remaining 106 patients. No information on group allocation. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Reports both ICU mortality and 60‐day mortality. No information on outcome assessment blinding. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No analysis plan or protocol available. Mortality reported as "ICU fatality rate" and "60‐day mortality". <br/>No information on analysis plans. Mortality might have been analysed at multiple time points and the most significant one chosen. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Several domains at some concern and one domain at high risk of bias.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.1 All‐cause mortality</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#riskOfBias2Table-1">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-2"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.1 Highest proportion of specific serious adverse events reported</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Asfar 2017</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computer‐generated randomization list stratified by site and presence or absence of ARDS using permuted blocks of random sizes (nQuery Advisor 6.0). No significant differences between groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clear separation of oxygenation levels between the two groups at both 12 and 24 hours. Intention‐to‐treat. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>442 patients were randomly assigned to either normoxia (n= 223) or hyperoxia (n= 219), of which 217 from each group (98.2%) was included in the intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients, the research staff, the safety committee, and the writing committee were blinded to the treatment assignments.<br/>Not explicitly specified if outcome assessors are blinded. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered prior to randomisation (NCT01722422), and all pre‐specified outcomes were reported on. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Barrot 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computer randomization was performed in blocks of four. Comparable groups at baseline.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clear separation in oxygenation levels between the two groups. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>4 out of 205 patients were lost to follow‐up (2 due to withrawn consent, 2 excluded due to not meeting eligibility criteria), thus leaving 201 patients in the analysis (98.0 %). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Details on assesment blinding not provided. Assessment of outcome judged to not to be influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered (NCT02713451).</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concers of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Gelissen 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Web‐based randomizationwith randomlypermuted blocks of size 4 to 8, stratified by age, sex, and reason of admittance (medical, surgical, or trauma). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Achieved separation in oxygentation targets, but did not achieve the aimed oxygenation target in high group (achieved: 12.8 kPa (IQR 10.9‐14.9) vs aimed: 14‐18 kPa). 1 patient excluded post‐randomisation due to development of severe ARDS. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>574 randomized, 400 in the intention‐to‐treat population (69.7%).</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Assessment of outcome judged not to be influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered trial protocol (NCT02321072). Proportion of patients with one or more serious adverse events (including death) not pre‐defined as outcome. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High proportion of loss to follow‐up, one patient excluded post‐randomization. Proportion of patients with one or more serious adverse events (including death) not pre‐defined as outcome. </p> </td> </tr> <tr class="study-data"> <td> <p>Girardis 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col10" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computerized random‐number generator. The randomization sequence was concealed from the researchers by use of sequentially numbered, closed, opaque envelopes that were opened after patient study inclusion. Comparable groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label. Clear separation of oxygenation levels between the two groups. A modified, not predefined, intent‐to‐treat population, consisting of all randomized patients with an ICU length of stay of 72 hours or longer and for whom at least 1 arterial blood gas analysis had been performed per day, was the primary population for analysis. However, the primary and secondary outcomes were also evaluated in the intent‐to‐treat population, which included all randomized patients, excluding those who withdrew consent. No justification for modification of intention‐to‐treat population reported. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on intention‐to‐treat population (n = 478) is available in supplement; 1 patient in each group withdrew consent. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not described; however, blinding of outcome assessment was clarified by email.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Primary analysis changed from intention‐to‐treat population to modified intention‐to‐treat population consisting of all randomized patients with an ICU length of stay of 72 hours or longer and for whom at least 1 arterial blood gas analysis had been performed per day. The trial was by us judged being registrered retrospectively (NCT01319643). 90‐day mortality defined as secondary outcome in protocol, but not reported. No justification for change to modified intention‐to‐treat population is reported. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Concern of bias due to change of analysed population, retrospective registration, and failure to report all prespecified outcome data. </p> </td> </tr> <tr class="study-data"> <td> <p>Gomersall 2002</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomization was performed using unmarked, ordered, sealed envelopes. The randomization order was deter‐ mined using a computer‐generated list of random numbers. No significant differences between the two groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were blinded to the target oxygen tension. Clear separation of oxygenation levels between the two groups. <br/>Unjustified, modified intention‐to‐treat analysis. Two patients in the low oxygen group were excluded post‐randomisationen due to violation of inclusion criteria. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>36 patients were recruited, 34 were included in analysis (94.4%).</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Only patients were blinded.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol could be found.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No prospective registration. No justification for modified intention‐to‐treat analysis.</p> </td> </tr> <tr class="study-data"> <td> <p>Jakkula 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A cryptographically strong random number generator with modulo bias eliminated is used to generate random numbers and an unbiased Fisher‐Yates (Durstenfeld) algorithm is used to shuffle blocks. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The treating clinicians and nurses will be made aware of treatment targets using laminated signs at the patient’s bedside and on mechanical ventilators. Clear separation in oxygenation between the two groups. Intention‐to‐treat. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>123 patients randomized, 3 were excluded post‐randomization (2 due to no consent, 1 due to randomization error), 120 included in analysis (97.6%). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No specification of outcome assessor blinding reported. Outcome assessment judged to not be influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered (NCT02698917). Trial protocol published before recruitment of last patient. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Jun 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Stated as randomized, but no details on randomization proces. No baseline data.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. No information on protocol deviations. No information on number of patients allocated to each of the groups. Event rate reported as percentage and number for two of three groups. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>87 patients enrolled. 9 events (31%) in moderate oxygen concentration group = 29 participants. 2 events (6.9%) in high oxygen concentration group = 29 participants. No information on the remaining 29 patients, but they were presumably allocated to low oxygen concentration. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on assesment of outcome. No information on blinding.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol could be found.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Multiple domains with some concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Lång 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Stated that the trial was randomized, but the method of sequence generation was not described. Sealed, opaque envelopes were used. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open label. Clear separation in provided intervention and oxygenation levels between the two groups. 5 patients were excluded du to loss‐to follow‐up, not specified group allocation. Clarified by mail. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>70 patients were randomised, 5 lost to follow‐up, leaving 65 (92.9). No information on reasons for loss provided, and no information on group allocation for patients lost to follow‐up. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on assessment blinding provided. Outcome assessment judged not to be influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered prior to randomization (NCT01201291), however quality of life is not reported; trial authors are planning to publish these results. Originally planned to include 500 patients, but due to lack of funding and a slow recruitment rate the study was presented as a pilot study. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Concerns of missing reporting of group allocation and proportion of missing data.</p> </td> </tr> <tr class="study-data"> <td> <p>Mackle 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomly assigned using a secure, centralized, internet‐based interface. The trial statistician generated the assignment sequence using computer‐generated random numbers with variable‐block randomization in a 1:1 ratio and stratification according to trial center. Comparable groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial‐group assignment was known to clinical staff members but was not disclosed to the patients or their families.<br/>Clear separation in oxygenation levels between groups. Intention‐to‐treat. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1000 patients randomized, 49 lost to follow‐up, leaving 951 patients (95.1%) for the analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients and outcome assessors were blinded to group allocation, as stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered protocol (ACTRN12615000957594).</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Martin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomly assigned on a 1:1 basis (www. sealedenvelope.com) into either the conservative or control group, stratified by study site, using random permuted blocks of different sizes. Randomisation was balanced between the two treatment groups (17:17) and was also balanced at each site (10:10 at site one and 7:7 at site two). No details on baseline characteristics stratified by group is provided. Only baseline characteristics for the entire cohort is reported. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Unblinded trial. Clear separation of oxygenation levels in the two groups. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome reported for all patients.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Unblinded trial. Assessment of outcome judged to not be influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered protocol (NCT03287466). Protocol published prior to completion of recruitment. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Mazdeh 2015</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Stated that the trial was randomized, but the method of sequence generation was not described. Only limited baseline data provided. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. No information on protocol adherence or oxygenation levels. No information provided. No CONSORT diagram provided. Not per‐protocol analyses provided. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1 out of 52 (2%) randomized participants was lost to follow‐up, and this was not described in the manuscript. It is not stated to which group this person was allocated. Patients of the control group which oxygen therapy were inevitable for them were also excluded from this study. It is unclear how many patients are excluded on this basis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No details on outcome assessment blinding. Assessment of outcome judged not to be influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged the trial to be registered retrospectively (IRCT201212199647N2). It was registered 3 November 2013 and submitted to journal 30 December 2013. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>One patient lost to follow‐up, but not described in manuscript. Uncertain amount of patients excluded from trial. No CONSORT‐diagram. No information on protocol adherence. Judged to be prospectively registrered. </p> </td> </tr> <tr class="study-data"> <td> <p>Panwar 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomization was done in a masked fashion, using opaque sealed envelopes, with a unique computer‐generated, permuted block randomization method with random block sizes. Comparable groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were unaware of their assigned group but blinding of treating clinicians was not considered feasible.<br/>Clear separation in oxygenation levels between the two groups. One patient in the lower group was in error treated according to the higher group protocol. Results from per‐protocol analysis was consistent with intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1 lost to follow‐up in conservative group due to consent withdrawn.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were not blinded. Clarified by email. Assessment of outcome judged to not be influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A study protocol was registered prior to randomization (ACTRN12613000505707), and all outcomes were reported on. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Schjørring 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized randomization and a computer‐generated concealed assignment sequence, with permuted blocks of varying sizes. The trial groups had similar charcteristics at baseline, except for the presence of cardiac arrest. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label. Clear separation of oxygenation levels in the two groups. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>2888 out of 2928 enrolled patients included in final analysis (98.6%).</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Stated as outcome assessment blinded. Asessment of outcome judged not to be influence by knowledge of intervention recieved. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered protocol (NCT03174002). Protocol and statistical analysis plan published prior to inclusion of last patient. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Schmidt 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Web‐based system using random permuted block sizes of 2, 4, or 6 that were stratified according to site.<br/>Comparable groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Some separation of oxygenation targets. Intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>802 patients randomized. Consent declined in 12 patients, 1 patient randomized twice. Data provided for 789 (98.4%). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Assessment of outcome not likely to be influenced by knowledge of group allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered protocol (NCT03141099). Protocol and statistical analysis plan published prior to inclusion of last patient. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All domains at overall low risk of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Semler 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Radomly generated cluster‐level crossover. The order of trial group assignments for each 2‐month period was generated by computerized randomization with the use of permuted blocks of three to minimize the effect of seasonal variation and temporal changes. The allocation remain concealed until the start of each 2‐months period. Patients recruited prospectively. Sequence of the individual cluster‐periods were unknown. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Reasons for protocol deviations are listed in supplement. Clear separation between allocated targets. Exclusion of patients enrolled during washout periods, as predefined in the trial protocol, and those positive for COVID‐19 (not predefined). No supplemental sensitivity‐analysis of of all included patients performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>2541/2987 patients included in analysis (85.1%). No supplemental sensitivity‐analysis of all included patients performed. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is a hard, objective endpoint. Blinded study personnel.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered (NCT03537937). Mortality predefined as an outcome.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Two domains at high risk of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Yang 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomized by a computerized random‐number generator. The randomization sequence was concealed in sequentially numbered, closed, opaque envelopes that were opened after patient study inclusion. Comparable groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The treating team was aware of allocation, but the included patients were unaware of their treatment group.<br/>Clear separation of oxygenation levels in the two groups. Intention‐to‐treat. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No patients lost to follow‐up.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on assesment blinding. Assessment of outcome judged not to be influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Pilot trial of prospectively registered trial (NCT02999932).</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Yang 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random number table allocation method. No information on allocation concealment. Limitid baseline information provided. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Intended interventions not achieved. Intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>110 patientens included, 4 were excluded. Complete data on remaining 106 patients. No information on group allocation. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Reports both ICU mortality and 60‐day mortality. No information on outcome assessment blinding. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No analysis plan or protocol available. Mortality reported as "ICU fatality rate" and "60‐day mortality". <br/>No information on analysis plans. Mortality might have been analysed at multiple time points and the most significant one chosen. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Several domains at some concern and one domain at high risk of bias.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.1 Highest proportion of specific serious adverse events reported</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#riskOfBias2Table-2">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-3"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.2 Cumulated number of serious adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Asfar 2017</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computer‐generated randomization list stratified by site and presence or absence of ARDS using permuted blocks of random sizes (nQuery Advisor 6.0). No significant differences between groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients, the research staff, the safety committee, and the writing committee were blinded to the treatment assignments. No blinding of carers reported. Clear separation of oxygenation levels between the two groups at both 12 and 24 hours. Intention‐to‐treat. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>442 patients were randomly assigned to either normoxia (n= 223) or hyperoxia (n= 219), of which 217 from each group (98.2%) was included in the intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not explicitly specified if outcome assessors are blinded. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered prior to randomisation (NCT01722422). However serious adverse events were not explicitly pre‐defined individually. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Serious adverse events were not explicitly pre‐defined individually.</p> </td> </tr> <tr class="study-data"> <td> <p>Barrot 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computer randomization was performed in blocks of four. Comparable groups at baseline.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label. Clear separation in oxygenation levels between the two groups. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>4 out of 205 patients were lost to follow‐up (2 due to withrawn consent, 2 excluded due to not meeting eligibility criteria), thus leaving 201 patients in the analysis (98.0 %). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Details on assesment blinding not provided. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not all serious adverse events were not explicitly pre‐defined individually.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not all serious adverse events were not explicitly pre‐defined individually.</p> </td> </tr> <tr class="study-data"> <td> <p>Gelissen 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Web‐based randomizationwith randomlypermuted blocks of size 4 to 8, stratified by age, sex, and reason of admittance (medical, surgical, or trauma). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Achieved separation in oxygentation targets, but did not achieve the aimed oxygenation target in high group (achieved: 12.8 kPa (IQR 10.9‐14.9) vs aimed: 14‐18 kPa). 1 patient excluded post‐randomisation due to development of severe ARDS. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>574 randomized, 400 in the intention‐to‐treat population (69.7%).</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Assessment of outcome judged not to be influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered trial protocol (NCT02321072). Proportion of patients with one or more serious adverse events (including death) not pre‐defined as outcome. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High proportion of loss to follow‐up, one patient excluded post‐randomization. Proportion of patients with one or more serious adverse events (including death) not pre‐defined as outcome. </p> </td> </tr> <tr class="study-data"> <td> <p>Girardis 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col10" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computerized random‐number generator. The randomization sequence was concealed from the researchers by use of sequentially numbered, closed, opaque envelopes that were opened after patient study inclusion. Comparable groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label trial. Clear separation of oxygenation levels between the two groups.</p> <p>A modified, not predefined, intent‐to‐treat population, consisting of all randomized patients with an ICU length of stay of 72 hours or longer and for whom at least 1 arterial blood gas analysis had been performed per day, was the primary population for analysis. </p> <p>However, the primary and secondary outcomes were also evaluated in the intent‐to‐treat population, which included all randomized patients, excluding those who withdrew consent. No justification for modification of intention‐to‐treat population reported. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on intention‐to‐treat population (n = 478) is available in supplement; 1 patient in each group withdrew consent. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not described; however, blinding of outcome assessment was clarified by email. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Primary analysis changed from intention‐to‐treat population to modified intention‐to‐treat population consisting of all randomized patients with an ICU length of stay of 72 hours or longer and for whom at least 1 arterial blood gas analysis had been performed per day. </p> <p>The trial was by us judged being registrered retrospectively (NCT01319643).</p> <p>90‐day mortality defined as secondary outcome in protocol, but not reported.</p> <p>No justification for change to modified intention‐to‐treat population is reported.</p> <p>Not all serious adverse event were pre‐specified individually.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No justification for change to modified intention‐to‐treat population is reported. Not all serious adverse event were pre‐specified individually. </p> </td> </tr> <tr class="study-data"> <td> <p>Gomersall 2002</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomization was performed using unmarked, ordered, sealed envelopes. The randomization order was deter‐ mined using a computer‐generated list of random numbers. No significant differences between the two groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were blinded to the target oxygen tension. Clear separation of oxygenation levels between the two groups. Modified intention‐to‐treat. Two patients in the low oxygen group were excluded post‐randomisationen due to violation of inclusion criteria. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>36 patients were recruited, 34 were included in analysis (94.4%).</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Only patients were blinded. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol could be found.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk of bias in multiple domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Jakkula 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A cryptographically strong random number generator with modulo bias eliminated is used to generate random numbers and an unbiased Fisher‐Yates (Durstenfeld) algorithm is used to shuffle blocks. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The treating clinicians and nurses will be made aware of treatment targets using laminated signs at the patient’s bedside and on mechanical ventilators. Clear separation in oxygenation between the two groups. Intention‐to‐treat. 3 patients in the high‐normal group were excluded post‐randomisation due to withdrawal of consent (n = 2) or randomisation error (n = 1). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>123 patients randomized, 3 were excluded post‐randomization (2 due to no consent, 1 due to randomization error), 120 included in analysis (97.6%). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No specification of outcome assessor blinding reported. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered (NCT02698917). Trial protocol published before recruitment of last patient. Serious adverse events not pre‐defined. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Serious adverse events not pre‐defined.</p> </td> </tr> <tr class="study-data"> <td> <p>Jun 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Stated as randomized, but no details on randomization proces. No baseline data.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. No information on protocol deviations. No information on number of patients allocated to each of the groups. Event rate reported as percentage and number for two of three groups. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on the remaining 29 patients, but they were presumably allocated to low oxygen concentration. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on assesment of outcome. No information on blinding. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol could be found.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concers of bias in multiple domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Lång 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Stated that the trial was randomized, but the method of sequence generation was not described. Sealed, opaque envelopes were used. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open label. Clear separation in provided intervention and oxygenation levels between the two groups. 5 patients were excluded du to loss‐to follow‐up, not specified group allocation. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>70 patients were randomised, 5 lost to follow‐up, leaving 65 (92.9). No information on reasons for loss provided, and no information on group allocation for patients lost to follow‐up. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on assessment blinding provided. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered prior to randomisation (NCT01722422), and all pre‐specified outcomes were reported on. Pneumonia not pre‐specified. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not all serious adverse events were pre‐specified individually. High loss to follow‐up. Five patients were excluded du to loss‐to follow‐up, not specified group allocation. </p> </td> </tr> <tr class="study-data"> <td> <p>Mackle 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomly assigned using a secure, centralized, internet‐based interface. The trial statistician generated the assignment sequence using computer‐generated random numbers with variable‐block randomization in a 1:1 ratio and stratification according to trial center. Comparable groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial‐group assignment was known to clinical staff members but was not disclosed to the patients or their families. Clear separation in oxygenation levels between groups. Intention‐to‐treat. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1000 patients randomized, 35 lost to follow‐up (withdrawal of consent), leaving 965 patients (96.5%) for the analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients and outcome assessors were blinded to group allocation, as stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered protocol (ACTRN12615000957594).</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concers of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Martin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomly assigned on a 1:1 basis (www. sealedenvelope.com) into either the conservative or control group, stratified by study site, using random permuted blocks of different sizes. Randomisation was balanced between the two treatment groups (17:17) and was also balanced at each site (10:10 at site one and 7:7 at site two). No details on baseline characteristics stratified by group is provided. Only baseline characteristics for the entire cohort is reported. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Unblinded trial. Clear separation of oxygenation levels in the two groups. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome reported for all patients.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Unblinded trial. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered protocol (NCT03287466). Protocol published prior to completion of recruitment. All reported serious adverse events were pre‐defined. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Mazdeh 2015</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Stated that the trial was randomized, but the method of sequence generation was not described. Only limited baseline data provided. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. No information on protocol adherence or oxygenation levels. No information provided. No CONSORT diagram provided.<br/>Not described. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1 out of 52 (2%) randomized participants was lost to follow‐up, and this was not described in the manuscript. It is not stated to which group this person was allocated. Patients of the control group which oxygen therapy were inevitable for them were also excluded from this study. It is unclear how many patients are excluded on this basis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not specified. Assessment of outcome judged not to be influenced by knowledge of intervention.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We judged the trial to be registered retrospectively (IRCT201212199647N2). It was registered 3 November 2013 and submitted to journal 30 December 2013. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk of bias in multiple domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Panwar 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomization was done in a masked fashion, using opaque sealed envelopes, with a unique computer‐generated, permuted block randomization method with random block sizes. Comparable groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were unaware of their assigned group but blinding of treating clinicians was not considered feasible.<br/>Clear separation in oxygenation levels between the two groups. One patient in the lower group was in error treated according to the higher group protocol. Results from per‐protocol analysis was consistent with intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1 lost to follow‐up in conservative group due to consent withdrawn.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were not blinded. Clarified by email. Outcome assessors were not blinded. Clarified by email. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A study protocol was registered prior to randomization (ACTRN12613000505707), and all outcomes were reported on. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Schjørring 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized randomization and a computer‐generated concealed assignment sequence, with permuted blocks of varying sizes. The trial groups had similar charcteristics at baseline, except for the presence of cardiac arrest. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label. Clear separation of oxygenation levels in the two groups. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>2910 out of 2928 enrolled patients included in final analysis (99.4%)</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Assessment of outcome judged not to be influenced by knowledge of intervention.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered protocol (NCT03174002). Protocol and statistical analysis plan published prior to inclusion of last patient. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concers of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Schmidt 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Web‐based system using random permuted block sizes of 2, 4, or 6 that were stratified according to site.<br/>Comparable groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Some separation of oxygenation targets. Intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>802 patients randomized. Consent declined in 12 patients, 1 patient randomized twice. Data provided for 789 (98.4%). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Assessment of outcome not likely to be influenced by knowledge of group allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered protocol (NCT03141099). Protocol and statistical analysis plan published prior to inclusion of last patient. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All domains at overall low risk of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Semler 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Radomly generated cluster‐level crossover. The order of trial group assignments for each 2‐month period was generated by computerized randomization with the use of permuted blocks of three to minimize the effect of seasonal variation and temporal changes. The allocation remain concealed until the start of each 2‐months period. Patients recruited prospectively. Sequence of the individual cluster‐periods were unknown. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Reasons for protocol deviations are listed in supplement. Clear separation between allocated targets. Exclusion of patients enrolled during washout periods, as predefined in the trial protocol, and those positive for COVID‐19 (not predefined). No supplemental sensitivity‐analysis of of all included patients performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Multiple outcomes only reported in patients recruited in first 24 of 36 months of trial conduct. No justification for this selection and no senisitivity analyses to evaluate the impact of missing data. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Blinded study personnel.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered (NCT03537937). Outcomes reported and cummulated were all predefined. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Two items at high risk of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Yang 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomized by a computerized random‐number generator. The randomization sequence was concealed in sequentially numbered, closed, opaque envelopes that were opened after patient study inclusion. Comparable groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The treating team was aware of allocation, but the included patients were unaware of their treatment group. Clear separation of oxygenation levels in the two groups. Intention‐to‐treat. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No patients lost to follow‐up.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on assesment blinding. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Pilot trial of prospectively registered trial (NCT02999932).</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Yang 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random number table allocation method. No information on allocation concealment. Limitid baseline information provided. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Intended interventions not achieved. Intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>110 patientens included, 4 were excluded. Complete data on remaining 106 patients. No information on group allocation. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Reports both ICU mortality and 60‐day mortality. No information on outcome assessment blinding. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No analysis plan or protocol available. Mortality reported as "ICU fatality rate" and "60‐day mortality". <br/>No information on analysis plans. Mortality might have been analysed at multiple time points and the most significant one chosen. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Several domains at some concern and one domain at high risk of bias.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.2 Cumulated number of serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#riskOfBias2Table-3">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-4"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.3 Proportion of patients with one or more serious adverse event (as defined by trialists)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Asfar 2017</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computer‐generated randomization list stratified by site and presence or absence of ARDS using permuted blocks of random sizes (nQuery Advisor 6.0). No significant differences between groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clear separation of oxygenation levels between the two groups at both 12 and 24 hours. Intention‐to‐treat. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>442 patients were randomly assigned to either normoxia (n= 223) or hyperoxia (n= 219), of which 217 from each group (98.2%) was included in the intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients, the research staff, the safety committee, and the writing committee were blinded to the treatment assignments.<br/>Not explicitly specified if outcome assessors are blinded. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered prior to randomisation (NCT01722422), and all pre‐specified outcomes were reported on. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Gelissen 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Web‐based randomizationwith randomlypermuted blocks of size 4 to 8, stratified by age, sex, and reason of admittance (medical, surgical, or trauma). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Achieved separation in oxygentation targets, but did not achieve the aimed oxygenation target in high group (achieved: 12.8 kPa (IQR 10.9‐14.9) vs aimed: 14‐18 kPa). 1 patient excluded post‐randomisation due to development of severe ARDS. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>574 randomized, 400 in the intention‐to‐treat population (69.7%).</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Assessment of outcome judged not to be influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered trial protocol (NCT02321072). Proportion of patients with one or more serious adverse events (including death) not pre‐defined as outcome. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High proportion of loss to follow‐up, one patient excluded post‐randomization. Proportion of patients with one or more serious adverse events (including death) not pre‐defined as outcome. </p> </td> </tr> <tr class="study-data"> <td> <p>Schjørring 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized randomization and a computer‐generated concealed assignment sequence, with permuted blocks of varying sizes. The trial groups had similar charcteristics at baseline, except for the presence of cardiac arrest. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label. Clear separation of oxygenation levels in the two groups. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>2910 out of 2928 enrolled patients included in final analysis of SAE (99.4%)</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Stated as outcome assessment blinded. Asessment of outcome judged not to be influence by knowledge of intervention recieved. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered protocol (NCT03174002). Protocol and statistical analysis plan published prior to inclusion of last patient. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.3 Proportion of patients with one or more serious adverse event (as defined by trialists)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#riskOfBias2Table-4">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-5"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.1 Quality of life</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Mackle 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomly assigned using a secure, centralized, internet‐based interface. The trial statistician generated the assignment sequence using computer‐generated random numbers with variable‐block randomization in a 1:1 ratio and stratification according to trial center. Comparable groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial‐group assignment was known to clinical staff members but was not disclosed to the patients or their families.<br/>Clear separation in oxygenation levels between groups. Intention‐to‐treat. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1000 patients randomized, 35 lost to follow‐up (withdrawal of consent). At 180 days Additionally 14 patients lost to follow‐up. 334 died at 180 days, leaving 617 eligible patients. 499 included in analysis (80.9%). No information on sensitivity analysis, additional handling of missing data or impact of missing data. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Long‐term functional outcome assessment was conducted blinded.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered protocol (ACTRN12615000957594).</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>One domain at high risk of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Schjørring 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized randomization and a computer‐generated concealed assignment sequence, with permuted blocks of varying sizes. The trial groups had similar charcteristics at baseline, except for the presence of cardiac arrest. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label. Clear separation of oxygenation levels in the two groups. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1150 patients of 1476 eligible included in analysis (77.9%). Patients lost to follow‐up were not substiantially different from those included. Effect of missing data assessed using multiple imputation and best‐worst/worst‐best case scenarios. Did not alter conclusion. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Blinded interviewer.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered protocol (NCT03174002). Protocol and statistical analysis plan published prior to inclusion of last patient. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.1 Quality of life</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#riskOfBias2Table-5">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-6"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.3 Acute respiratory distress syndrome</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Gelissen 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Web‐based randomizationwith randomlypermuted blocks of size 4 to 8, stratified by age, sex, and reason of admittance (medical, surgical, or trauma). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Achieved separation in oxygentation targets, but did not achieve the aimed oxygenation target in high group (achieved: 12.8 kPa (IQR 10.9‐14.9) vs aimed: 14‐18 kPa). 1 patient excluded post‐randomisation due to development of severe ARDS. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>574 randomized, 400 in the intention‐to‐treat population (69.7%). 1 patient excluded post‐randomisation due to development of severe ARDS. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Assessment of outcome judged not to be influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered trial protocol (NCT02321072). Reporting of serious adverse events was not explicitly pre‐defined in neither protocol nor trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High proportion of loss to follow‐up, one patient excluded post‐randomization. Not predefined outcome. </p> </td> </tr> <tr class="study-data"> <td> <p>Jakkula 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A cryptographically strong random number generator with modulo bias eliminated is used to generate random numbers and an unbiased Fisher‐Yates (Durstenfeld) algorithm is used to shuffle blocks. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Intention‐to‐treat. 3 patients in the high‐normal group were excluded post‐randomisation due to withdrawal of consent (n = 2) or randomisation error (n = 1). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>123 patients randomized, 3 were excluded post‐randomization (2 due to no consent, 1 due to randomization error), 120 included in analysis (97.6%) </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No specification of outcome assessor blinding reported. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered (NCT02698917). Trial protocol published before recruitment of last patient. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Lång 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Stated that the trial was randomized, but the method of sequence generation was not described. Sealed, opaque envelopes were used. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>5 patients were excluded du to loss‐to follow‐up, not specified group allocation.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>70 patients were randomised, 5 lost to follow‐up, leaving 65 (92.9). No information on reasons for loss provided, and no information on group allocation for patients lost to follow‐up. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on assessment blinding provided. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered prior to randomization (NCT01201291), however quality of life is not reported; however trial authors are planning to publish these results. Originally planned to include 500 patients, but due to lack of funding and a slow recruitment rate the study was presented as a pilot study. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk of bias in multiple domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Panwar 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomization was done in a masked fashion, using opaque sealed envelopes, with a unique computer‐generated, permuted block randomization method with random block sizes. Comparable groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were unaware of their assigned group but blinding of treating clinicians was not considered feasible.<br/>Clear separation in oxygenation levels between the two groups. One patient in the lower group was in error treated according to the higher group protocol. Results from per‐protocol analysis was consistent with intention‐to‐treat analysis. Intention‐to‐treat. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1 lost to follow‐up in conservative group due to consent withdrawn.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were not blinded. Clarified by email. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A study protocol was registered prior to randomization (ACTRN12613000505707), and all outcomes were reported on. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.3 Acute respiratory distress syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#riskOfBias2Table-6">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-7"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.4 Pneumonia</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Asfar 2017</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computer‐generated randomization list stratified by site and presence or absence of ARDS using permuted blocks of random sizes (nQuery Advisor 6.0). No significant differences between groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients, the research staff, the safety committee, and the writing committee were blinded to the treatment assignments.<br/>No blinding of carers reported. Clear separation of oxygenation levels between the two groups at both 12 and 24 hours. Intention‐to‐treat. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>442 patients were randomly assigned to either normoxia (n= 223) or hyperoxia (n= 219), of which 217 from each group (98.2%) was included in the intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not explicitly specified if outcome assessors are blinded. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered prior to randomisation (NCT01722422), but pneumonia was not a pre‐defined as serious adverse event. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Pneumonia was not explicitly predefined as an outcome.</p> </td> </tr> <tr class="study-data"> <td> <p>Barrot 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computer randomization was performed in blocks of four. Comparable groups at baseline.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label. Clear separation in oxygenation levels between the two groups. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>4 out of 205 patients were lost to follow‐up (2 due to withrawn consent, 2 excluded due to not meeting eligibility criteria), thus leaving 201 patients in the analysis (98.0 %). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Details on assesment blinding not provided. Assessment of outcome judged not the be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered (NCT02713451). Ventilator associated pneumonia was a pre‐defined secondary outcome. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Girardis 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col10" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computerized random‐number generator. The randomization sequence was concealed from the researchers by use of sequentially numbered, closed, opaque envelopes that were opened after patient study inclusion. Comparable groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label trial. Clear separation of oxygenation levels between the two groups. A modified, not predefined, intent‐to‐treat population, consisting of all randomized patients with an ICU length of stay of 72 hours or longer and for whom at least 1 arterial blood gas analysis had been performed per day, was the primary population for analysis. However, the primary and secondary outcomes were also evaluated in the intent‐to‐treat population, which included all randomized patients, excluding those who withdrew consent. Modified intent‐to‐treat analysis: Absolute risk difference 0.031 (95% CI, ‐0.038 ‐ 0.099, P = .37). Intention‐to‐treat analysis: Absolute risk difference 0.049 (95% CI, ‐.026 ‐ 0.124, P = .20). No justification for modification of intention‐to‐treat population reported. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on intention‐to‐treat population (n = 478) is available in supplement; 1 patient in each group withdrew consent. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not described; however, blinding of outcome assessment was clarified by email. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Primary analysis changed from intention‐to‐treat population to modified intention‐to‐treat population consisting of all randomized patients with an ICU length of stay of 72 hours or longer and for whom at least 1 arterial blood gas analysis had been performed per day. The trial was by us judged being registrered retrospectively (NCT01319643). Respiratory infections defined as secondary outcome in protocol. No justification for change to modified intention‐to‐treat population is reported. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk of bias due to unjustified modified intention‐to‐treat analysis.</p> </td> </tr> <tr class="study-data"> <td> <p>Lång 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Stated that the trial was randomized, but the method of sequence generation was not described. Sealed, opaque envelopes were used. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open label. Clear separation in provided intervention and oxygenation levels between the two groups. 5 patients were excluded du to loss‐to follow‐up, not specified group allocation. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>70 patients were randomised, 5 lost to follow‐up, leaving 65 (92.9). No information on reasons for loss provided, and no information on group allocation for patients lost to follow‐up. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on assessment blinding provided. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered prior to randomization (NCT01201291), however quality of life is not reported; however trial authors are planning to publish these results. Originally planned to include 500 patients, but due to lack of funding and a slow recruitment rate the study was presented as a pilot study. Pneumonia not pre‐defined as SAE outcome </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk of bias in multiple domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Yang 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random number table allocation method. No information on allocation concealment. Limitid baseline information provided. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Intended interventions not achieved. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>110 patientens included, 4 were excluded but no information on group allocation. Complete data on remaining 106 patients. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Criteria for ventilator associated pneumonia not defined. No information on outcome assessor blinding. Assesment of pneumoni is borderline subjective. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol or statistical analysis plan published.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Two domains at some concern and three domains at high risk of bias.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.4 Pneumonia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#riskOfBias2Table-7">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-8"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.1 Myocardial infarction</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Gelissen 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Web‐based randomizationwith randomlypermuted blocks of size 4 to 8, stratified by age, sex, and reason of admittance (medical, surgical, or trauma). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Achieved separation in oxygentation targets, but did not achieve the aimed oxygenation target in high group (achieved: 12.8 kPa (IQR 10.9‐14.9) vs aimed: 14‐18 kPa). 1 patient excluded post‐randomisation due to development of severe ARDS. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>574 randomized, 400 in the intention‐to‐treat population (69.7%).</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Assessment of outcome judged not to be influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered trial protocol (NCT02321072). Reporting of serious adverse events was not explicitly pre‐defined in neither protocol nor trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High proportion of loss to follow‐up, one patient excluded post‐randomization. Not predefined outcome. </p> </td> </tr> <tr class="study-data"> <td> <p>Jun 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Stated as randomized, but no details on randomization proces. No baseline data.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on number of patients allocated to each of the groups. Event rate reported as percentage and number for two of three groups. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on the remaining 29 patients, but they were presumably allocated to low oxygen concentration. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on assesment of outcome. No information on blinding.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol could be found.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No supportive informative information, high risk of bias in multiple domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Schjørring 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized randomization and a computer‐generated concealed assignment sequence, with permuted blocks of varying sizes. The trial groups had similar charcteristics at baseline, except for the presence of cardiac arrest. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label. Clear separation of oxygenation levels in the two groups. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>2910 out of 2928 enrolled patients included in final analysis (98.6%)</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Predefined criteria for event.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered protocol (NCT03174002). Protocol and statistical analysis plan published prior to inclusion of last patient. Myocardial ischaemia pre‐defined as SAE. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns fo bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Semler 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Radomly generated cluster‐level crossover. The order of trial group assignments for each 2‐month period was generated by computerized randomization with the use of permuted blocks of three to minimize the effect of seasonal variation and temporal changes. The allocation remain concealed until the start of each 2‐months period. Patients recruited prospectively. Sequence of the individual cluster‐periods were unknown. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Reasons for protocol deviations are listed in supplement. Clear separation between allocated targets. Exclusion of patients enrolled during washout periods, as predefined in the trial protocol, and those positive for COVID‐19 (not predefined). No supplemental sensitivity‐analysis of of all included patients performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data only reported in patients recruited in first 24 of 36 months of trial conduct. No justification for this selection and no senisitivity analyses to evaluate the impact of missing data. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Assessor‐blinding. Evaluation of myocardial infarction is unlikely to be affected by knowledge of group allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered (NCT03537937). Myocardial infarction is prespecified as an exploratory safety outcome. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Two domains at high risk of bias.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.1 Myocardial infarction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#riskOfBias2Table-8">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-9"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.1 Stroke</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Barrot 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computer randomization was performed in blocks of four. Comparable groups at baseline.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label. Clear separation in oxygenation levels between the two groups. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>4 out of 205 patients were lost to follow‐up (2 due to withrawn consent, 2 excluded due to not meeting eligibility criteria), thus leaving 201 patients in the analysis (98.0 %). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Details on assesment blinding not provided. Assessment judged not to be incluenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered (NCT02713451). Stroke pre‐defined as secondary outcome.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Gelissen 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Web‐based randomizationwith randomlypermuted blocks of size 4 to 8, stratified by age, sex, and reason of admittance (medical, surgical, or trauma). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Achieved separation in oxygentation targets, but did not achieve the aimed oxygenation target in high group (achieved: 12.8 kPa (IQR 10.9‐14.9) vs aimed: 14‐18 kPa). 1 patient excluded post‐randomisation due to development of severe ARDS. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>574 randomized, 400 in the intention‐to‐treat population (69.7%).</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Assessment of outcome judged not to be influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered trial protocol (NCT02321072). Reporting of serious adverse events was not explicitly pre‐defined in neither protocol nor trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High proportion of loss to follow‐up, one patient excluded post‐randomization. Not predefined outcome. </p> </td> </tr> <tr class="study-data"> <td> <p>Mackle 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomly assigned using a secure, centralized, internet‐based interface. The trial statistician generated the assignment sequence using computer‐generated random numbers with variable‐block randomization in a 1:1 ratio and stratification according to trial center. Comparable groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial‐group assignment was known to clinical staff members but was not disclosed to the patients or their families. Clear separation in oxygenation levels between groups. Intention‐to‐treat. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>1000 patients randomized, 35 lost to follow‐up (withdrawal of consent), leaving 965 patients (96.5%) for the analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No defition on diagnosis of stroke provided. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered protocol (ACTRN12615000957594). Stroke not predefined as outcome. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Stroke not predefined as outcome.</p> </td> </tr> <tr class="study-data"> <td> <p>Schjørring 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized randomization and a computer‐generated concealed assignment sequence, with permuted blocks of varying sizes. The trial groups had similar charcteristics at baseline, except for the presence of cardiac arrest. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label. Clear separation of oxygenation levels in the two groups. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>2910 out of 2928 enrolled patients included in final analysis (99.4%)</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Assesment of stroke was pre‐defined.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered protocol (NCT03174002). Protocol and statistical analysis plan published prior to inclusion of last patient. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Semler 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Radomly generated cluster‐level crossover. The order of trial group assignments for each 2‐month period was generated by computerized randomization with the use of permuted blocks of three to minimize the effect of seasonal variation and temporal changes. The allocation remain concealed until the start of each 2‐months period. Patients recruited prospectively. Sequence of the individual cluster‐periods were unknown. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Reasons for protocol deviations are listed in supplement. Clear separation between allocated targets. Exclusion of patients enrolled during washout periods, as predefined in the trial protocol, and those positive for COVID‐19 (not predefined). No supplemental sensitivity‐analysis of of all included patients performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data only reported in patients recruited in first 24 of 36 months of trial conduct. No justification for this selection and no senisitivity analyses to evaluate the impact of missing data. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Assessor‐blinding. Evaluation of stroke is unlikely to be affected by knowledge of group allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered (NCT03537937). Stroke is prespecified as an exploratory safety outcome. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Two domains at high risk of bias.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.1 Stroke</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#riskOfBias2Table-9">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-10"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 8.1 Sepsis</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Barrot 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computer randomization was performed in blocks of four. Comparable groups at baseline.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label. Clear separation in oxygenation levels between the two groups. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>4 out of 205 patients were lost to follow‐up (2 due to withrawn consent, 2 excluded due to not meeting eligibility criteria), thus leaving 201 patients in the analysis (98.0 %). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Details on assesment blinding not provided. Assessment of outcome judged not to be incluenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered (NCT02713451). Septicaemia pre‐defined as secondary outcome.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Girardis 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col10" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computerized random‐number generator. The randomization sequence was concealed from the researchers by use of sequentially numbered, closed, opaque envelopes that were opened after patient study inclusion. Comparable groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label trial<br/>Clear separation of oxygenation levels between the two groups. </p> <p>A modified, not predefined, intent‐to‐treat population, consisting of all randomized patients with an ICU length of stay of 72 hours or longer and for whom at least 1 arterial blood gas analysis had been performed per day, was the primary population for analysis. </p> <p>However, the primary and secondary outcomes were also evaluated in the intent‐to‐treat population, which included all randomized patients, excluding those who withdrew consent.<br/>Modified intent‐to‐treat analysis: Absolute risk reduction 0.086 (95% CI, 0.017‐0.150, P = .01).<br/>Intention‐to‐treat analysis: Absolute risk reduction 0.087 (95% CI, 0.021‐0.152, P = .009). </p> <p>No justification for modification of intention‐to‐treat population reported.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on intention‐to‐treat population (n = 478) is available in supplement; 1 patient in each group withdrew consent. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not described; however, blinding of outcome assessment was clarified by email. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Primary analysis changed from intention‐to‐treat population to modified intention‐to‐treat population consisting of all randomized patients with an ICU length of stay of 72 hours or longer and for whom at least 1 arterial blood gas analysis had been performed per day. </p> <p>The trial was by us judged being registrered retrospectively (NCT01319643).</p> <p>No justification for change to modified intention‐to‐treat population is reported.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk of bias i multiple domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Yang 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random number table allocation method. No information on allocation concealment. Limitid baseline information provided. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Intended interventions not achieved. Intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>110 patientens included, 4 were excluded. Complete data on remaining 106 patients. No information on group allocation. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Criteria for blood stream infection not defined. No information on outcome assessor blinding. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol or statistical analysis plan published.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Two domains at some concern and one at high risk of bias.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 8.1 Sepsis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#riskOfBias2Table-10">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-11"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.6 Delirium</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Barrot 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computer randomization was performed in blocks of four. Comparable groups at baseline.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label. Clear separation in oxygenation levels between the two groups. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>4 out of 205 patients were lost to follow‐up (2 due to withrawn consent, 2 excluded due to not meeting eligibility criteria), thus leaving 201 patients in the analysis (98.0 %). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Details on assesment blinding not provided. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered (NCT02713451). Delirium pre‐defined as secondary outcome.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Martin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomly assigned on a 1:1 basis (www. sealedenvelope.com) into either the conservative or control group, stratified by study site, using random permuted blocks of different sizes. Randomisation was balanced between the two treatment groups (17:17) and was also balanced at each site (10:10 at site one and 7:7 at site two). No details on baseline characteristics stratified by group is provided. Only baseline characteristics for the entire cohort is reported. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Unblinded trial. Clear separation of oxygenation levels in the two groups. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome reported for all patients.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Unblinded trial. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered protocol (NCT03287466). Protocol published prior to completion of recruitment. Delirium pre‐defined as expected adverse event. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.6 Delirium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#riskOfBias2Table-11">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-12"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.7 Pneumothorax</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Asfar 2017</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computer‐generated randomization list stratified by site and presence or absence of ARDS using permuted blocks of random sizes (nQuery Advisor 6.0). No significant differences between groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients, the research staff, the safety committee, and the writing committee were blinded to the treatment assignments. No blinding of carers reported. Clear separation of oxygenation levels between the two groups at both 12 and 24 hours. Intention‐to‐treat. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>442 patients were randomly assigned to either normoxia (n= 223) or hyperoxia (n= 219), of which 217 from each group (98.2%) was included in the intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not explicitly specified if outcome assessors are blinded. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered prior to randomisation (NCT01722422), and all pre‐specified outcomes were reported on. Pneumothorax defined as SAE in paper. In trial registration "safety data" is defined as secondary outcome, but no further details are provided. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Pneumothorax not explicitly predefined as outcome.</p> </td> </tr> <tr class="study-data"> <td> <p>Barrot 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computer randomization was performed in blocks of four. Comparable groups at baseline.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label. Clear separation in oxygenation levels between the two groups. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>4 out of 205 patients were lost to follow‐up (2 due to withrawn consent, 2 excluded due to not meeting eligibility criteria), thus leaving 201 patients in the analysis (98.0 %). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Details on assesment blinding not provided. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered (NCT02713451). Pneumothorax pre‐defined as serious adverse event. Reported in supplement. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Semler 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Radomly generated cluster‐level crossover. The order of trial group assignments for each 2‐month period was generated by computerized randomization with the use of permuted blocks of three to minimize the effect of seasonal variation and temporal changes. The allocation remain concealed until the start of each 2‐months period. Patients recruited prospectively. Sequence of the individual cluster‐periods were unknown. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Reasons for protocol deviations are listed in supplement. Clear separation between allocated targets. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Reasons for protocol deviations are listed in supplement. Clear separation between allocated targets. Exclusion of patients enrolled during washout periods, as predefined in the trial protocol, and those positive for COVID‐19 (not predefined). No supplemental sensitivity‐analysis of of all included patients performed. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Assessor‐blinding. Evaluation of pneumothorax or pneumomediastinum is unlikely to be affected by knowledge of group allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered (NCT03537937). Reported as the combination of either pneumothorax or pneumomediastinum. Prespecified as an exploratory safety outcome. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Two domains at high risk of bias.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.7 Pneumothorax</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#riskOfBias2Table-12">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-13"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.8 Intestinal ischaemia</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Asfar 2017</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computer‐generated randomization list stratified by site and presence or absence of ARDS using permuted blocks of random sizes (nQuery Advisor 6.0). No significant differences between groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients, the research staff, the safety committee, and the writing committee were blinded to the treatment assignments. No blinding of carers reported. Clear separation of oxygenation levels between the two groups at both 12 and 24 hours. Intention‐to‐treat. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>442 patients were randomly assigned to either normoxia (n= 223) or hyperoxia (n= 219), of which 217 from each group (98.2%) was included in the intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not explicitly specified if outcome assessors are blinded. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered prior to randomisation (NCT01722422), and all pre‐specified outcomes were reported on. Intestinal sichemia not prespecified. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Intestinal ischaemia not predifined as outcome.</p> </td> </tr> <tr class="study-data"> <td> <p>Barrot 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computer randomization was performed in blocks of four. Comparable groups at baseline.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label. Clear separation in oxygenation levels between the two groups. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>4 out of 205 patients were lost to follow‐up (2 due to withrawn consent, 2 excluded due to not meeting eligibility criteria), thus leaving 201 patients in the analysis (98.0 %). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Details on assesment blinding not provided. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered (NCT02713451). Intestinal ischaemia not pre‐defined as secondary outcome. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Intestinal ischaemia not pre‐defined as secondary outcome.</p> </td> </tr> <tr class="study-data"> <td> <p>Schjørring 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized randomization and a computer‐generated concealed assignment sequence, with permuted blocks of varying sizes. The trial groups had similar charcteristics at baseline, except for the presence of cardiac arrest. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label. Clear separation of oxygenation levels in the two groups. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>2910 out of 2928 enrolled patients included in final analysis (99.4%).</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Assessment of outcome judged not to be influenced by knowledge of intervention.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered protocol (NCT03174002). Protocol and statistical analysis plan published prior to inclusion of last patient. Intestinal ischaemia pre‐defined as SAE. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.8 Intestinal ischaemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#riskOfBias2Table-13">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-14"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.9 Cardiovascular failure including shock</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Girardis 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col10" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computerized random‐number generator. The randomization sequence was concealed from the researchers by use of sequentially numbered, closed, opaque envelopes that were opened after patient study inclusion. Comparable groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label trial<br/>Clear separation of oxygenation levels between the two groups. </p> <p>A modified, not predefined, intent‐to‐treat population, consisting of all randomized patients with an ICU length of stay of 72 hours or longer and for whom at least 1 arterial blood gas analysis had been performed per day, was the primary population for analysis. </p> <p>However, the primary and secondary outcomes were also evaluated in the intent‐to‐treat population, which included all randomized patients, excluding those who withdrew consent.<br/>Modified intent‐to‐treat analysis: Absolute risk reduction 0.086 (95% CI, 0.017‐0.150, P = .01).<br/>Intention‐to‐treat analysis: Absolute risk reduction 0.087 (95% CI, 0.021‐0.152, P = .009). </p> <p>No justification for modification of intention‐to‐treat population reported.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on intention‐to‐treat population (n = 478) is available in supplement; 1 patient in each group withdrew consent. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not described; however, blinding of outcome assessment was clarified by email. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No justification for change to modified intention‐to‐treat population is reported. Modified intention‐to‐treat: absolute risk reduction 0.068 (95% CI: 0.020‐0.120, p=0.006). Intention‐to‐treat: absolute risk reduction 0.070 (95% IC: 0.023‐0.121, p=0.004). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk of bias du to unjustified modified intention‐to‐treat analysis.</p> </td> </tr> <tr class="study-data"> <td> <p>Schjørring 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Centralized randomization and a computer‐generated concealed assignment sequence, with permuted blocks of varying sizes. The trial groups had similar charcteristics at baseline, except for the presence of cardiac arrest. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label. Clear separation of oxygenation levels in the two groups. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>2910 out of 2928 enrolled patients included in final analysis (99.4%).</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Assessment of outcome judged not to be influenced by knowledge of intervention.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered protocol (NCT03174002). Protocol and statistical analysis plan published prior to inclusion of last patient. Shock pre‐defined as SAE. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.9 Cardiovascular failure including shock</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#riskOfBias2Table-14">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-15"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.10 Cardiac arrhythmia</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Asfar 2017</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computer‐generated randomization list stratified by site and presence or absence of ARDS using permuted blocks of random sizes (nQuery Advisor 6.0). No significant differences between groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients, the research staff, the safety committee, and the writing committee were blinded to the treatment assignments. No blinding of carers reported. Clear separation of oxygenation levels between the two groups at both 12 and 24 hours. Intention‐to‐treat. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>442 patients were randomly assigned to either normoxia (n= 223) or hyperoxia (n= 219), of which 217 from each group (98.2%) was included in the intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients, the research staff, the safety committee, and the writing committee were blinded to the treatment assignments.<br/>Not explicitly specified if outcome assessors are blinded. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was registered prior to randomisation (NCT01722422), and all pre‐specified outcomes were reported on. Ventricular arryhtmias not pre‐defined as outcome. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Barrot 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computer randomization was performed in blocks of four. Comparable groups at baseline.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label. Clear separation in oxygenation levels between the two groups. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>4 out of 205 patients were lost to follow‐up (2 due to withrawn consent, 2 excluded due to not meeting eligibility criteria), thus leaving 201 patients in the analysis (98.0 %). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Details on assesment blinding not provided. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered (NCT02713451). Cardiac arrhythmia pre‐defined as secondary outcome. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Gomersall 2002</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomization was performed using unmarked, ordered, sealed envelopes. The randomization order was deter‐ mined using a computer‐generated list of random numbers. No significant differences between the two groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were blinded to the target oxygen tension. Clear separation of oxygenation levels between the two groups. Modified intention‐to‐treat. Two patients in the low oxygen group were excluded post‐randomisationen due to violation of inclusion criteria. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>36 patients were recruited, 34 were included in analysis (94.4%).</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Only patients were blinded.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol could be found.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>One domain at some concerns and one at high risk of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Martin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomly assigned on a 1:1 basis (www. sealedenvelope.com) into either the conservative or control group, stratified by study site, using random permuted blocks of different sizes. Randomisation was balanced between the two treatment groups (17:17) and was also balanced at each site (10:10 at site one and 7:7 at site two). No details on baseline characteristics stratified by group is provided. Only baseline characteristics for the entire cohort is reported. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Unblinded trial. Clear separation of oxygenation levels in the two groups. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome reported for all patients.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Unblinded trial. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered protocol (NCT03287466). Protocol published prior to completion of recruitment. Arrhythmia pre‐defined as SAE in protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concers of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Schmidt 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Web‐based system using random permuted block sizes of 2, 4, or 6 that were stratified according to site.<br/>Comparable groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Some separation of oxygenation targets. Intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>802 patients randomized. Consent declined in 12 patients, 1 patient randomized twice. Data provided for 789 (98.4%). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>802 patients randomized. Consent declined in 12 patients, 1 patient randomized twice. Data provided for 789 (98.4%). </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered protocol (NCT03141099). Protocol and statistical analysis plan published prior to inclusion of last patient. Cardiac arrhythmia pre‐defined as secondary outcome. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All domains at overall low risk of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Semler 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Radomly generated cluster‐level crossover. The order of trial group assignments for each 2‐month period was generated by computerized randomization with the use of permuted blocks of three to minimize the effect of seasonal variation and temporal changes. The allocation remain concealed until the start of each 2‐months period. Patients recruited prospectively. Sequence of the individual cluster‐periods were unknown. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Radomly generated cluster‐level crossover. The order of trial group assignments for each 2‐month period was generated by computerized randomization with the use of permuted blocks of three to minimize the effect of seasonal variation and temporal changes. The allocation remain concealed until the start of each 2‐months period. Patients recruited prospectively. Sequence of the individual cluster‐periods were unknown. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data only reported in patients recruited in first 24 of 36 months of trial conduct. No justification for this selection and no senisitivity analyses to evaluate the impact of missing data. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Assessor‐blinding. Evaluation of arrhythmia is unlikely to be affected by knowledge of group allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Cardiac arrythmia as an outcome not predified. Combinded information from atrial and ventricular arrhythmias, both prespecified as exploratory safety outcomes. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Two domains at high risk of bias.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.10 Cardiac arrhythmia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#riskOfBias2Table-15">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-16"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.11 Liver failure</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Gelissen 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Web‐based randomizationwith randomlypermuted blocks of size 4 to 8, stratified by age, sex, and reason of admittance (medical, surgical, or trauma). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Achieved separation in oxygentation targets, but did not achieve the aimed oxygenation target in high group (achieved: 12.8 kPa (IQR 10.9‐14.9) vs aimed: 14‐18 kPa). 1 patient excluded post‐randomisation due to development of severe ARDS. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>574 randomized, 400 in the intention‐to‐treat population (69.7%).</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Assessment of outcome judged not to be influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered trial protocol (NCT02321072). Reporting of serious adverse events was not explicitly pre‐defined in neither protocol nor trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High proportion of loss to follow‐up, one patient excluded post‐randomization. Not predefined outcome. </p> </td> </tr> <tr class="study-data"> <td> <p>Girardis 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col10" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computerized random‐number generator. The randomization sequence was concealed from the researchers by use of sequentially numbered, closed, opaque envelopes that were opened after patient study inclusion. Comparable groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label. Clear separation of oxygenation levels between the two groups. A modified, not predefined, intent‐to‐treat population, consisting of all randomized patients with an ICU length of stay of 72 hours or longer and for whom at least 1 arterial blood gas analysis had been performed per day, was the primary population for analysis. However, the primary and secondary outcomes were also evaluated in the intent‐to‐treat population, which included all randomized patients, excluding those who withdrew consent. No justification for modification of intention‐to‐treat population reported. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on intention‐to‐treat population (n = 478) is available in supplement; 1 patient in each group withdrew consent. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not described; however, blinding of outcome assessment was clarified by email.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Primary analysis changed from intention‐to‐treat population to modified intention‐to‐treat population consisting of all randomized patients with an ICU length of stay of 72 hours or longer and for whom at least 1 arterial blood gas analysis had been performed per day. The trial was by us judged being registrered retrospectively (NCT01319643). Liver failure defined as secondary outcome in protocol. No justification for change to modified intention‐to‐treat population is reported. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Concern of bias due to change of analysed population, retrospective registration, and failure to report all prespecified outcome data. </p> </td> </tr> <tr class="study-data"> <td> <p>Yang 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random number table allocation method. No information on allocation concealment. Limitid baseline information provided. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Intended interventions not achieved. Intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>110 patientens included, 4 were excluded. Complete data on remaining 106 patients. No information on group allocation. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Criteria for liver failure not defined. No information on outcome assessor blinding. Assessment of liver failure is border line subjective. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol or statistical analysis plan published.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Two domains at some concern and two at high risk of bias.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.11 Liver failure</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#riskOfBias2Table-16">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-17"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.12 Renal failure</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Gelissen 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Web‐based randomizationwith randomlypermuted blocks of size 4 to 8, stratified by age, sex, and reason of admittance (medical, surgical, or trauma). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Achieved separation in oxygentation targets, but did not achieve the aimed oxygenation target in high group (achieved: 12.8 kPa (IQR 10.9‐14.9) vs aimed: 14‐18 kPa). 1 patient excluded post‐randomisation due to development of severe ARDS. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>574 randomized, 400 in the intention‐to‐treat population (69.7%).</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Assessment of outcome judged not to be influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered trial protocol (NCT02321072). Reporting of serious adverse events was not explicitly pre‐defined in neither protocol nor trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High proportion of loss to follow‐up, one patient excluded post‐randomization. Not predefined outcome. </p> </td> </tr> <tr class="study-data"> <td> <p>Girardis 2016</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col10" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Computerized random‐number generator. The randomization sequence was concealed from the researchers by use of sequentially numbered, closed, opaque envelopes that were opened after patient study inclusion. Comparable groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Open‐label. Clear separation of oxygenation levels between the two groups. A modified, not predefined, intent‐to‐treat population, consisting of all randomized patients with an ICU length of stay of 72 hours or longer and for whom at least 1 arterial blood gas analysis had been performed per day, was the primary population for analysis. However, the primary and secondary outcomes were also evaluated in the intent‐to‐treat population, which included all randomized patients, excluding those who withdrew consent. No justification for modification of intention‐to‐treat population reported. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data on intention‐to‐treat population (n = 478) is available in supplement; 1 patient in each group withdrew consent. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Not described; however, blinding of outcome assessment was clarified by email.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Primary analysis changed from intention‐to‐treat population to modified intention‐to‐treat population consisting of all randomized patients with an ICU length of stay of 72 hours or longer and for whom at least 1 arterial blood gas analysis had been performed per day. The trial was by us judged being registrered retrospectively (NCT01319643). Renal failure defined secondary outcome in protocol. No justification for change to modified intention‐to‐treat population is reported. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Concern of bias due to change of analysed population, retrospective registration, and failure to report all prespecified outcome data. </p> </td> </tr> <tr class="study-data"> <td> <p>Martin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomly assigned on a 1:1 basis (www. sealedenvelope.com) into either the conservative or control group, stratified by study site, using random permuted blocks of different sizes. Randomisation was balanced between the two treatment groups (17:17) and was also balanced at each site (10:10 at site one and 7:7 at site two). No details on baseline characteristics stratified by group is provided. Only baseline characteristics for the entire cohort is reported. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Unblinded trial. Clear separation of oxygenation levels in the two groups. Intention‐to‐treat.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome reported for all patients.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Unblinded trial. Assessment of outcome judged not to be influenced by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered protocol (NCT03287466). Protocol published prior to completion of recruitment. Arrhythmia pre‐defined as SAE in protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concers of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Schmidt 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Web‐based system using random permuted block sizes of 2, 4, or 6 that were stratified according to site.<br/>Comparable groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Some separation of oxygenation targets. Intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>802 patients randomized. Consent declined in 12 patients, 1 patient randomized twice. Data provided for 789 (98.4%). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on blinding. Assessment of outcome not likely to be influenced by knowledge of group allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered protocol (NCT03141099). Protocol and statistical analysis plan published prior to inclusion of last patient. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All domains at overall low risk of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Semler 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Radomly generated cluster‐level crossover. The order of trial group assignments for each 2‐month period was generated by computerized randomization with the use of permuted blocks of three to minimize the effect of seasonal variation and temporal changes. The allocation remain concealed until the start of each 2‐months period. Patients recruited prospectively. Sequence of the individual cluster‐periods were unknown. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Radomly generated cluster‐level crossover. The order of trial group assignments for each 2‐month period was generated by computerized randomization with the use of permuted blocks of three to minimize the effect of seasonal variation and temporal changes. The allocation remain concealed until the start of each 2‐months period. Patients recruited prospectively. Sequence of the individual cluster‐periods were unknown. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>2541/2987 patients included in analysis (85.1%). No supplemental sensitivity‐analysis of all included patients performed. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Renal failure as defined by KDIGO‐criteria. Objective measures. Blinded study personnel.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Prospectively registered (NCT03537937). Renal failure (Stage II or greater AKI by Kidney Disease: Improving Global Outcomes <br/>(KDIGO) creatinine criteria) predefined as an exploratory organ function outcome. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Two domains at high risk of bias.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.12 Renal failure</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012631.pub3/references#riskOfBias2Table-17">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012631.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012631-note-0014">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012631-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012631-note-0013">Français</a> </li> <li class="section-language"> <a class="" href="id#CD012631-note-0012">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ko#CD012631-note-0009">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD012631-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD012631-note-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012631-note-0007">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012631\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012631\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012631\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012631\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012631\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012631\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012631\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012631\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012631\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012631\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012631\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012631\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012631\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012631\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012631\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012631\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012631\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012631\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Oy81c7tH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012631.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012631.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012631.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012631.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012631.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716270154"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012631.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716270158"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012631.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d9b5d0af21bf6',t:'MTc0MDcxNjI3MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 